<SEC-DOCUMENT>0001047469-18-007084.txt : 20181106
<SEC-HEADER>0001047469-18-007084.hdr.sgml : 20181106
<ACCEPTANCE-DATETIME>20181106170226
ACCESSION NUMBER:		0001047469-18-007084
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		23
FILED AS OF DATE:		20181106
DATE AS OF CHANGE:		20181106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OvaScience, Inc.
		CENTRAL INDEX KEY:			0001544227
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				451472564
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-228209
		FILM NUMBER:		181163834

	BUSINESS ADDRESS:	
		STREET 1:		9 FOURTH AVE
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		617-500-2802

	MAIL ADDRESS:	
		STREET 1:		9 FOURTH AVE
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>a2237017zs-3.htm
<DESCRIPTION>S-3
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg10401_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>As filed with the Securities and Exchange Commission on November&nbsp;6, 2018  </B></FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B> Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1><B><BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1><B> <div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=1><B>Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>FORM S-3<BR>  </B></FONT><FONT SIZE=1><B>REGISTRATION STATEMENT<BR>
Under<BR>
The Securities Act of 1933  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>OVASCIENCE,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=1>(Exact name of registrant as specified in its charter) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Delaware</B></FONT><FONT SIZE=1><BR>
(State or other jurisdiction of<BR>
incorporation or organization)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B> 45-1472564</B></FONT><FONT SIZE=1><BR>
(I.R.S. Employer<BR>
Identification Number)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>9 Fourth Avenue<BR>
Waltham, MA 02451<BR>
(617)&nbsp;500-2802</B></FONT><FONT SIZE=1><BR>
(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Christopher A. Kroeger, M.D., M.B.A.<BR>
President&nbsp;&amp; Chief Executive Officer<BR>
OvaScience,&nbsp;Inc.<BR>
9 Fourth Avenue<BR>
Waltham, MA 02451<BR>
(617)&nbsp;500-2802<BR>  </B></FONT><FONT SIZE=1>(Name, address, including zip code, and telephone number, including area code, of agent for service) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Copy to:</B></FONT><BR><FONT SIZE=1><B>William C. Hicks, Esq.<BR>
Megan N. Gates, Esq.<BR>
Daniel A. Bagliebter, Esq.<BR>
Mintz, Levin, Cohn, Ferris, Glovsky&nbsp;&amp; Popeo, P.C.<BR>
One Financial Center<BR>
Boston, MA 02111<BR>
(617)&nbsp;542-6000</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Approximate date of proposed sale to the public:<BR>
From time to time after the effective date of this Registration Statement.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the following
box.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of
1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box:&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this form is a registration statement pursuant to General Instruction&nbsp;I.D. or a post-effective amendment thereto that shall become effective upon filing
with the Commission pursuant to Rule&nbsp;462(e) under the Securities Act, check the following box.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this form is a post-effective amendment to a registration statement filed pursuant to General Instruction&nbsp;I.D. filed to register additional securities
or additional classes of securities pursuant to Rule&nbsp;413(b) under the Securities Act, check the following box.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the
definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule&nbsp;12b-2 of the Exchange Act. (Check one): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="105pt" style="font-family:times;"></TD>
<TD WIDTH="11%" style="font-family:times;"></TD>
<TD WIDTH="82pt" style="font-family:times;"></TD>
<TD WIDTH="11%" style="font-family:times;"></TD>
<TD WIDTH="98pt" style="font-family:times;"></TD>
<TD WIDTH="11%" style="font-family:times;"></TD>
<TD WIDTH="128pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Large accelerated filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Accelerated filer&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Non-accelerated filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;text-align:center;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"text-align:center;" -->


 Smaller reporting company&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT></font> <p align=center style="font-family:times;margin-top:0pt;margin-left:0pt;"> <FONT SIZE=1> Emerging Growth Company&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section&nbsp;13(a) of the Exchange Act&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>CALCULATION OF REGISTRATION FEE  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="30%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Title of Each Class of Securities<BR>
to be Registered</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Amount to be<BR>
Registered(1)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Proposed Maximum<BR>
Offering Price Per<BR>
Share(2)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Proposed Maximum<BR>
Aggregate Offering<BR>
Price(2)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Amount of<BR>
Registration Fee</B></FONT><BR></TH>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1><B> </B></FONT><FONT SIZE=1>Common stock, par value $0.001 per share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>1,886,574 shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>$0.77</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>$1,452,661.98</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>$176.07</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"> &nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Pursuant
to Rule&nbsp;416(a) of the Securities Act of 1933, as amended, this Registration Statement shall also cover any additional shares of the Registrant's
common stock that become issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of the
Registrant's outstanding shares of common stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Estimated
in accordance with Rule&nbsp;457(c) solely for purposes of calculating the registration fee on the basis of the average of the high and low prices of
Registrant's common stock as reported on The Nasdaq Capital Market on November&nbsp;5, 2018.  </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=1><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall
file&nbsp;a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or
until this Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine.  </B></FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=1>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <P style="font-family:times;"><FONT SIZE=1><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=722599,FOLIO='blank',FILE='DISK121:[18ZEU1.18ZEU10401]BA10401A.;18',USER='CHE105536',CD=';5-NOV-2018;22:31' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bb10401_explanatory_note"> </A>
<A NAME="toc_bb10401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPLANATORY NOTE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This registration statement relates to the resale by the selling stockholders of up to an aggregate of 1,886,574 shares of OvaScience's common
stock (the "Shares"). OvaScience,&nbsp;Inc. ("OvaScience") is filing this registration statement in connection with its merger with Millendo Therapeutics,&nbsp;Inc. ("Millendo") pursuant to an
Agreement and Plan of Merger and Reorganization, as may be amended from time to time (the "Merger Agreement"), pursuant to which a wholly owned subsidiary of OvaScience will merge with and into
Millendo, with Millendo surviving as a wholly owned subsidiary of OvaScience (the "Merger"). At the closing of the Merger (the "Effective Time"), each share of Millendo common stock, par value $0.001
per share ("Millendo Common Stock") (excluding certain shares to be cancelled pursuant to the Merger Agreement, and shares held by stockholders who have exercised and perfected appraisal rights or
dissenters' rights), outstanding immediately prior to the Effective Time will be converted into the right to receive shares of OvaScience common stock, par value $0.001 per share ("OvaScience Common
Stock") equal to an exchange ratio set forth in the Merger Agreement and as described further in this registration statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Shares registered for resale on this registration statement will be sold to the selling stockholders pursuant to a Stock Purchase Agreement, dated November&nbsp;1, 2018 (as amended
from time to time, the "Purchase Agreement"), by and among OvaScience, Millendo and the investors listed therein (the "Investors"). Pursuant to the terms of the Purchase Agreement, the Investors
agreed to purchase
shares of OvaScience Common Stock for an aggregate purchase price of approximately $20.0&nbsp;million as part of a private placement financing (the "Post-Closing Financing"). The consummation of the
Post-Closing Financing and the other transactions contemplated by the Purchase Agreement are conditioned upon the satisfaction or waiver of the conditions set forth in the Purchase Agreement.
OvaScience and the Investors intend to complete the Post-Closing Financing after the Effective Time. Under the terms of the Post-Closing Financing, the Shares issued in the Post-Closing Financing will
be issued pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended. The resale of the Shares by the Investors is being registered for resale on this
registration statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;OvaScience
expects this registration statement to become effective promptly after the closing of the Post-Closing Financing. Following the Merger, the business of Millendo will continue
as the business of the combined organization. Additionally, it has been determined that Millendo will be the accounting acquirer in the Merger, based upon the terms of the Merger Agreement and other
factors including: (i)&nbsp;holders of Millendo stock and other persons holding securities convertible, exercisable or exchangeable directly or indirectly for Millendo Common Stock were initially
estimated to own at least 82% of OvaScience immediately following the Effective Time, (ii)&nbsp;Millendo will hold the majority (seven of eight) of board seats of the combined company and
(iii)&nbsp;Millendo's management will hold all key positions in the management of the combined company. Because of these factors, OvaScience has included herein and has incorporated by reference to
information about the Millendo business and operations in this registration statement. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=187772,FOLIO='blank',FILE='DISK121:[18ZEU1.18ZEU10401]BB10401A.;5',USER='CHE105536',CD=';5-NOV-2018;22:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT COLOR="#FF4040" SIZE=2><B>The information in this prospectus is not complete and may be changed. A registration statement relating to these securities has been filed with the
Securities and Exchange Commission. The selling stockholders may not sell these securities until the Securities and Exchange Commission declares the registration statement effective. This prospectus
is not an offer to sell these securities and the selling stockholders named in this prospectus are not soliciting offers to buy these securities in any state where the offer or sale is not permitted.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT COLOR="#FF4040" SIZE=2><B>Subject to Completion, dated November&nbsp;6, 2018</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Prospectus  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g352623.jpg" ALT="LOGO" WIDTH="309" HEIGHT="117">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>1,886,574 Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> Common Stock  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=4><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The selling stockholders of OvaScience,&nbsp;Inc. ("OvaScience," "we," "us" or the "Company") listed beginning on page 14 may offer and resell up
to 1,886,574 shares of OvaScience common stock, par value $0.001 per share ("OvaScience Common Stock") under this prospectus. The selling stockholders will acquire these shares pursuant to a Stock
Purchase Agreement, dated November&nbsp;1, 2018 (as amended from time to time, the "Purchase Agreement"), by and among OvaScience, Millendo Therapeutics,&nbsp;Inc. ("Millendo") and the investors
listed therein (the "Investors"). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the terms of the Purchase Agreement, the Investors agreed to purchase shares of OvaScience Common Stock. On August&nbsp;9, 2018, the Company announced that it had entered
into an Agreement and Plan of Merger and Reorganization, as may be amended from time to time (the "Merger Agreement"), pursuant to which a wholly owned subsidiary of OvaScience will merge with and
into Millendo, with Millendo surviving as a wholly owned subsidiary of OvaScience (the "Merger"). At the closing of the Merger (the "Effective Time"), each share of Millendo common stock, par value
$0.001 per share ("Millendo Common Stock") (excluding certain shares to be cancelled pursuant to the Merger Agreement, and shares held by stockholders who have exercised and perfected appraisal rights
or dissenters' rights), outstanding immediately prior to the Effective Time will be converted into the right to receive shares of OvaScience Common Stock equal to an exchange ratio, as further
discussed in the Merger Agreement (the "Exchange Ratio"). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the terms of the Purchase Agreement, the Investors agreed to purchase shares of OvaScience Common Stock for an aggregate purchase price of approximately $20.0&nbsp;million
as part of a private placement financing (the "Post-Closing Financing"). The consummation of the Post-Closing Financing and the other transactions contemplated by the Purchase Agreement are
conditioned upon the satisfaction or waiver of the conditions set forth in the Purchase Agreement. OvaScience and the Investors intend to complete the Post-Closing Financing after the Effective Time.
Under the terms of the Post-Closing Financing, the Shares issued in the Post-Closing Financing will be issued pursuant to an
exemption from the registration requirements of the Securities Act of 1933, as amended. The resale of the Shares by the Investors are being registered for resale on this registration statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
selling stockholders (which term as used herein includes their respective donees, transferees or other successors in interest) may sell these shares through public or private
transactions at market prices prevailing at the time of sale or at negotiated prices. We will not receive any proceeds from the sale of the shares by the selling stockholders. In addition, the selling
stockholders may sell or otherwise dispose of the shares of OvaScience Common Stock offered by this prospectus from time to time on terms to be determined at the time of sale through ordinary
brokerage transactions or through any other means described in this prospectus under "Plan of Distribution." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until
October&nbsp;31, 2018, the OvaScience Common Stock was listed on The Nasdaq Global Market under the symbol "OVAS"; effective October&nbsp;31, 2018, the listing of the
OvaScience Common Stock was transferred to The Nasdaq Capital Market under the symbol "OVAS." The last reported sale price of OvaScience Common Stock on November&nbsp;5, 2018 was $0.78 per share. In
connection with the Merger, OvaScience has filed an initial listing application with The Nasdaq Capital Market pursuant to Nasdaq's rules for companies conducting a business combination that results
in a change of control. After completion of the Merger, OvaScience is expected to be renamed "Millendo Therapeutics,&nbsp;Inc." and is expected to trade on The Nasdaq Capital Market under the symbol
"MLND." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
prices at which the selling stockholders may sell all or a portion of the shares will be determined by the prevailing market price for the shares or in negotiated transactions. You
are urged to obtain current market quotations for the OvaScience Common Stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=3><B>Investing in OvaScience Common Stock is highly speculative and involves a significant degree of risk. See "Risk Factors" beginning on
page&nbsp;11 of this prospectus for a discussion of information that should be considered before making a decision to purchase OvaScience Common Stock.</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon
the accuracy or adequacy of the disclosures in this prospectus. Any representation to the contrary is a criminal offense. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>

<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"> <FONT SIZE=2><B>The date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018.</B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=411314,FOLIO='blank',FILE='DISK121:[18ZEU1.18ZEU10401]BC10401A.;18',USER='HYUNG',CD=';6-NOV-2018;14:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bg10401_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="BG10401A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg10401_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<A NAME="BG10401_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="17pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#bi10401_information_incorporated_by_reference"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INFORMATION INCORPORATED BY REFERENCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#bi10401_information_incorporated_by_reference"><FONT SIZE=2>2</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ca10401_prospectus_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROSPECTUS SUMMARY</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ca10401_prospectus_summary"><FONT SIZE=2>4</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cc10401_the_offering"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>THE OFFERING</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc10401_the_offering"><FONT SIZE=2>6</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da10401_description_of_the_merger"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF THE MERGER</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da10401_description_of_the_merger"><FONT SIZE=2>7</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da10401_description_of_the_private_placement"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF THE PRIVATE PLACEMENT</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da10401_description_of_the_private_placement"><FONT SIZE=2>10</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc10401_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc10401_risk_factors"><FONT SIZE=2>11</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc10401_cautionary_note_regarding_forward-looking_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc10401_cautionary_note_regarding_forward-looking_statements"><FONT SIZE=2>12</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc10401_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc10401_use_of_proceeds"><FONT SIZE=2>13</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc10401_selling_stockholders"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SELLING STOCKHOLDERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc10401_selling_stockholders"><FONT SIZE=2>14</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc10401_plan_of_distribution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PLAN OF DISTRIBUTION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc10401_plan_of_distribution"><FONT SIZE=2>16</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc10401_legal_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc10401_legal_matters"><FONT SIZE=2>18</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc10401_experts"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc10401_experts"><FONT SIZE=2>19</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc10401_where_you_can_find_additional_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND ADDITIONAL INFORMATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc10401_where_you_can_find_additional_information"><FONT SIZE=2>20</FONT></A></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg10401_about_this_prospectus"> </A>
<BR></FONT><FONT SIZE=2><B>  ABOUT THIS PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus is part of a registration statement that we have filed with the Securities and Exchange Commission (the "SEC") pursuant to which
the selling stockholders named herein may, from time to time, offer and sell or otherwise dispose of the shares of our common stock covered by this prospectus. You should not assume that the
information contained in this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus or that any information we have incorporated by reference is
correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus is delivered or shares of common stock are sold or otherwise disposed of on a later
date. It is important for you to read and consider all information contained in this prospectus, including the documents incorporated by reference therein, in making your investment decision. You
should also read and consider the information in the documents to which we have referred you under the captions "Where You Can Find Additional Information" and "Information Incorporated by Reference"
in this prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not authorized any dealer, salesman or other person to give any information or to make any representation other than those contained or incorporated by reference in this
prospectus. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus. This prospectus does not constitute an offer to sell or the
solicitation of an offer to buy any of our shares of common stock other than the shares of our common stock covered hereby, nor does this prospectus constitute an offer to sell or the solicitation of
an offer to buy any securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. Persons who come into possession of this prospectus in
jurisdictions outside the United States are required to inform themselves about, and to observe, any restrictions as to the offering and the distribution of this prospectus applicable to those
jurisdictions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
we have indicated otherwise, or the context otherwise requires, references in this prospectus supplement and the accompanying prospectus to "OvaScience," the "Company," "we," "us"
and "our" refer to OvaScience,&nbsp;Inc. and its subsidiaries. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=626573,FOLIO='1',FILE='DISK121:[18ZEU1.18ZEU10401]BG10401A.;9',USER='CHE105545',CD=';6-NOV-2018;02:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bi10401_1_2"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bi10401_information_incorporated_by_reference"> </A>
<A NAME="toc_bi10401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  INFORMATION INCORPORATED BY REFERENCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are allowed to incorporate by reference information contained in documents that we file with the SEC. This means that we can disclose
important information to you by referring you to those documents and that the information in this prospectus is not complete and you should read the information incorporated by reference for more
detail. Information in this prospectus supersedes information incorporated by reference that we filed with the Commission prior to the date of this prospectus, while information that we file later
with the SEC will automatically update and supersede the information in this prospectus. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
incorporate by reference the documents listed below and any future filings we will make with the SEC under Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act
(i)&nbsp;after the date of the initial filing of the registration statement of which this prospectus is a part and prior to effectiveness of such registration statement, and (ii)&nbsp;from the
date of this prospectus but prior to the termination of the
offering of the securities covered by this prospectus (other than Current Reports or portions thereof furnished under Item&nbsp;2.02 or 7.01 of
Form&nbsp;8-K):</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our proxy statement filed on Schedule&nbsp;14A dated November&nbsp;5, 2018 in connection with the Company's special meeting of
stockholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2017; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our proxy statement on Schedule&nbsp;14A filed on April&nbsp;30, 2018 in connection with the Company's annual meeting of stockholders; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our Quarterly Reports on Form&nbsp;10-Q for the quarters ended March&nbsp;31, 2018 and June&nbsp;30, 2018; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our Current Reports on Form&nbsp;8-K and 8-K/A filed with the SEC on January&nbsp;3, 2018, January&nbsp;8, 2018, February&nbsp;1, 2018,
March&nbsp;15, 2018, May&nbsp;3, 2018, June&nbsp;26, 2018, August&nbsp;9, 2018 and November&nbsp;1, 2018 (other than any portions thereof deemed furnished and not filed); and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The description of our common stock set forth in the registration statement on Form&nbsp;8-A registering our common stock under
Section&nbsp;12 of the Exchange Act, which was filed with the Commission on April&nbsp;25, 2013, including any amendments or reports filed for purposes of updating such description. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will provide to each person, including any beneficial owner, to whom a prospectus is delivered, a copy of any or all of the information that is incorporated by reference in this
prospectus but not
delivered with this prospectus, including exhibits that are specifically incorporated by reference in such documents. You may request a copy of such documents, which will be provided to you at no
cost, by writing or telephoning us at the following address or telephone number: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>OvaScience,&nbsp;Inc.<BR>
9 Fourth Avenue<BR>
Waltham, MA 02451<BR>
(617)&nbsp;500-2802<BR>
Attn: Jonathan Gillis </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should rely only on the information incorporated by reference or provided in this prospectus. We have not authorized anyone to provide you with different information. You should not
assume that the information in this prospectus is accurate as of any date other than the date on the front of this document. Any statement contained in a document incorporated in this prospectus will
be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus modifies or supersedes that statement. Any statement that is modified
or superseded will not constitute a part of this prospectus, except as modified or superseded. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=5,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=995652,FOLIO='2',FILE='DISK121:[18ZEU1.18ZEU10401]BI10401A.;7',USER='CHE105536',CD=';5-NOV-2018;23:21' -->
<A NAME="page_bi10401_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Copies
of the documents incorporated by reference may also be found on our website at www.ovascience.com. Except with respect to the documents expressly incorporated by reference above
which are accessible at our website, the information contained on our website is not a part of, and should not be construed as being incorporated by reference into, this prospectus. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
information incorporated herein by reference includes information about Millendo. Following the Effective Time, the business of Millendo will continue as the business of the combined
organization. Additionally, it has been determined that Millendo will be the accounting acquirer in the Merger, based upon the terms of the Merger Agreement and other factors including:
(i)&nbsp;holders of Millendo stock and other persons holding securities convertible, exercisable or exchangeable directly or indirectly for Millendo Common Stock were initially estimated to own at
least 82% of OvaScience immediately following the Effective Time, (ii)&nbsp;Millendo will hold the majority (seven of eight) of board seats of the combined company and (iii)&nbsp;Millendo's
management will hold all key positions in the management of the combined company. Because of these factors, OvaScience has incorporated by reference to information about the Millendo business and
operations into this prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=6,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=627695,FOLIO='3',FILE='DISK121:[18ZEU1.18ZEU10401]BI10401A.;7',USER='CHE105536',CD=';5-NOV-2018;23:21' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ca10401_1_4"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ca10401_prospectus_summary"> </A>
<A NAME="toc_ca10401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This summary description about us and our business highlights selected information contained elsewhere in this prospectus or incorporated by
reference into this prospectus. It does not contain all the information you should consider before investing in our securities. Important information is incorporated by reference into this prospectus.
To understand this offering fully, you should read carefully the entire prospectus, including "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements", together with the additional
information described under "Information Incorporated By Reference". </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ca10401_about_ovascience,_inc.__ca101936"> </A>
<A NAME="toc_ca10401_2"> </A>
<BR></FONT><FONT SIZE=2><B>  ABOUT OVASCIENCE,&nbsp;INC. AND MILLENDO THERAPEUTICS,&nbsp;INC.    <BR>    </B></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


OvaScience,&nbsp;Inc.  </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>OvaScience,&nbsp;Inc.<BR>
9 Fourth Avenue<BR>
Waltham, MA 02451<BR>
(617)&nbsp;500-2802 </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;OvaScience
is a company focused on the discovery and development of new treatment options for women and families struggling with infertility. To date OvaScience has been leveraging the
breakthrough discovery of egg precursor, or EggPC<SUP>SM</SUP>, cells to transform the treatment landscape for women's fertility. OvaScience's operations to date have been limited to organizing and
staffing the company, business planning, raising capital, acquiring and developing our technology, identifying potential fertility treatments, developing the OvaPrime<SUP>SM</SUP> treatment, the
OvaTure<SUP>SM</SUP> treatment and the AUGMENT<SUP>SM</SUP> treatment, introducing AUGMENT in select international in vitro fertilization ("IVF") clinics and determining the regulatory and
development path for OvaScience's fertility treatments. OvaScience has generated limited revenues to date, and does not anticipate significant revenues in the
near term. In June 2017, OvaScience announced that it would continue to focus on advancing OvaPrime in clinical development and OvaTure in preclinical development and would discontinue ongoing efforts
related to the AUGMENT treatment outside of North America. To better align its organization with these strategic priorities, OvaScience restructured its workforce and reduced its workforce by
approximately 50%. On January&nbsp;3, 2018, OvaScience announced a further restructuring of its organization and a workforce reduction of approximately 50%. On May&nbsp;3, 2018, OvaScience
announced that its Board of Directors had approved a corporate restructuring plan furthering its on-going efforts to effectively align its resources. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Millendo Therapeutics,&nbsp;Inc.  </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>Millendo
Therapeutics,&nbsp;Inc.<BR>
301 N. Main Street<BR>
Suite&nbsp;100<BR>
Ann Arbor, MI 48104<BR>
(734)&nbsp;845-9000 </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Millendo
is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. The
endocrine system is a collection of glands that secrete hormones into the blood stream to regulate a number of functions, including appetite, metabolism, growth, development and reproduction. Diseases
of the endocrine system can cause multiple and varied symptoms, including appetite dysregulation, metabolic dysfunction, obesity, cardiovascular disease, menstrual irregularity, excessive facial and
body hair growth, and infertility. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Millendo
is currently advancing two product candidates to treat three indications. Millendo's most advanced product candidate, livoletide (AZP-531), is a potential treatment for
Prader-Willi syndrome, </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=7,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=43699,FOLIO='4',FILE='DISK121:[18ZEU1.18ZEU10401]CA10401A.;9',USER='CHE105536',CD=';5-NOV-2018;23:34' -->
<A NAME="page_ca10401_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;"><FONT SIZE=2>or
PWS, a rare and complex genetic endocrine disease characterized by hyperphagia, or insatiable hunger, that contributes to serious complications, a significant burden on patients and caregivers and
early mortality. In a randomized, double-blind, placebo-controlled Phase&nbsp;2 clinical trial in 47 patients with PWS, Millendo observed that administration of livoletide once daily was associated
with a clinically meaningful improvement in hyperphagia, as well as a reduction in appetite. In a pre-specified analysis of 38 home-resident PWS patients from the Phase&nbsp;2 trial, Millendo
observed a larger and statistically significant decrease in hyperphagia following administration of livoletide as compared to placebo. Millendo expects to initiate a pivotal Phase&nbsp;2b/3 clinical
trial of livoletide in home-resident PWS patients in the first quarter of 2019, with results expected in the first half of 2020. Millendo is also developing nevanimibe (ATR-101) with a primary focus
on treating patients with classic congenital adrenal hyperplasia, or CAH, a rare, monogenic adrenal disease that requires lifelong treatment with exogenous cortisol, often at high doses. These chronic
high doses of cortisol can result in side effects that include diabetes, obesity, hypertension and psychological problems. When on suboptimal doses of cortisol, female CAH patients can experience
male-pattern hair growth, male physical characteristics, infertility and menstrual irregularity, and male CAH patients can experience testicular atrophy, infertility and testicular tumors, making it
difficult for physicians to appropriately treat CAH without causing adverse consequences. Millendo recently reported results from its Phase&nbsp;2 clinical trial of nevanimibe in patients with CAH
and initiated a Phase&nbsp;2b trial in the third quarter of 2018. Millendo is also investigating nevanimibe in a Phase&nbsp;2 clinical trial for the treatment of patients with endogenous Cushing's
syndrome, or CS, a rare endocrine disease characterized by excessive cortisol production from the adrenal glands. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Orion Merger Sub,&nbsp;Inc.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Orion Merger Sub,&nbsp;Inc. ("Merger Sub") is a wholly owned subsidiary of OvaScience, and was formed solely for the purposes of carrying out
the Merger. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recent Events  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On August&nbsp;9, 2018, OvaScience announced that it had entered into an Agreement and Plan of Merger and Reorganization, as may be amended
from time to time with Millendo Therapeutics,&nbsp;Inc. ("Millendo"), pursuant to which Merger Sub will merge with and into Millendo, with Millendo surviving as a wholly owned subsidiary of
OvaScience (the "Merger"). The Shares registered for resale on this registration statement will be sold to the selling stockholders pursuant to a Stock Purchase Agreement, dated November&nbsp;1,
2018 (as amended from time to time, the "Purchase Agreement"), by and among OvaScience, Millendo and the investors listed therein (the "Investors"). Pursuant to the terms of the Purchase Agreement,
the Investors agreed to purchase shares of OvaScience Common Stock for an aggregate purchase price of approximately $20.0&nbsp;million as part of a private placement financing (the "Post-Closing
Financing"). The consummation of the Post-Closing Financing and the other transactions contemplated by the Purchase Agreement are conditioned upon the satisfaction or waiver of the conditions set
forth in the Purchase Agreement. OvaScience and the Investors intend to complete the Post-Closing Financing after the Effective Time. Under the terms of the Post-Closing Financing, the Shares issued
in the Post-Closing Financing will be issued pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended. The resale of the Shares by the Investors are being
registered for resale on this registration statement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;OvaScience was incorporated under the laws of the State of Delaware in April 2011 under the name Ovastem,&nbsp;Inc. and changed its name to
OvaScience,&nbsp;Inc. in May 2011. OvaScience's principal executive offices are located at 9 4th&nbsp;Avenue, Waltham, Massachusetts 02451, and its telephone number is (617)&nbsp;500-2802.
OvaScience's website address is www.ovascience.com. The information contained on, or that can be accessed through, OvaScience's website is not a part of this registration statement. OvaScience has
included OvaScience's website address in this registration statement solely as an inactive textual reference. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=8,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=734033,FOLIO='5',FILE='DISK121:[18ZEU1.18ZEU10401]CA10401A.;9',USER='CHE105536',CD=';5-NOV-2018;23:34' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_cc10401_1_6"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cc10401_the_offering"> </A>
<A NAME="toc_cc10401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  THE OFFERING    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Shares of common stock that may be offered by the selling stockholders</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Up to 1,886,574 shares.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Use of Proceeds</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We will not receive any proceeds from the sale of the common stock by the selling stockholders.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Offering Price</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The selling stockholders may sell all or a portion of their shares through public or private transactions at prevailing
market prices or at privately negotiated prices.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Nasdaq Capital Market symbol</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Until October&nbsp;31, 2018, the OvaScience Common Stock was listed on The Nasdaq Global Market under the symbol "OVAS";
effective October&nbsp;31, 2018, the listing of the OvaScience Common Stock was transferred to The Nasdaq Capital Market under the symbol "OVAS." The last reported sale price of OvaScience Common Stock on November&nbsp;5, 2018 was $0.78&nbsp;per
share.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>OvaScience has filed an initial listing application with The Nasdaq Capital Market pursuant to Nasdaq's rules for companies
conducting a business combination that results in a change of control. After completion of the Merger, OvaScience will be renamed "Millendo Therapeutics,&nbsp;Inc." and expects to trade on The Nasdaq Capital Market under the symbol
"MLND."</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Risk Factors</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Investing in our common stock involves a high degree of risk. See "Risk Factors" below.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=9,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=501041,FOLIO='6',FILE='DISK121:[18ZEU1.18ZEU10401]CC10401A.;6',USER='CHE105536',CD=';5-NOV-2018;23:38' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_da10401_1_7"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da10401_description_of_the_merger"> </A>
<A NAME="toc_da10401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF THE MERGER    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On August&nbsp;9, 2018, OvaScience announced that it had entered into an Agreement and Plan of Merger and Reorganization, as may be amended
from time to time (the "Merger Agreement") with Millendo under which Millendo will merge with OvaScience in an all-stock transaction (the "Merger"). If the Merger is completed, a wholly owned
subsidiary of OvaScience ("Merger Sub") will merge with and into Millendo, with Millendo surviving as a wholly owned subsidiary of OvaScience. In connection with the Merger, holders of OvaScience
stock have been asked to approve an amendment to OvaScience's restated certificate of incorporation effecting a reverse stock split of OvaScience Common Stock at a ratio mutually agreed to between
OvaScience and Millendo in the range of one new share for every 5 to 15 shares outstanding (the "Reverse Stock Split"). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Immediately
prior to closing of the Merger (the "Effective Time"), each share of Millendo preferred stock and Millendo class-1 common stock will be converted into Millendo Common Stock.
At the Effective Time, each share of Millendo's common stock, par value $0.001 per share ("Millendo
Common Stock") outstanding immediately prior to the Effective Time (excluding shares held by stockholders who have exercised and perfected appraisal rights or dissenters' rights, but including shares
of Millendo Common Stock that will be issued pursuant to certain existing Millendo shareholders in a pre-closing private placement of Millendo Common Stock (the "Pre-Closing Financing")) will be
converted into the right to receive a number of shares of OvaScience Common Stock based on an exchange ratio set forth in the Merger Agreement (the "Exchange Ratio"). OvaScience will assume all
outstanding and unexercised options to purchase shares of Millendo Common Stock (each, a "Millendo Option," and each holder of a Millendo Option, a "Millendo Optionholder") and warrants to purchase
Millendo Common Stock, and each such Millendo Options and warrants will be converted into an option or warrant, respectively, to purchase shares of OvaScience Common Stock, with the number of shares
of OvaScience Common Stock subject to such option or warrant and the exercise price being appropriately adjusted to reflect the Exchange Ratio. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
final Exchange Ratio will be determined pursuant to a formula described in more detail in the Merger Agreement. As of the date of the execution of the Merger Agreement, it was
estimated that immediately after the consummation of the Merger, based solely on the sample Exchange Ratio of 0.1173 set forth below, holders of shares of Millendo Common Stock, Millendo Optionholders
and other persons holding securities and rights directly or indirectly convertible, exercisable or exchangeable for Millendo Common Stock (collectively, "Millendo Securityholders") would own
approximately 82% of Fully Diluted Closing OvaScience Common Stock, and holders of shares of OvaScience Common Stock, holders of options to purchase shares of OvaScience Common Stock and other persons
holding securities and rights directly or indirectly convertible, exercisable or exchangeable for OvaScience Common Stock (collectively, "OvaScience Securityholders") would own approximately 18% of
Fully Diluted Closing OvaScience Common Stock (as defined below), subject to adjustment of the Exchange Ratio as set forth in the Merger Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
percentages set forth above assume that the initial estimate of the Exchange Ratio is not changed; however, the Exchange Ratio is subject to change as set forth in the Merger
Agreement. The initial estimate of the Exchange Ratio set forth below assumed (i)&nbsp;that OvaScience would have between $40&nbsp;million and $42&nbsp;million in net cash immediately prior to
Closing, (ii)&nbsp;a Pre-Closing Financing amount of $30.0&nbsp;million, (iii)&nbsp;OvaScience outstanding shares and options as of the Closing would be equal to 3,721,460 (on a post reverse
stock split basis), (iv)&nbsp;Millendo shares as of the Closing would be equal to 148,171,273 (on a fully-diluted, as-converted basis) and (v)&nbsp;a reverse stock split of every 10 shares of
outstanding OvaScience Common Stock being combined and reclassified into one share of OvaScience Common Stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Exchange Ratio is calculated using a formula intended to allocate a percentage of the combined organization to existing Millendo Securityholders. Based on the assumptions described
above, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=10,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=65695,FOLIO='7',FILE='DISK121:[18ZEU1.18ZEU10401]DA10401A.;7',USER='CHE105545',CD=';6-NOV-2018;02:18' -->
<A NAME="page_da10401_1_8"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>the
Exchange Ratio would have been equal to approximately 0.1173 post-reverse split shares of OvaScience Common Stock for each share of Millendo Common Stock, which Exchange Ratio is subject to change
based on the amount of OvaScience net cash, changes in the capitalization of OvaScience or Millendo prior to the Closing and the amount raised by Millendo in the Pre-Closing Financing (and as a
result, OvaScience Securityholders and Millendo Securityholders could own more or less of the combined organization). After the initial signing of the Merger Agreement, the valuations for Millendo and
OvaScience were reduced. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;OvaScience
currently estimates that, assuming for this purpose a closing date of November&nbsp;30, 2018, (i)&nbsp;it will have approximately $37.6&nbsp;million in net cash
immediately prior to Closing, (ii)&nbsp;the Pre-Closing Financing amount will be approximately $29.5&nbsp;million, (iii)&nbsp;OvaScience outstanding shares and options as of the Closing will be
equal to 3,727,669 (on a post reverse stock split basis) and (iv)&nbsp;the Millendo shares as of the Closing on a fully diluted and as-converted basis will be equal to 152,629,595. Accordingly, it
is currently estimated that the Exchange Ratio at Closing will be approximately 0.1070 and, based solely on such Exchange Ratio, at Closing: (a)&nbsp;Millendo Securityholders as of immediately prior
to the Merger (not including the shares issued in the Pre-Closing Financing) will own approximately 67.1% of the Fully Diluted Closing OvaScience Common Stock (as defined below), (b)&nbsp;the shares
issued in the Pre-Closing Financing to Millendo Securityholders as of immediately prior to the Merger will represent approximately 13.1% of the Fully Diluted Closing OvaScience Common Stock,
(c)&nbsp;the OvaScience Securityholders as of immediately prior to the Merger (excluding for this purpose certain out-of-the-money OvaScience Options) will own approximately 18.6% of the Fully
Diluted Closing OvaScience Common Stock, and (d)&nbsp;the shares available for issuance under the Millendo Plan as of immediately prior to the Merger will represent approximately 1.2% of the Fully
Diluted Closing OvaScience Common Stock, in each case, subject to adjustment of the Exchange Ratio as set forth in the Merger Agreement and described herein. Additionally, it is anticipated that the
Post-Closing Financing (as defined below) will close shortly after the Closing, which would dilute, and thereby reduce, each then existing OvaScience Securityholder's proportionate holdings. Assuming
that the Post-Closing Financing closes immediately after the Merger as well as the other aforementioned assumptions, it is expected that (a)&nbsp;Millendo Securityholders as of immediately prior to
the Merger (not including the shares issued in the Pre-Closing Financing) will own approximately 61.7% of the Fully Diluted Post-Financing OvaScience Common Stock (as defined below), (b)&nbsp;the
shares issued in the Pre-Closing Financing to Millendo Securityholders as of immediately prior to the Merger will represent approximately 12.0% of the Fully Diluted Post-Financing OvaScience Common
Stock, (c)&nbsp;the OvaScience Securityholders as of immediately prior to the Merger (excluding for this purpose certain out-of-the-money OvaScience Options) will own approximately 17.1% of the
Fully Diluted Post-Financing OvaScience Common Stock, (d)&nbsp;the shares issued in the Post-Closing Financing to the Post-Closing Financing Investor (as defined below) will represent approximately
8.1% of the Fully Diluted Post-Financing OvaScience Common Stock, and (e)&nbsp;the shares available for issuance under the Millendo Plan as of immediately prior to the Merger will represent
approximately 1.1% of the Fully Diluted Post-Financing OvaScience Common Stock, in each case, subject to adjustment of the Exchange Ratio as set forth in the Merger Agreement and described herein.
"Fully Diluted Closing OvaScience Common Stock" as used herein means (x)&nbsp;Orion Outstanding Shares (as defined in the Merger Agreement, which figure excludes the shares available for issuance
under the 2012 Plan and a portion of the out-of-the-money OvaScience Options) plus (y)&nbsp;Company Outstanding Shares (as defined in the Merger Agreement, which figure includes the shares available
for issuance under the Millendo Plan). "Fully Diluted Post-Financing OvaScience Common Stock" as used herein means (x)&nbsp;Orion Outstanding Shares (as defined in the Merger Agreement, which figure
excludes the shares available
for issuance under the 2012 Plan and a portion of the out-of-the-money OvaScience Options) plus (y)&nbsp;Company Outstanding Shares (as defined in the Merger Agreement, which figure includes the
shares available for issuance under the Millendo Plan) plus (z)&nbsp;the Post-Closing Financing shares. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=11,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=38561,FOLIO='8',FILE='DISK121:[18ZEU1.18ZEU10401]DA10401A.;7',USER='CHE105545',CD=';6-NOV-2018;02:18' -->
<A NAME="page_da10401_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Closing will occur no later than the second business day after the last of the conditions to the Merger has been satisfied or waived (other than those conditions that by their nature
are to be satisfied at the Closing, but subject to the satisfaction or waiver of each such conditions), or at such other time as OvaScience and Millendo agree. OvaScience and Millendo anticipate that
the consummation of the Merger will occur in the fourth quarter of 2018. However, because the Merger is subject to a number of conditions, neither OvaScience nor Millendo can predict exactly when the
Closing will occur or if it will occur at all. After completion of the Merger, assuming that OvaScience receives the required stockholder approval of its proposal to change the name of the company,
OvaScience will be renamed "Millendo Therapeutics,&nbsp;Inc." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
September&nbsp;25, 2018, OvaScience and Millendo entered into the First Amendment to the Merger Agreement (the "First Amendment"). The First Amendment provides, among other things,
that shares of OvaScience Common Stock to be issued in exchange for shares of Millendo Common Stock to be issued in the Pre-Closing Financing would not be registered pursuant to the Registration
Statement on Form&nbsp;S-4, originally filed by OvaScience on September&nbsp;26, 2018. The First Amendment also increased the size of the board of directors of the combined company by one seat.
Further, it provides, among other things, that shares of OvaScience Common Stock to be issued in exchange for shares of Millendo Common Stock to be issued to certain of the investors in the
Pre-Closing Financing that were not previously stockholders of Millendo would be registered pursuant to a separate resale registration statement on Form&nbsp;S-3. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
November&nbsp;1, 2018, OvaScience and Millendo entered into the Second Amendment to the Merger Agreement (the "Second Amendment"). The Second Amendment was proposed by Millendo in
order to lower Millendo's valuation from $191.9&nbsp;million to $155.0&nbsp;million in connection with the Post-Closing Financing. The Second Amendment provides that as a result of the reduction
in Millendo's valuation, the Pre-Closing Financing, including the conversion of any convertible promissory notes issued after the date of the Second Amendment, would be consummated at a price per
share for Millendo Common Stock of not less than $1.2096. The Second Amendment also provides that Millendo's Valuation would equal the sum of $155&nbsp;million plus any proceeds received in the
Pre-Closing Financing, and that OvaScience's Valuation would be lowered to $45.5&nbsp;million, subject to certain adjustments set forth in the Merger Agreement. The Second Amendment additionally
(i)&nbsp;provides that the definition of Millendo outstanding shares used for purposes of the exchange ratio shall include shares of Millendo Common Stock available for issuance under its stock
option plans, (ii)&nbsp;provides for an adjustment to the Company's net cash in connection with certain litigation matters, and (iii)&nbsp;revises the definition of the Company's outstanding lease
obligations with respect to its principal office space. It also revises certain representations and warranties being made by Millendo. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
description of the Merger Agreement is not complete and is qualified in its entirety by reference to Merger Agreement, which has been filed as an annex to our proxy statement on
Schedule&nbsp;14A, filed with the SEC on November&nbsp;5, 2018 and which is incorporated by reference herein. See "Where You Can Find Additional Information" and "Information Incorporated by
Reference." The representations, warranties and covenants made by us in the Merger Agreement were made solely for the benefit of the parties to such agreement, including, in some cases, for the
purpose of allocating risk among the parties thereto, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were made as
of an earlier date. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=12,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=701896,FOLIO='9',FILE='DISK121:[18ZEU1.18ZEU10401]DA10401A.;7',USER='CHE105545',CD=';6-NOV-2018;02:18' -->
<A NAME="page_da10401_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da10401_description_of_the_private_placement"> </A>
<A NAME="toc_da10401_2"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF THE PRIVATE PLACEMENT    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On November&nbsp;1, 2018, OvaScience and Millendo entered into a Stock Purchase Agreement (as may be amended from time to time, the "Purchase
Agreement") with certain investors (the "Investors"), which provided for the sale and issuance of shares (the "Shares") of OvaScience Common Stock (the "Post-Closing Financing") for an aggregate
purchase price of approximately $20&nbsp;million at a per share purchase price of (i)&nbsp;$1.2096 </FONT><FONT SIZE=2><I>divided by</I></FONT><FONT SIZE=2> (ii)&nbsp;the Exchange Ratio. The
consummation of the Post-Closing Financing and the other transactions contemplated by the Purchase Agreement are conditioned upon the satisfaction or waiver of the conditions set forth in the Purchase
Agreement. OvaScience and the Investors intend to complete the Post-Closing Financing after the Effective Time. Under the terms of the Post-Closing Financing, the Shares issued in the Post-Closing
Financing will be issued pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended. The resale of the Shares by the Investors are being registered for
resale on this registration statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concurrently
with the execution of the Purchase Agreement, OvaScience entered into a Registration Rights Agreement (as may be amended from time to time, the "Registration Rights
Agreement") with the Investors, pursuant to which OvaScience agreed to file, as promptly as reasonably possible after the execution of the Registration Rights Agreement, a registration statement (the
"Resale Registration Shelf") with the SEC covering the resale of the shares sold to the Investors in the Post-Closing Financing and to use its reasonable best efforts to have the registration
statement declared effective as promptly as practicable following the filing of the Resale Registration Shelf. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the Registration Rights Agreement, OvaScience also agreed to use its reasonable best efforts to maintain the effectiveness of the Resale Registration Shelf until the earliest of
(a)&nbsp;the date as of which Investors may sell all of their securities covered by the Resale Registration Shelf without restriction pursuant to Rule&nbsp;144 or (b)&nbsp;all Shares covered by
the Resale Registration Shelf otherwise cease to be registrable securities, as defined in the Registration Rights Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
descriptions of the Purchase Agreement and the Registration Agreement are not complete and are qualified in their entirety by reference to the Purchase Agreement and the Registration
Rights Agreement, each of which have been filed as an exhibit to the registration statement of which this prospectus is a part. See "Where You Can Find Additional Information" and "Information
Incorporated by Reference." The representations, warranties and covenants made by us in such agreements were made solely for the benefit of the parties to such agreements, including, in some cases,
for the purpose of allocating risk among the parties thereto, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were
made as of an earlier date. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=13,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=372784,FOLIO='10',FILE='DISK121:[18ZEU1.18ZEU10401]DA10401A.;7',USER='CHE105545',CD=';6-NOV-2018;02:18' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dc10401_1_11"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc10401_risk_factors"> </A>
<A NAME="toc_dc10401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An investment in our common stock involves a high degree of risk. Prior to making a decision about investing in our common stock, you should
carefully consider the risks, uncertainties and assumptions discussed under (i)&nbsp;the section entitled "Risk Factors," in our proxy statement on Schedule&nbsp;14A, filed with the SEC on
November&nbsp;5, 2018 and (ii)&nbsp;Item&nbsp;1A, "Risk Factors," in our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2017 filed with the SEC on
March&nbsp;15, 2018, as updated by our subsequent filings with the SEC under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are incorporated herein by reference,
together with the information in this prospectus and any other information incorporated by reference into this prospectus. See "Where You Can Find Additional Information" and "Information Incorporated
by Reference." Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business, financial condition or results of operations. The
occurrence of any of these known or unknown risks might cause you to lose all or part of your investment in our common stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=14,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=247233,FOLIO='11',FILE='DISK121:[18ZEU1.18ZEU10401]DC10401A.;20',USER='HYUNG',CD=';6-NOV-2018;14:02' -->
<A NAME="page_dc10401_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc10401_cautionary_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_dc10401_2"> </A>
<BR></FONT><FONT SIZE=2><B>  CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This registration statement and the documents incorporated by reference into this registration statement contain forward-looking statements
(including within the meaning of Section&nbsp;21E of the United States Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Section&nbsp;27A of the Securities Act) concerning
OvaScience, Millendo, the proposed Merger and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial
condition, or otherwise, based on current beliefs of the management of OvaScience, as well as assumptions made by, and information currently available to, management. Forward-looking statements
generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan,"
"believe," "intend," "look forward," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any
forward-looking statement as a result of various factors, including, without limitation: the risk that the conditions to the closing of the Merger are not satisfied, including the failure to timely or
at all obtain stockholder approval for the Merger; uncertainties as to the timing of the consummation of the Merger and the ability of each of OvaScience and Millendo to consummate the Merger; risks
and uncertainties as to the ability of the parties to consummate the Post-Closing Financing; risks related to OvaScience's ability to correctly estimate its operating expenses and its expenses
associated with the Merger; risks related to the changes in market price of the OvaScience Common Stock relative to the Exchange Ratio; the ability of OvaScience or Millendo to protect their
respective intellectual property rights; competitive responses to the Merger; unexpected costs, charges or expenses resulting from the Merger; potential adverse reactions or changes to business
relationships resulting from the announcement or completion of the Merger; and legislative, regulatory, political and economic developments. The foregoing review of important factors that could cause
actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere. OvaScience can give no
assurance that the conditions to the Merger will be satisfied. Except as required by applicable law, OvaScience undertakes no obligation to revise or update any forward-looking statement, or to make
any other forward looking statements, whether as a result of new information, future events or otherwise. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
a discussion of the factors that may cause OvaScience, Millendo or the combined organization's actual results, performance or achievements to differ materially from any future
results, performance or achievements expressed or implied in such forward-looking statements, or for a discussion of risks associated with the ability of OvaScience and Millendo to complete the Merger
and the effect of the Merger on the business of OvaScience, Millendo and the combined organization, see (i)&nbsp;the section entitled "Risk Factors," in our proxy statement on Schedule&nbsp;14A,
filed with the SEC on November&nbsp;5,
2018 and (ii)&nbsp;Item&nbsp;1A, "Risk Factors," in our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2017 filed with the SEC on March&nbsp;15, 2018, as updated
by our subsequent filings with the SEC under the Exchange Act. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional
factors that could cause actual results to differ materially from those expressed in the forward-looking statements are discussed in reports filed with the SEC by OvaScience.
See the section titled "</FONT><FONT SIZE=2><I>Where You Can Find More Information</I></FONT><FONT SIZE=2>" in this registration statement. There can be no assurance that the Merger will be
completed, or if it is completed, that it will be completed within the anticipated time period or that the expected benefits of the Merger will be realized. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>If any of these risks or uncertainties materialize or any of these assumptions prove incorrect, the results of operations of OvaScience, Millendo or the combined
organization could differ materially from the forward-looking statements. All forward-looking statements in this registration statement are current only as of the date on which the statements were
made. OvaScience and Millendo do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any statement is made, the
occurrence of unanticipated events or any new information that becomes available in the future.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=15,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=807156,FOLIO='12',FILE='DISK121:[18ZEU1.18ZEU10401]DC10401A.;20',USER='HYUNG',CD=';6-NOV-2018;14:02' -->
<A NAME="page_dc10401_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc10401_use_of_proceeds"> </A>
<A NAME="toc_dc10401_3"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will not receive any of the proceeds from the sale of the common stock by the selling stockholders named in this prospectus. All proceeds
from the resale of the shares of our common stock offered by this prospectus will belong to the selling stockholders identified in this prospectus under "Selling Stockholders." </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=16,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=779612,FOLIO='13',FILE='DISK121:[18ZEU1.18ZEU10401]DC10401A.;20',USER='HYUNG',CD=';6-NOV-2018;14:02' -->
<A NAME="page_dc10401_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc10401_selling_stockholders"> </A>
<A NAME="toc_dc10401_4"> </A>
<BR></FONT><FONT SIZE=2><B>  SELLING STOCKHOLDERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus covers the resale by the selling stockholders identified below of up to 1,886,574 shares of our common stock that will be issued
to the selling stockholders. The selling stockholders will acquire our securities pursuant to the Post-Closing Financing following the closing of the Merger. See "Prospectus
Summary&#151;Description of the Merger" and "Prospectus Summary&#151;Description of the Private Placement." We will not receive any proceeds from the resale of the common stock by the
selling stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
our knowledge, none of the selling stockholders has been an officer or director of ours or any of our predecessors or affiliates within the past three years and no selling stockholder
had a material relationship with OvaScience or any of its affiliates within the last three years. Our knowledge is based on information provided by the selling stockholders in connection with the
filing of this prospectus, as well as information obtained from relevant Schedule&nbsp;13D and 13G filings. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
shares registered for resale on this registration statement will be sold to the selling stockholders under the Purchase Agreement, pursuant to which the Investors agreed to purchase
shares of OvaScience Common Stock following the closing of the Merger. The table below sets forth information, to our knowledge, for the selling stockholders and other information regarding the
beneficial ownership (as determined under Section&nbsp;13(d) of the Exchange Act and the rules and regulations thereunder) of the shares of OvaScience Common Stock that would be held by the selling
stockholders, assuming the closing of the Merger occurred on November&nbsp;30, 2018. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
percentage of ownership is based on 18,859,542 shares of OvaScience Common Stock expected to be outstanding upon the Closing, including the effect of the Reverse Stock Split, if
approved and implemented at a 1:10&nbsp;ratio, and the Pre-Closing Financing, adjusted as required by the rules promulgated by the SEC to determine beneficial ownership. The following table and the
related notes assume that, at the Effective Time, each share of Millendo Common Stock will convert into the right to receive 0.1070 post-Reverse Stock Split shares of OvaScience Common Stock (which is
the current estimate of the Exchange Ratio and is subject to change as described elsewhere in this prospectus) and to account for the occurrence of certain events. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
table and footnotes assume that the selling stockholders will sell all of the shares listed. However, because the selling stockholders may sell all or some of their shares under this
prospectus from time to time, or in another permitted manner, we cannot assure you as to the actual number of shares that will be sold by the selling stockholders or that will be held by the selling
stockholders after completion of any sales. We do not know how long the selling stockholders will hold the shares before selling them. The inclusion of any shares in this table does not constitute an
admission of beneficial ownership by the persons named below. The selling stockholders listed below are sorted alphabetically by first name. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Information
about the selling stockholders may change over time. Any changed information will be set forth in an amendment to the registration statement or supplement to this prospectus,
to the extent required by law. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares Beneficially<BR>
Owned as of the date of<BR>
this Prospectus </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares Beneficially<BR>
Owned After the<BR>
Offering(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares<BR>
Offered by<BR>
this<BR>
Prospectus </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of Selling Stockholder

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percent(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percent(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Great Point Partners,&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,769,179</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,886,574</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Less
than 1%. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=17,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=815106,FOLIO='14',FILE='DISK121:[18ZEU1.18ZEU10401]DC10401A.;20',USER='HYUNG',CD=';6-NOV-2018;14:02' -->
<A NAME="page_dc10401_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Applicable
percentage ownership is based on 18,859,542 shares of our common stock outstanding as of November&nbsp;30, 2018, which includes shares expected to be
issued by Millendo as part of the Pre-Closing Financing and by OvaScience in the Post-Closing Financing.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Assumes
the sale of all shares offered pursuant to this prospectus.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
number of shares offered for resale by this Prospectus is based on an estimated Exchange Ratio of 0.1141, which accounts for potential reductions in OvaScience
cash. Currently, the Exchange Ratio is estimated to be 0.1070, which Exchange Ratio is subject to change as described elsewhere in this Prospectus.  </FONT></DD></DL>
 </DIV>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=18,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=860471,FOLIO='15',FILE='DISK121:[18ZEU1.18ZEU10401]DC10401A.;20',USER='HYUNG',CD=';6-NOV-2018;14:02' -->
<A NAME="page_dc10401_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc10401_plan_of_distribution"> </A>
<A NAME="toc_dc10401_5"> </A>
<BR></FONT><FONT SIZE=2><B>  PLAN OF DISTRIBUTION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The selling stockholders, which as used herein includes donees, pledgees, transferees or other successors-in-interest selling shares of common
stock or interests in shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer, may, from time to
time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are
traded or in private transactions. These
dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at
negotiated prices. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
selling stockholders may use any one or more of the following methods when disposing of shares or interests therein:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as
principal to facilitate the transaction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an exchange distribution in accordance with the rules of the applicable exchange; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> privately negotiated transactions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> short sales effected after the date the registration statement of which this Prospectus is a part is declared effective by the SEC; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a combination of any such methods of sale; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any other method permitted by applicable law. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
selling stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of
their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under
Rule&nbsp;424(b)(3) or other applicable provision of the Securities Act amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling
stockholders under this prospectus. The selling stockholders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in
interest will be the selling beneficial owners for purposes of this prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the sale of our common stock or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions,
which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of our common stock short and deliver
these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or
other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial
institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such
transaction). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=19,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=303306,FOLIO='16',FILE='DISK121:[18ZEU1.18ZEU10401]DC10401A.;20',USER='HYUNG',CD=';6-NOV-2018;14:02' -->
<A NAME="page_dc10401_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or commissions, if any.
Each of the selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made
directly or through agents. We will not receive any of the proceeds from this offering. Upon any exercise of the warrants by payment of cash, however, we will receive the exercise price of the
warrants. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
selling stockholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule&nbsp;144 under the Securities Act of 1933, provided that they
meet the criteria and conform to the requirements of that rule. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
selling stockholders and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be "underwriters" within the meaning of
Section&nbsp;2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities
Act. Selling stockholders who are "underwriters" within the meaning of Section&nbsp;2(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent required, the shares of our common stock to be sold, the names of the selling stockholders, the respective purchase prices and public offering prices, the names of any
agents, dealer or underwriter, any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a
post-effective amendment to the registration statement that includes this prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In
addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is
complied with. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have advised the selling stockholders that the anti-manipulation rules of Regulation&nbsp;M under the Exchange Act may apply to sales of shares in the market and to the activities
of the selling stockholders and their affiliates. In addition, to the extent applicable we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the
selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates in
transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will pay all expenses of the registration of the shares of common stock pursuant to the registration rights agreement, including, without limitation, Securities and Exchange
Commission filing fees and expenses of compliance with state securities or "blue sky" laws; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT> <FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that each selling stockholder will pay all
underwriting discounts and selling commissions, if any and any related legal expenses incurred by
it. We will indemnify the selling stockholders against certain liabilities, including some liabilities under the Securities Act, in accordance with the registration rights agreement, or the selling
stockholders will be entitled to contribution. We may be indemnified by the selling stockholders against civil liabilities, including liabilities under the Securities Act, that may arise from any
written information furnished to us by the selling stockholders specifically for use in this prospectus, in accordance with the related registration rights agreement, or we may be entitled to
contribution. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have agreed with the selling stockholders to keep the registration statement of which this prospectus constitutes a part effective until the earlier of (1)&nbsp;such time as all of
the shares covered by this prospectus have been disposed of pursuant to and in accordance with the registration statement or (2)&nbsp;the date on which all of the shares may be sold without
restriction pursuant to Rule&nbsp;144 of the Securities Act. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=20,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=195337,FOLIO='17',FILE='DISK121:[18ZEU1.18ZEU10401]DC10401A.;20',USER='HYUNG',CD=';6-NOV-2018;14:02' -->
<A NAME="page_dc10401_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc10401_legal_matters"> </A>
<A NAME="toc_dc10401_6"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The validity of the shares of common stock offered in this prospectus has been passed upon for us by Mintz, Levin, Cohn, Ferris, Glovsky and
Popeo, P.C., Boston, Massachusetts. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=21,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=64165,FOLIO='18',FILE='DISK121:[18ZEU1.18ZEU10401]DC10401A.;20',USER='HYUNG',CD=';6-NOV-2018;14:02' -->
<A NAME="page_dc10401_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc10401_experts"> </A>
<A NAME="toc_dc10401_7"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The consolidated financial statements of OvaScience, Inc. appearing in OvaScience, Inc.'s Annual Report (Form&nbsp;10-K) for the year ended
December&nbsp;31, 2017, have been audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein
by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
consolidated financial statements of Millendo Therapeutics,&nbsp;Inc. as of December&nbsp;31, 2017 and 2016 and for each of the years then ended that are incorporated by
reference in this prospectus and elsewhere in this registration statement have been audited by Ernst&nbsp;&amp; Young&nbsp;LLP, independent auditors, as set forth in their report thereon (which
contains an explanatory paragraph describing conditions that raise substantial doubt about the Company's ability to continue as a going concern as described in Note&nbsp;1 to the consolidated
financial statements), included therein, and incorporated herein by reference. Such financial statements are incorporated herein in reliance upon such report given on the authority of such firm as
experts in accounting and auditing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
financial statements of Millendo Therapeutics SAS, which comprise the balance sheet as of December&nbsp;31, 2016 and the related statements of income and cash flows for the year
then ended, and the balance sheet as of December&nbsp;19, 2017 and the related statements of income and cash flows for the period from January&nbsp;1 to December&nbsp;19, 2017, and the related
notes to the financial statements that are incorporated by reference in this prospectus and elsewhere in this registration statement have been audited by RSM Rh&ocirc;ne-Alpes, as set forth
in their report thereon, included therein, and incorporated herein by reference. Such financial statements are incorporated by reference herein in reliance upon such report given on the authority of
such firm as experts in accounting and auditing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=22,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=236449,FOLIO='19',FILE='DISK121:[18ZEU1.18ZEU10401]DC10401A.;20',USER='HYUNG',CD=';6-NOV-2018;14:02' -->
<A NAME="page_dc10401_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc10401_where_you_can_find_additional_information"> </A>
<A NAME="toc_dc10401_8"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND ADDITIONAL INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to the information requirements of the Exchange Act and we therefore file periodic reports, proxy statements and other
information with the SEC relating to our business, financial statements and other matters. The reports, proxy statements and other information we file may be inspected and copied at prescribed rates
at the SEC's Public Reference Room located at 100&nbsp;F Street, N.E., Washington, D.C. 20549. You may obtain information on the operation of the SEC's Public Reference Room by calling the SEC at
1-800-SEC-0330. The SEC also maintains web site that contains reports, proxy and information statements and other information regarding issuers like us that file electronically with the SEC. The
address of the SEC's web site is http://www.sec.gov. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus constitutes part of a registration statement filed under the Securities Act with respect to the shares of common stock covered hereby. As permitted by the SEC's rules,
this prospectus omits some of the information, exhibits and undertakings included in the registration statement. You may read and copy the information omitted from this prospectus but contained in the
registration statement, as well as the periodic reports and other information we file with the SEC, at the public reference room and web site of the SEC referred to above. You may also access our
filings with the SEC on our web site, which is located at http://www.ovascience.com. The information contained on our web site is not part of this prospectus. We have included our website address in
this prospectus solely as an inactive textual reference. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Statements
contained in this prospectus as to the contents of any contract or other document are not necessarily complete, and in each instance we refer you to the copy of the contract
or other document filed or incorporated by reference as an exhibit to the registration statement or as an exhibit to our Exchange Act filings, each such statement being qualified in all respects by
such reference. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=23,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=799564,FOLIO='20',FILE='DISK121:[18ZEU1.18ZEU10401]DC10401A.;20',USER='HYUNG',CD=';6-NOV-2018;14:02' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>1,886,574 Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> Common Stock  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=4><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>PROSPECTUS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=3><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>

<P style="font-family:times;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=24,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=904887,FOLIO='blank',FILE='DISK121:[18ZEU1.18ZEU10401]HO10401A.;7',USER='CHE105536',CD=';5-NOV-2018;23:43' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ja10401_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ja10401_part_ii_information_not_required_in_prospectus"> </A>
<A NAME="toc_ja10401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PART II<BR>  <BR>    INFORMATION NOT REQUIRED IN PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja10401_item_14._other_expenses_of_issuance_and_distribution"> </A>
<A NAME="toc_ja10401_2"> </A></FONT> <FONT SIZE=2><B>  ITEM 14.&nbsp;&nbsp;&nbsp;&nbsp;OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth the fees and expenses incurred and to be incurred in connection with the registration of the securities being
registered hereby, all of which will be borne by us. Except for the SEC registration fee, all amounts are estimates. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SEC Registration Fee</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>176.07</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounting Fees and Expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,000.00</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal Fees and Expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,000.00</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Printing Expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,000.00</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Miscellaneous Fees and Expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,823.93</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>70,000.00</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><A
NAME="ja10401_item_15._indemnification_of_officers_and_directors"> </A>
<A NAME="toc_ja10401_3"> </A></FONT> <FONT SIZE=2><B>  ITEM 15.&nbsp;&nbsp;&nbsp;&nbsp;INDEMNIFICATION OF OFFICERS AND DIRECTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subsection&nbsp;(a) of Section&nbsp;145 of the General Corporation Law of the State of Delaware ("DGCL"), empowers a
corporation to indemnify any person who was or is a party or who is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal,
administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation,
or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses
(including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in
good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable
cause to believe the person's conduct was unlawful. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subsection&nbsp;(b)
of Section&nbsp;145 empowers a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or
completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person acted
in any of the capacities set forth above, against expenses (including attorneys' fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or
suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made in
respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which
such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably
entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;145
further provides that to the extent a director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or
proceeding referred to in subsections&nbsp;(a) and (b)&nbsp;of Section&nbsp;145, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including
attorneys' fees) actually and reasonably incurred by such person in connection therewith; that indemnification provided for by Section&nbsp;145 shall not be deemed exclusive of any other rights to
which the indemnified party may be entitled; and the indemnification provided for by Section&nbsp;145 shall, unless otherwise provided when authorized or ratified, continue as to a person who has
ceased to be a director, officer, employee or agent and shall inure to the benefit of such person's heirs, executors and administrators. Section&nbsp;145 also empowers the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=25,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=1028393,FOLIO='II-1',FILE='DISK121:[18ZEU1.18ZEU10401]JA10401A.;9',USER='HYUNG',CD=';6-NOV-2018;14:05' -->
<A NAME="page_ja10401_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>corporation
to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person
in any such capacity, or arising out of his status as such, whether or not the corporation would have the power to indemnify such person against such liabilities under Section&nbsp;145. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;102(b)(7)
of the DGCL provides that a corporation's certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director to
the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director
(i)&nbsp;for any breach of the director's duty of loyalty to the corporation or its stockholders, (ii)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a
knowing violation of law, (iii)&nbsp;under Section&nbsp;174 of the DGCL or (iv)&nbsp;for any transaction from which the director derived an improper personal benefit. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;OvaScience's
restated certificate of incorporation provides that OvaScience shall indemnify and advance expenses to each person who was or is a party or threatened to be made a party to
any threatened, pending or completed action, suit or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact that he or she is or was, or has agreed to become, a
director or officer of OvaScience, or is or was serving, or has agreed to serve, at the request of OvaScience, as a director,
officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been
taken or omitted in such capacity, against all expenses (including attorneys' fees), liabilities, losses, judgments, fines, and amounts paid in settlement actually and reasonably incurred in
connection with such action, suit or proceeding and any appeal therefrom. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;OvaScience
has indemnification agreements with its directors, in addition to the indemnification provided for in its restated certificate of incorporation, and intends to enter into
indemnification agreements with any new directors in the future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;OvaScience
has purchased and intends to maintain insurance on behalf of any person who is or was a director or officer of OvaScience against any loss arising from any claim asserted
against him or her and incurred by him or her in any such capacity, subject to certain exclusions. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the terms of the Merger Agreement and subject to applicable law, from the Effective Time through the sixth anniversary of the date on which the Effective Time occurs,
OvaScience shall indemnify and hold harmless each person who is now, or has been at any time prior to the date thereof, or who becomes prior to the Effective Time, a director or officer of OvaScience
or Millendo, respectively, against all Costs incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of
or pertaining to the fact that such person is or was a director or officer of OvaScience or Millendo, whether asserted or claimed prior to, at or after the Effective Time, in each case, to the fullest
extent permitted under the DGCL for directors or officers of Delaware corporations, provided that such officer or director acted in good faith and in a manner such party reasonable believed to be in
or not opposed to the best interest of OvaScience or the Surviving Corporation, as applicable, and, with respect to any criminal proceeding, such officer or director had no reasonable cause to believe
such conducted was unlawful; provided, further, that, if applicable law so provides, no indemnification against such Costs shall be made in respect of any claim, issue or matter in such proceeding as
to which the director or officer shall have been adjudged to be liable to OvaScience or the Surviving Corporation unless and to the extent that the Court of Chancery of the State of Delaware shall
determine that such indemnification may be made. Subject to applicable law, each such director and officer will be entitled to advancement of expenses incurred in the defense of any such claim,
action, suit, proceeding or investigation from each of OvaScience and the Surviving Corporation, jointly and severally, upon receipt by OvaScience or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=26,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=455130,FOLIO='II-2',FILE='DISK121:[18ZEU1.18ZEU10401]JA10401A.;9',USER='HYUNG',CD=';6-NOV-2018;14:05' -->
<A NAME="page_ja10401_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>the
Surviving Corporation from such director or officer of a request therefor; provided that any such person to whom expenses are advanced provides an undertaking to OvaScience or the Surviving
Corporation, as applicable, to the extent then required by the DGCL, to repay such advances if it is ultimately determined that such person is not entitled to indemnification. Such statement or
statements shall reasonably evidence the expenses incurred by the directors and officers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further,
pursuant to the Merger Agreement, the provisions of the OvaScience restated certificate of incorporation and the OvaScience by-laws with respect to indemnification, advancement
of expenses and exculpation of present and former directors and officers of OvaScience shall not be amended, modified or repealed for a period of six years from the Effective Time in a manner that
would adversely affect the rights thereunder of individuals who, at or prior to the Effective Time, were officers or directors of OvaScience, unless such modification is required by applicable law. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
and after the Effective Time, (i)&nbsp;the Surviving Corporation shall fulfill and honor in all respects the obligations of Millendo to each person who is or has served as a
director or officer of Millendo as of immediately prior to the Closing pursuant to any indemnification provisions under the Millendo certificate of incorporation or Millendo bylaws and pursuant to any
indemnification agreements between Millendo and such directors and officers, with respect to claims arising out of matters occurring at or prior to the Effective Time and (ii)&nbsp;OvaScience shall
fulfill and honor in all respects the obligations of OvaScience to each person who is or has served as a director or officer of OvaScience as of immediately prior to the Closing pursuant to any
indemnification provisions under the OvaScience Charter or OvaScience Bylaws and pursuant to any indemnification agreements between OvaScience and such directors and officers that were in effect prior
to the date of the Merger Agreement, with respect to claims arising out of matters occurring at or prior to the Effective Time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Merger Agreement also provides that OvaScience shall maintain directors' and officers' liability insurance policies commencing at the closing time of the Merger, on commercially
available terms and conditions with coverage limits customary for U.S. public companies similar situated to OvaScience. In addition, OvaScience shall purchase, prior to the Effective Time, a six-year
prepaid "D&amp;O tail policy" for the non-cancellable extension of the directors' and officers' liability coverage of OvaScience's existing directors' and officers' insurance policies and OvaScience's
existing fiduciary liability insurance policies, in each case, for a claims reporting or discovery period of at least six years from and after the Effective Time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
and after the Effective Time, OvaScience shall pay all expenses, including reasonable attorneys' fees, that are incurred by indemnified persons in connection with their successful
enforcement of the rights provided to such persons in the Merger Agreement. The director and officer indemnification provisions of the Merger Agreement are intended to be in addition to the rights
otherwise available to the current and former officers and directors of OvaScience and Millendo by law, charter, statute, bylaw or agreement, and shall operate for the benefit of, and shall be
enforceable by, each of such indemnified persons, their heirs and their representatives. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event OvaScience or the Surviving Corporation or any of their respective successors or assigns (i)&nbsp;consolidates with or merges into any other person and shall not be the
continuing or surviving corporation or entity of such consolidation or merger, or (ii)&nbsp;transfers all or substantially all of its properties and assets to any person, then, and in each such
case, proper provision shall be made so that the successors and assigns of OvaScience or the Surviving Corporation, as the case may be, shall succeed to the indemnification obligations set forth in
the Merger Agreement. OvaScience shall cause the Surviving Corporation to perform all of the director and officer indemnification obligations of the Surviving Corporation under the Merger Agreement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=27,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=554092,FOLIO='II-3',FILE='DISK121:[18ZEU1.18ZEU10401]JA10401A.;9',USER='HYUNG',CD=';6-NOV-2018;14:05' -->
<A NAME="page_ja10401_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja10401_item_16._exhibits_and_financial_statement_schedules"> </A>
<A NAME="toc_ja10401_4"> </A></FONT> <FONT SIZE=2><B>  ITEM 16.&nbsp;&nbsp;&nbsp;&nbsp;EXHIBITS AND FINANCIAL STATEMENT SCHEDULES    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A list of exhibits filed herewith is contained in the exhibit index that immediately precedes such exhibits and is incorporated herein by
reference.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja10401_item_17._undertakings"> </A>
<A NAME="toc_ja10401_5"> </A></FONT> <FONT SIZE=2><B>  ITEM 17.&nbsp;&nbsp;&nbsp;&nbsp;UNDERTAKINGS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned registrant hereby undertakes: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;To
file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act of 1933;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment
thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in
volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering
range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule&nbsp;424(b) if, in the aggregate, the changes in volume and price represent no
more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(iii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such
information in the registration statement; </FONT></DD></DL>
</UL>
</UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>Provided
however, that paragraphs&nbsp;(1)(i), (1)(ii) and (1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is
contained in reports filed with or furnished to the Commission by the registrant pursuant to section&nbsp;13 or section&nbsp;15(d) of the Securities Exchange Act of 1934 that are incorporated by
reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule&nbsp;424(b) that is part of the registration statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;That,
for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;&nbsp;&nbsp;To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;&nbsp;&nbsp;That,
for the purpose of determining liability under the Securities Act of 1933 to any purchaser: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>If
the registrant is relying on Rule&nbsp;430B:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(A)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Each
prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(3) shall be deemed to be part of the registration statement as of the date the filed
prospectus was deemed part of and included in the registration statement; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(B)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Each
prospectus required to be filed pursuant to Rule&nbsp;424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule&nbsp;430B
relating to an offering made pursuant to Rule&nbsp;415(a)(1)(i), (vii), or (x)&nbsp;for the purpose of providing the </FONT></DD></DL>
</DD></DL>
</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=28,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=478943,FOLIO='II-4',FILE='DISK121:[18ZEU1.18ZEU10401]JA10401A.;9',USER='HYUNG',CD=';6-NOV-2018;14:05' -->
<A NAME="page_ja10401_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>information
required by Section&nbsp;10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of
prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule&nbsp;430B, for liability
purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the
registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no
statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration
statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made
in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; or  </FONT></P>

</UL>
</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>If
the registrant is subject to Rule&nbsp;430C, each prospectus filed pursuant to Rule&nbsp;424(b) as part of a registration statement relating to an offering,
other than registration statements relying on Rule&nbsp;430B or other than prospectuses filed in reliance on Rule&nbsp;430A, shall be deemed to be part of and included in the registration
statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in
a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of
sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document
immediately prior to such date of first use. </FONT></DD></DL>
</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant to
section&nbsp;13(a) or section&nbsp;15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section&nbsp;15(d) of
the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and
the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the
foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the
Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a
director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by a director, officer or controlling person in connection with the
securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question
whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=29,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=306033,FOLIO='II-5',FILE='DISK121:[18ZEU1.18ZEU10401]JA10401A.;9',USER='HYUNG',CD=';6-NOV-2018;14:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_jc10401_1_6"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="jc10401_exhibit_index"> </A>
<A NAME="toc_jc10401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXHIBIT INDEX    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following exhibits are filed as part of this Registration Statement: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1544227/000104746918006980/a2236886zs-4a.htm">Agreement and Plan of Merger and Reorganization, dated as of August&nbsp;8, 2018, by and among OvaScience,&nbsp;Inc., Orion
Merger Sub,&nbsp;Inc. and Millendo Therapeutics,&nbsp;Inc. (incorporated by reference from Annex A to Amendment No. 1 to the Registration Statement on Form&nbsp;S-4, as filed with the Securities and Exchange Commission on November&nbsp;1, 2018, File
No. 333-227547)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>2.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1544227/000104746918006980/a2236886zs-4a.htm">First Amendment to Agreement and Plan of Merger and Reorganization, dated as of August&nbsp;8, 2018, by and among
OvaScience,&nbsp;Inc., Orion Merger Sub,&nbsp;Inc. and Millendo Therapeutics,&nbsp;Inc. (incorporated by reference from Annex A to Amendment No. 1 to the Registration Statement on Form&nbsp;S-4, as filed with the Securities and Exchange Commission on
November&nbsp;1, 2018, File No. 333-227547)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>2.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1544227/000104746918006980/a2236886zs-4a.htm">Second Amendment to Agreement and Plan of Merger and Reorganization, dated as of August&nbsp;8, 2018, by and among
OvaScience,&nbsp;Inc., Orion Merger Sub,&nbsp;Inc. and Millendo Therapeutics,&nbsp;Inc. (incorporated by reference from Annex A to Amendment No. 1 to the Registration Statement on Form&nbsp;S-4, as filed with the Securities and Exchange Commission on
November&nbsp;1, 2018, File No. 333-227547)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1544227/000110465913035188/a13-10863_1ex3d1.htm">Restated Certificate of Incorporation of OvaScience,&nbsp;Inc. (incorporated by reference from the Current Report on
Form&nbsp;8-K filed by the Registrant on April&nbsp;30, 2013, File&nbsp;No.&nbsp;001-35890)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1544227/000110465918050995/a18-18482_1ex3d1.htm">Third Amended and Restated Bylaws, as amended, of OvaScience,&nbsp;Inc. (incorporated by reference from the Current
Report on Form&nbsp;8-K filed by the Registrant on August&nbsp;9, 2018, File No. 001-35890).</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1544227/000104746912008575/a2210793zex-4_1.htm">Specimen Stock Certificate evidencing shares of Common Stock of OvaScience,&nbsp;Inc. (incorporated by reference to the
Registration Statement on Form&nbsp;S-1 filed by the registrant on August&nbsp;29, 2012, File No. 333-183602)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1544227/000104746918006980/a2236886zex-10_46.htm">Registration Rights Agreement, dated November&nbsp;1, 2018, by and among OvaScience, Inc. and the persons listed on
Schedule A thereto (incorporated by reference from Exhibit&nbsp;10.46 to Amendment No.&nbsp;1 to the Registration Statement on Form S-4, as filed with the Securities and Exchange Commission on November 1, 2018, File
No.&nbsp;333-227547).</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1544227/000104746918006980/a2236886zex-10_45.htm">Stock Purchase Agreement, dated November&nbsp;1, 2018, by and among OvaScience, Inc., the purchasers set forth on
Schedule I thereto and Millendo Therapeutics, Inc. (incorporated by reference from Exhibit&nbsp;10.45 to Amendment No.&nbsp;1 to the Registration Statement on Form&nbsp;S-4, as filed with the Securities and Exchange Commission on November&nbsp;1,
2018, File&nbsp;No.&nbsp;333-227547).</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>*</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2237017zex-4_6.htm">Second Amended and Restated Investor Rights Agreement by and among Millendo Therapeutics,&nbsp;Inc. and certain of its stockholders, dated December&nbsp;19, 2017.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>*</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2237017zex-4_7.htm">First Amendment to Second Amended and Restated Investor Rights Agreement, dated October&nbsp;24, 2018.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>*</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2237017zex-4_8.htm">Shareholders and Option Agreement, by and between Millendo Therapeutics,&nbsp;Inc. and Otonnale SAS, dated December&nbsp;19, 2017.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>*</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2237017zex-4_9.htm">First Amendment to Shareholders and Option Agreement, dated September&nbsp;28, 2018.</A></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=30,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=889943,FOLIO='II-6',FILE='DISK121:[18ZEU1.18ZEU10401]JC10401A.;15',USER='HYUNG',CD=';6-NOV-2018;14:19' -->
<A NAME="page_jc10401_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="a2237017zex-5_1.htm">Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. regarding the validity of the securities.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>*</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2237017zex-10_1.htm">Lease Agreement, by and between Millendo Therapeutics,&nbsp;Inc. and 301 N. Main Street, L.L.C., dated December&nbsp;31, 2015.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>*</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2237017zex-10_2.htm">Lease Extension and Modification Agreement, by and between Millendo Therapeutics,&nbsp;Inc. and 301 N. Main Street, L.L.C., dated November&nbsp;30, 2017.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>*</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2237017zex-10_3.htm">Lease Extension and Modification Agreement, by and between Millendo Therapeutics,&nbsp;Inc. and 301 N. Main Street, L.L.C., dated October&nbsp;22, 2018.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>*#</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2237017zex-10_4.htm">Amendment No.&nbsp;1 to the Atterocor,&nbsp;Inc. (n/k/a Millendo Therapeutics,&nbsp;Inc.) 2012 Stock Plan, dated December 17, 2015.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>*#</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2237017zex-10_5.htm">Millendo Therapeutics,&nbsp;Inc. Amendment to 2012 Stock Plan, dated June&nbsp;21, 2018.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>23.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>*</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2237017zex-23_1.htm">Consent of Ernst&nbsp;&amp; Young&nbsp;LLP, Independent Registered Public Accounting Firm to OvaScience,&nbsp;Inc.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>23.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>*</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2237017zex-23_2.htm">Consent of Ernst&nbsp;&amp; Young&nbsp;LLP, Independent Auditors to Millendo Therapeutics,&nbsp;Inc.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>23.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>*</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2237017zex-23_3.htm">Consent of RSM Rh&ocirc;ne-Alpes, Independent Auditors to Millendo Therapeutics SAS</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>23.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>*</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2237017zex-5_1.htm">Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit&nbsp;5.1)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>24.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="#POA">Power of Attorney (included on the signature page of this Registration Statement)</A></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Filed
herewith.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>#</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Indicates
a management contract or compensatory plan, contract or arrangement.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=31,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=804471,FOLIO='II-7',FILE='DISK121:[18ZEU1.18ZEU10401]JC10401A.;15',USER='HYUNG',CD=';6-NOV-2018;14:19' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_je10401_1_8"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="POA"></A>SIGNATURES  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that
it meets all of the requirements for filing on Form&nbsp;S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of
Waltham, Commonwealth of Massachusetts, on the 6th day of November, 2018. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="279pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><B> OvaScience,&nbsp;Inc.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>  By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;CHRISTOPHER&nbsp;A.&nbsp;KROEGER,&nbsp;M.D.,&nbsp;M.B.A.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Christopher A. Kroeger, M.D., M.B.A.<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="je10401_power_of_attorney"> </A>
<A NAME="toc_je10401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  POWER OF ATTORNEY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each person whose signature appears below hereby constitutes and appoints Christopher A. Kroeger, M.D., M.B.A. and Jonathan Gillis, and each of
them, as his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all
amendments (including post-effective amendments and registration statements filed pursuant to Rule&nbsp;462) to this registration statement, and to file the same, with all exhibits thereto, and
other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every act and
thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact
and agent or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form&nbsp;S-3 has been signed by the following persons in the capacities and on
the dates indicated. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="202pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="105pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Date


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>/s/&nbsp;CHRISTOPHER&nbsp;A.&nbsp;KROEGER,&nbsp;M.D.,&nbsp;M.B.A.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Christopher A. Kroeger, M.D., M.B.A.</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>President and Chief Executive Officer (Principal Executive Officer)</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>November&nbsp;6, 2018</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;JONATHAN GILLIS<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Jonathan Gillis</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Senior Vice President, Finance (Principal Financial Officer)</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>November&nbsp;6, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;JEFFREY D. CAPELLO<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Jeffrey D. Capello</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>November&nbsp;6, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;RICHARD ALDRICH<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Richard Aldrich</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>November&nbsp;6, 2018</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=32,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=514399,FOLIO='II-8',FILE='DISK121:[18ZEU1.18ZEU10401]JE10401A.;26',USER='HYUNG',CD=';6-NOV-2018;11:21' -->
<A NAME="page_je10401_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg10401a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="202pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="105pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Date


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>/s/&nbsp;MARY FISHER<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Mary Fisher</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>November&nbsp;6, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;JOHN P. HOWE, III, M.D.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> John P. Howe, III, M.D.</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>November&nbsp;6, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;MARC KOZIN<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Marc Kozin</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>November&nbsp;6, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;JOHN SEXTON, PH.D.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> John Sexton, Ph.D.</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>November&nbsp;6, 2018</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=33,EFW="2237017",CP="OVASCIENCE",DN="1",CHK=384084,FOLIO='II-9',FILE='DISK121:[18ZEU1.18ZEU10401]JE10401A.;26',USER='HYUNG',CD=';6-NOV-2018;11:21' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>2
<FILENAME>a2237017zex-4_6.htm
<DESCRIPTION>EX-4.6
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 4.6<a name="38204-3-KK-01_Exhibt4_6_085307"></a></font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">EXECUTION VERSION</font></i></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">MILLENDO THERAPEUTICS</font></b><b>,&nbsp;</b><b>INC.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman"><font style="font-size:10.0pt;font-weight:bold;">SECOND AMENDED AND RESTATED</font><br> INVESTOR RIGHTS AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THIS SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT </font></b>(the &#147;<b><i style="font-weight:bold;">Agreement</i></b>&#148;) is entered into as of the 19th day of December, 2017, by and among <b>MILLENDO THERAPEUTICS,&nbsp;INC.</b>, a Delaware corporation (formerly known as Atterocor,&nbsp;Inc.) (the &#147;<b><i style="font-weight:bold;">Company</i></b>&#148;), the persons or entities listed on <u>Exhibit&nbsp;A</u> hereto, referred to hereinafter as the &#147;<b><i style="font-weight:bold;">Investors</i></b>&#148; and each individually as an &#147;<b><i style="font-weight:bold;">Investor</i></b>&#148;.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RECITALS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHEREAS</font></b>, certain of the Investors (the &#147;<b><i style="font-weight:bold;">Existing Investors</i></b>&#148;) hold shares of the Company&#146;s Series&nbsp;A Preferred Stock, par value $0.001 per share (the &#147;<b><i style="font-weight:bold;">Series&nbsp;A Preferred Stock</i></b>&#148;), Series&nbsp;B Preferred Stock, par value $0.001 per share (the &#147;<b><i style="font-weight:bold;">Series&nbsp;B Preferred Stock</i></b>&#148;), and/or shares of Common Stock issued upon conversion thereof and possess registration rights, information rights, rights of first offer and other rights pursuant to that certain Amended and Restated Investor Rights Agreement dated as of December&nbsp;18, 2015 by and among the Company and such Existing Investors (the &#147;<b><i style="font-weight:bold;">Prior Agreement</i></b>&#148;);</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHEREAS</font></b>, the Prior Agreement may be amended, and any provision therein waived, with the consent of the Company and the holders of a majority of the outstanding Registrable Securities (as such term is defined in the Prior Agreement);</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHEREAS</font></b>, the Existing Investors as holders of a majority of the outstanding Registrable Securities (as such term is defined in the Prior Agreement) of the Company desire to terminate the Prior Agreement and to accept the rights created pursuant hereto in lieu of the rights granted to them under the Prior Agreement;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHEREAS, </font></b>certain Investors are acquiring shares of the Company&#146;s Series&nbsp;A-1 Preferred Stock, par value $0.001 per share (the &#147;<b><i style="font-weight:bold;">Series&nbsp;A-1 Preferred Stock</i></b>&#148;) and Series&nbsp;B-1 Preferred Stock, par value $0.001 per share (the &#147;<b><i style="font-weight:bold;">Series&nbsp;B-1 Preferred Stock</i></b>&#148;) pursuant to that certain Share Sale and Contribution Agreement, by and among the Company, the shareholders of Aliz&#233; Pharma SAS (&#147;<b><i style="font-weight:bold;">Aliz&#233;</i></b>&#148;), Aliz&#233;, the Manager (as defined therein), the Contributing Holder Representative (as defined therein) and Eumedix FR S.&#192;. R.L. (the &#147;<b><i style="font-weight:bold;">Share Contribution Agreement</i></b>&#148;) of even date herewith (the &#147;<b><i style="font-weight:bold;">Transaction</i></b>&#148;);</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHEREAS,</font></b> the obligations in the Share Contribution Agreement are conditioned upon the execution and delivery of this Agreement; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHEREAS,</font></b> in connection with the consummation of the Transaction, the parties desire to enter into this Agreement in order to grant registration rights, information rights and other rights to the Investors as set forth below.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">1<a name="38204-3-KK-01_PB_1_085323_3736"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=774840,FOLIO='1',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-01_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 08:55 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NOW, THEREFORE, </font></b>in consideration of these premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;1.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>GENERAL.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.1</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Definitions</b><b>.&#160; </b>As used in this Agreement the following terms shall have the following respective meanings:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#147;<b><i style="font-weight:bold;">Affiliate</i></b>&#148; means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company with, such Person.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>&#147;<i>Anti-Corruption Laws</i></b>&#148; means, in the case of U.S. persons or entities, the U.S. Foreign Corrupt Practices Act of 1977, as amended, and any foreign laws or regulations with an extraterritorial scope relating to anti-bribery applicable to such persons or entities, and, in the case of French persons or entities, any applicable French legislation relating to anti-bribery including but not limited to provisions of Titles III and IV, Book IV of the French Criminal Code, as amended, and any foreign laws or regulations with an extraterritorial scope relating to anti-bribery applicable to such persons or entities.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#147;<b><i style="font-weight:bold;">Anti-Money Laundering Laws</i></b>&#148; means, in the case of U.S. persons or entities, any US and foreign laws or regulations with an extraterritorial scope relating to anti-money laundering applicable to such persons or entities, and, in the case of French persons or entities, any applicable French legislation relating to anti-money laundering including but not limited to provisions of Title VI, Book V of the French Monetary and Financial Code, as amended, and any foreign laws or regulations with an extraterritorial scope relating to anti- money laundering applicable to such persons or entities.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><i style="font-weight:bold;">&#147;Class&nbsp;Common-1 Stock&#148;</i></b> shall have the meaning ascribed to such term in the Charter.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(e)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><i style="font-weight:bold;">&#147;Common Shares&#148;</i></b> shall have the meaning ascribed to such term in the Charter.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(f)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><i style="font-weight:bold;">&#147;Common Stock&#148;</i></b> shall have the meaning ascribed to such term in the Charter.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(g)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><i style="font-weight:bold;">&#147;Convertible Stock&#148;</i></b> shall have the meaning ascribed to such term in the Charter.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="38204-3-KK-01_PB_2_085348_9621"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=803556,FOLIO='2',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-01_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 08:55 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(h)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><i style="font-weight:bold;">&#147;Exchange Act&#148;</i></b> means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(i)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><i style="font-weight:bold;">&#147;Form&nbsp;S-3&#148;</i></b> means such form under the Securities Act as in effect on the date hereof or any successor or similar registration form under the Securities Act subsequently adopted by the SEC which permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(j)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><i style="font-weight:bold;">&#147;Holder&#148;</i></b> means any person owning of record Registrable Securities that have not been sold to the public or any assignee of record of such Registrable Securities in accordance with Section&nbsp;2.9 hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(k)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><i style="font-weight:bold;">&#147;Initial Offering&#148;</i></b> means the Company&#146;s first firm commitment underwritten public offering of its Common Stock registered under the Securities Act.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(l)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><i style="font-weight:bold;">&#147;New Preferred Stock&#148;</i></b> means, collectively, the Series&nbsp;A-1 Preferred Stock and the Series&nbsp;B-1 Preferred Stock.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(m)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><i style="font-weight:bold;">&#147;Preferred Stock&#148;</i></b> means, collectively, the Series&nbsp;A Preferred Stock, the Series&nbsp;A-1 Preferred Stock, the Series&nbsp;B Preferred Stock and the Series&nbsp;B-1 Preferred Stock.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(n)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><i style="font-weight:bold;">&#147;Register,&#148; &#147;registered,&#148;</i></b> and <b><i style="font-weight:bold;">&#147;registration&#148;</i></b> refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act, and the declaration or ordering of effectiveness of such registration statement or document.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(o)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><i style="font-weight:bold;">&#147;Registrable Securities&#148;</i></b> means (a)&nbsp;Common Stock of the Company issuable or issued upon conversion of the Shares and (b)&nbsp;any Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, such above-described securities.&#160; Notwithstanding the foregoing, Registrable Securities shall not include any securities (i)&nbsp;sold by a person to the public either pursuant to a registration statement or Rule&nbsp;144 or (ii)&nbsp;sold in a private transaction in which the transferor&#146;s rights under Section&nbsp;2 of this Agreement are not assigned.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(p)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><i style="font-weight:bold;">&#147;Registrable Securities then outstanding&#148;</i></b> shall be the number of shares of the Company&#146;s Common Stock that are Registrable Securities and either (a)&nbsp;are then issued and outstanding or (b)&nbsp;are issuable pursuant to then exercisable or convertible securities.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(q)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><i style="font-weight:bold;">&#147;Registration Expenses&#148;</i></b> shall mean all expenses incurred by the Company in complying with Sections&nbsp;2.2, 2.3 and 2.4 hereof, including, without limitation, all registration and filing fees, printing expenses, fees and disbursements of counsel for the Company, reasonable fees and disbursements not to exceed thirty-seven thousand five hundred dollars ($37,500) of a single special counsel for the Holders, blue sky fees and expenses and the expense of any special audits incident to or required by any such registration (but excluding the compensation of regular employees of the Company which shall be paid in any event by the Company).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(r)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><i style="font-weight:bold;">&#147;SEC&#148;</i></b> or <b><i style="font-weight:bold;">&#147;Commission&#148;</i></b> means the Securities and Exchange Commission.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="38204-3-KK-01_PB_3_085355_8715"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=671914,FOLIO='3',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-01_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 08:55 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(s)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><i style="font-weight:bold;">&#147;Securities Act&#148;</i></b> shall mean the Securities Act of 1933, as amended.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(t)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><i style="font-weight:bold;">&#147;Selling Expenses&#148;</i></b> means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Section&nbsp;2.5.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(u)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><i style="font-weight:bold;">&#147;Shares&#148;</i></b> shall mean the Series&nbsp;A Preferred Stock, Series&nbsp;A-1 Preferred Stock, Series&nbsp;B Preferred Stock, Series&nbsp;B-1 Preferred Stock, the Class&nbsp;Common-1 Stock and any other Common Stock held from time to time by the Investors listed on <u>Exhibit&nbsp;A</u> hereto and their permitted assigns.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(v)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><i style="font-weight:bold;">&#147;Special Registration Statement&#148;</i></b> shall mean (i)&nbsp;a registration statement relating to any employee benefit plan or (ii)&nbsp;with respect to any corporate reorganization or transaction under Rule&nbsp;145 of the Securities Act, any registration statements related to the issuance or resale of securities issued in such a transaction or (iii)&nbsp;a registration related to stock issued upon conversion of debt securities.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;2.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>REGISTRATION; RESTRICTIONS ON TRANSFER.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.1</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Restrictions on Transfer.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Each Holder agrees not to make any disposition of all or any portion of the Shares or Registrable Securities unless and until:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(i)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; there is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(ii)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (A)&nbsp;the transferee has agreed in writing to be bound by the terms of this Agreement, (B)&nbsp;such Holder shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and (C)&nbsp;if reasonably requested by the Company, such Holder shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration of such shares under the Securities Act.&#160; It is agreed that the Company will not require opinions of counsel for transactions made pursuant to Rule&nbsp;144, except in unusual circumstances.&#160; After its Initial Offering, the Company will not require any transferee pursuant to Rule&nbsp;144 to be bound by the terms of this Agreement if the shares so transferred do not remain Registrable Securities hereunder following such transfer.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Notwithstanding the provisions of subsection (a)&nbsp;above, no such restriction shall apply to a transfer by a Holder that is (i)&nbsp;a partnership transferring to its partners or former partners in accordance with partnership interests, (ii)&nbsp;a partnership transferring to one or more affiliated partnerships or funds managed by it or any of its respective directors, officers or partners, (iii)&nbsp;a corporation transferring to a wholly-owned subsidiary or a parent corporation that owns all of the capital stock of the Holder, (iv)&nbsp;a limited liability company transferring to its members or former members in accordance with their interest in the limited liability company, or (v)&nbsp;an individual transferring to the Holder&#146;s family member or trust for the benefit of an individual</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="38204-3-KK-01_PB_4_085408_563"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=827894,FOLIO='4',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-01_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 08:55 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Holder; <i>provided</i> that in each case the transferee will agree in writing to be subject to the terms of this Agreement to the same extent as if he were an original Holder hereunder.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Each certificate representing Shares or Registrable Securities shall be stamped or otherwise imprinted with legends substantially similar to the following (in addition to any legend required under applicable state securities laws):</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE &#147;<b><i style="font-weight:bold;">ACT</i></b>&#148;) AND MAY&nbsp;NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN INVESTOR RIGHTS AGREEMENT BY AND BETWEEN THE STOCKHOLDER AND THE COMPANY.&#160; COPIES OF SUCH AGREEMENT MAY&nbsp;BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company shall be obligated to reissue promptly unlegended certificates at the request of any Holder thereof if the Company has completed its Initial Offering and the Holder shall have obtained an opinion of counsel (which counsel may be counsel to the Company) reasonably acceptable to the Company to the effect that the securities proposed to be disposed of may lawfully be so disposed of without registration, qualification and legend, <i>provided </i><i>that</i> the second legend listed above shall be removed only at such time as the Holder of such certificate is no longer subject to any restrictions hereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(e)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Any legend endorsed on an instrument pursuant to applicable state securities laws and the stop-transfer instructions with respect to such securities shall be removed upon receipt by the Company of an order of the appropriate blue sky authority authorizing such removal.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.2</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Demand Registration.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Subject to the conditions of this Section&nbsp;2.2, if the Company shall receive a written request from the Holders of at least twenty percent (20%) of the Registrable Securities (the &#147;<b><i style="font-weight:bold;">Initiating Holders</i></b>&#148;) that the Company file a registration statement under the Securities Act covering the registration of at least forty percent (40%) of the Registrable Securities then outstanding (or a lesser percent if the anticipated aggregate offering price, net of underwriting discounts and commissions, would exceed $10,000,000), then the Company shall, within fifteen (15) days of the receipt thereof, give written notice of such request to all Holders, and subject to</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="38204-3-KK-01_PB_5_085421_9497"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=76291,FOLIO='5',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-01_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 08:55 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the limitations of this Section&nbsp;2.2, as soon as practicable, </font>and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, and effect, as expeditiously as reasonably possible, the registration under the Securities Act of all Registrable Securities that all Holders request to be registered.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section&nbsp;2.2 or any request pursuant to Section&nbsp;2.4 and the Company shall include such information in the written notice referred to in Section&nbsp;2.2(a)&nbsp;or Section&nbsp;2.4(a), as applicable.&#160; In such event, the right of any Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder&#146;s participation in such underwriting and the inclusion of such Holder&#146;s Registrable Securities in the underwriting to the extent provided herein.&#160; All Holders proposing to distribute their securities through such underwriting shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by the Holders of a majority of the Registrable Securities held by all Initiating Holders (which underwriter or underwriters shall be reasonably acceptable to the Company).&#160; Notwithstanding any other provision of this Section&nbsp;2.2 or Section&nbsp;2.4, if the underwriter advises the Company in writing that marketing factors require a limitation of the number of securities to be underwritten (including Registrable Securities) then the Company shall so advise all Holders of Registrable Securities that would otherwise be underwritten pursuant hereto, and the number of shares that may be included in the underwriting shall be allocated to the Holders of such Registrable Securities on a <i>pro rata</i> basis based on the number of Registrable Securities held by all such Holders (including the Initiating Holders<b>)</b>; <i>provided, however</i>, that the number of shares of Registrable Securities to be included in such underwriting and registration shall not be reduced unless all other securities of the Company are first entirely excluded from the underwriting and registration.&#160; Any Registrable Securities excluded or withdrawn from such underwriting shall be withdrawn from the registration.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company shall not be required to effect a registration pursuant to this Section&nbsp;2.2:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(i)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; prior to the earlier of (A)&nbsp;the fifth (5<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>) anniversary of the date of this Agreement or (B)&nbsp;the expiration of the restrictions on transfer set forth in Section&nbsp;2.11 following the Initial Offering;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(ii)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; after the Company has effected one (1)&nbsp;registration pursuant to this Section&nbsp;2.2, and such registration have been declared or ordered effective;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(iii)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; during the period starting with the date of filing of, and ending on the date one hundred eighty (180) days following the effective date of the registration statement pertaining to the Initial Offering (or such longer period as may be determined pursuant to Section&nbsp;2.11 hereof); <i>provided</i> that the Company makes reasonable good faith efforts to cause such registration statement to become effective;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="38204-3-KK-01_PB_6_085427_3641"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=910765,FOLIO='6',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-01_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 08:55 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(iv)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; if within thirty (30) days of receipt of a written request from Initiating Holders pursuant to Section&nbsp;2.2(a), the Company gives notice to the Holders of the Company&#146;s intention to file a registration statement for its Initial Offering within ninety (90) days;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(v)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; if the Company shall furnish to Holders requesting a registration statement pursuant to this Section&nbsp;2.2 a certificate signed by the Chairman of the Board stating that in the good faith judgment of the Board of Directors of the Company (the &#147;<b><i style="font-weight:bold;">Board</i></b>&#148;), such registration would (i)&nbsp;materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii)&nbsp;require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii)&nbsp;render the Company unable to comply with requirements under the Securities Act or Exchange Act, in which event the Company shall have the right to defer such filing for a period of not more than one hundred twenty (120) days after receipt of the request of the Initiating Holders; <i>provided</i> that such right to delay a request shall be exercised by the Company not more than once in any twelve (12) month period;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(vi)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form&nbsp;S-3 pursuant to a request made pursuant to Section&nbsp;2.4 below; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(vii)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or compliance.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.3</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Piggyback Registrations.&#160; </b>The Company shall notify all Holders of Registrable Securities in writing at least fifteen (15) days prior to the filing of any registration statement under the Securities Act for purposes of a public offering of securities of the Company (including, but not limited to, registration statements relating to secondary offerings of securities of the Company, but excluding Special Registration Statements) and will afford each such Holder an opportunity to include in such registration statement all or part of such Registrable Securities held by such Holder.&#160; Each Holder desiring to include in any such registration statement all or any part of the Registrable Securities held by it shall, within fifteen (15) days after the above-described notice from the Company, so notify the Company in writing.&#160; Such notice shall state the intended method of disposition of the Registrable Securities by such Holder.&#160; If a Holder decides not to include all of its Registrable Securities in any registration statement thereafter filed by the Company, such Holder shall nevertheless continue to have the right to include any Registrable Securities in any subsequent registration statement or registration statements as may be filed by the Company with respect to offerings of its securities, all upon the terms and conditions set forth herein.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Underwriting.&#160; </b>If the registration statement of which the Company gives notice under this Section&nbsp;2.3 is for an underwritten offering, the Company shall so advise the Holders of Registrable Securities.&#160; In such event, the right of any such Holder to include Registrable Securities in a registration pursuant to this Section&nbsp;2.3 shall be conditioned upon such Holder&#146;s participation in such underwriting and the inclusion of such Holder&#146;s Registrable Securities in the underwriting to the extent provided herein.&#160; All Holders proposing to distribute their Registrable Securities through such underwriting shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by the</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="38204-3-KK-01_PB_7_085437_5250"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=225410,FOLIO='7',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-01_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 08:55 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Company.&#160; Notwithstanding any other provision of this Agreement, if the Company determines in good faith, based on consultation with the underwriter, that marketing factors require a limitation of the number of shares to be underwritten, the number of shares that may be included in the underwriting shall be allocated, first, to the Company; second, to the Holders on a <i>pro rata</i> basis based on the total number of Registrable Securities held by the Holders; and third, to any stockholder of the Company (other than a Holder) on a <i>pro rata</i> basis; provided, however, that no such reduction shall reduce the amount of securities of the selling Holders included in the registration below thirty percent (30%) of the total amount of securities included in such registration, unless such offering is the Initial Offering and such registration does not include shares of any other selling stockholders, in which event any or all of the Registrable Securities of the Holders may be excluded in accordance with the immediately preceding clause.&#160; In no event will shares of any other selling stockholder be included in such registration that would reduce the number of shares which may be included by Holders without the written consent of Holders of a majority of the Registrable Securities proposed to be sold in the offering.&#160; If any Holder disapproves of the terms of any such underwriting, such Holder may elect to withdraw therefrom by written notice to the Company and the underwriter, delivered at least ten (10)&nbsp;business days prior to the effective date of the registration statement.&#160; Any Registrable Securities excluded or withdrawn from such underwriting shall be excluded and withdrawn from the registration.&#160; For any Holder which is a partnership, limited liability company or corporation, the partners, retired partners, members, retired members and stockholders of such Holder, or the estates and family members of any such partners, retired partners, members and retired members and any trusts for the benefit of any of the foregoing person shall be deemed to be a single &#147;Holder,&#148; and any <i>pro rata</i> reduction with respect to such &#147;Holder&#148; shall be based upon the aggregate amount of shares carrying registration rights owned by all entities and individuals included in such &#147;Holder,&#148; as defined in this sentence.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Right to Terminate Registration.&#160; </b>The Company shall have the right to terminate or withdraw any registration initiated by it under this Section&nbsp;2.3 whether or not any Holder has elected to include securities in such registration, and shall promptly notify any Holder that has elected to include shares in such registration of such termination or withdrawal.&#160; The Registration Expenses of such withdrawn registration shall be borne by the Company in accordance with Section&nbsp;2.5 hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.4</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Form&nbsp;S-3 Registration.&#160; </b>If at any time when it is eligible to use a Form&nbsp;S-3 registration statement, the Company shall receive from the Initiating Holders a written request or requests that the Company effect a registration on Form&nbsp;S-3 (or any successor to&nbsp;Form&nbsp;S-3) or any similar short-form registration statement and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder or Holders, the Company will:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; promptly give written notice of the proposed registration, and any related qualification or compliance, to all other Holders of Registrable Securities; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; as soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, effect such registration and all such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holder&#146;s or Holders&#146; Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any other Holder or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="38204-3-KK-01_PB_8_085451_7672"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=352138,FOLIO='8',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-01_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 08:55 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Holders joining in such request as are specified in a written request given within fifteen (15) days after receipt of such written notice from the Company; <i>provided, however</i>, that the Company shall not be obligated to effect any such registration, qualification or compliance pursuant to this Section&nbsp;2.4:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(i)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; if Form&nbsp;S-3 is not available for such offering by the Holders, or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(ii)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; if the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public of less than one million dollars ($1,000,000), or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(iii)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; if within thirty (30) days of receipt of a written request from any Holder or Holders pursuant to this Section&nbsp;2.4, the Company gives notice to such Holder or Holders of the Company&#146;s intention to make a public offering within ninety (90) days, other than pursuant to a Special Registration Statement, or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(iv)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; if the Company shall furnish to the Holders a certificate signed by the Chairman of the Board stating that in the good faith judgment of the Board, such registration would (i)&nbsp;materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii)&nbsp;require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii)&nbsp;render the Company unable to comply with requirements under the Securities Act or Exchange Act, in which event the Company shall have the right to defer the filing of the Form&nbsp;S-3 registration statement for a period of not more than one hundred twenty (120) days after receipt of the request of the Holder or Holders under this Section&nbsp;2.4; <i>provided</i>, that such right to delay a request shall be exercised by the Company not more than once in any twelve (12) month period, or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(v)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; if the Company has, within the twelve (12) month period preceding the date of such request, already effected two (2)&nbsp;registrations on Form&nbsp;S-3 for the Holders pursuant to this Section&nbsp;2.4, or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(vi)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or compliance.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Subject to the foregoing, the Company shall file a Form&nbsp;S-3 registration statement covering the Registrable Securities and other securities so requested to be registered as soon as practicable after receipt of the requests of the Holders.&#160; Registrations effected pursuant to this Section&nbsp;2.4 shall not be counted as demands for registration or registrations effected pursuant to Section&nbsp;2.2.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.5</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Expenses of Registration.&#160; </b>All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section&nbsp;2, including all registration, filing, and qualification fees; printers&#146; and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements, not to exceed thirty-five thousand dollars ($35,000), of one counsel for the selling Holders (&#147;<b><i style="font-weight:bold;">Selling Holder Counsel</i></b>&#148;), shall be borne and paid by the Company.&#160; All Selling Expenses incurred in connection with any</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="38204-3-KK-01_PB_9_085458_536"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=196647,FOLIO='9',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-01_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 08:55 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">registrations hereunder, shall be borne by the holders of the securities so registered <i>pro rata</i> on the basis of the number of shares so registered; <i>provided</i>, <i>however</i>, the Company shall not be required to pay for expenses of any registration proceeding begun pursuant to Section&nbsp;2.2 or 2.4, the request of which has been subsequently withdrawn by the Initiating Holders unless (a)&nbsp;the withdrawal is based upon material adverse information concerning the Company of which the Initiating Holders were not aware at the time of such request or (b)&nbsp;the Holders of a majority of Registrable Securities agree to deem such registration to have been effected as of the date of such withdrawal for purposes of determining whether the Company shall be obligated pursuant to Section&nbsp;2.2(c)&nbsp;or 2.4(b)(v), as applicable, to undertake any subsequent registration, in which event such right shall be forfeited by all Holders).&#160; If the Holders are required to pay the Registration Expenses, such expenses shall be borne by the holders of securities (including Registrable Securities) requesting such registration in proportion to the number of shares for which registration was requested.&#160; If the Company is required to pay the Registration Expenses of a withdrawn offering pursuant to clause&nbsp;(a)&nbsp;above, then such registration shall not be deemed to have been effected for purposes of determining whether the Company shall be obligated pursuant to Section&nbsp;2.2(c)&nbsp;or 2.4(b)(v), as applicable, to undertake any subsequent registration.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.6</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Obligations of the Company.&#160; </b>Whenever required to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; prepare and file with the SEC a registration statement with respect to such Registrable Securities and use all reasonable efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for up to one hundred and twenty (120) days or, if earlier, until the Holder or Holders have completed the distribution related thereto; provided, however, that at any time, upon written notice to the participating Holders and for a period not to exceed sixty (60) days thereafter (the &#147;<b><i style="font-weight:bold;">Suspension Period</i></b>&#148;), the Company may delay the filing or effectiveness of any registration statement or suspend the use or effectiveness of any registration statement (and the Initiating Holders hereby agree not to offer or sell any Registrable Securities pursuant to such registration statement during the Suspension Period) if the Company reasonably believes that there is or may be in existence material nonpublic information or events involving the Company, the failure of which to be disclosed in the prospectus included in the registration statement could result in a Violation (as defined below).&#160; In the event that the Company shall exercise its right to delay or suspend the filing or effectiveness of a registration hereunder, the applicable time period during which the registration statement is to remain effective shall be extended by a period of time equal to the duration of the Suspension Period.&#160; The Company may extend the Suspension Period for an additional consecutive thirty (30) days with the consent of the holders of at least a majority of the Registrable Securities registered under the applicable registration statement, which consent shall not be unreasonably withheld.&#160; No more than two such Suspension Periods shall occur in any twelve (12) month period.&#160; If so directed by the Company, all Holders registering shares under such registration statement shall (i)&nbsp;not offer to sell any Registrable Securities pursuant to the registration statement during the period in which the delay or suspension is in effect after receiving notice of such delay or suspension; and (ii)&nbsp;use their reasonable efforts to deliver to the Company (at the Company&#146;s expense) all copies, other than permanent file copies then in such Holders&#146; possession, of the prospectus relating to such Registrable Securities current at the time of receipt of such notice. &#160;Notwithstanding the foregoing, the Company shall not be required to file, cause to become effective or maintain the effectiveness</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">10<a name="38204-3-KK-01_PB_10_085507_5926"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=8901,FOLIO='10',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-01_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 08:55 2018' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of any registration statement other than a registration statement on Form&nbsp;S-3 that contemplates a distribution of securities on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement for the period set forth in subsection&nbsp;(a)&nbsp;above.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Furnish to the Holders such number of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders; <i>provided </i>that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(e)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter(s)&nbsp;of such offering.&#160; Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(f)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing.&#160; The Company will use reasonable efforts to amend or supplement such prospectus in order to cause such prospectus not to include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(g)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Use its reasonable efforts to furnish, on the date that such Registrable Securities are delivered to the underwriters for sale, if such securities are being sold through underwriters, (i)&nbsp;an opinion, dated as of such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and (ii)&nbsp;a letter, dated as of such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering addressed to the underwriters.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">11<a name="38204-3-KK-03_PB_11_085823_3920"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=737548,FOLIO='11',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-03_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 08:59 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.7</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Delay of Registration; Furnishing Information.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section&nbsp;2.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; It shall be a condition precedent to the obligations of the Company to take any action pursuant to Sections&nbsp;2.2, 2.3 or 2.4 that the selling Holders shall furnish to the Company such information regarding themselves, the Registrable Securities held by them and the intended method of disposition of such securities as shall be required to effect the registration of their Registrable Securities.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company shall have no obligation with respect to any registration requested pursuant to Section&nbsp;2.2 or Section&nbsp;2.4 if the number of shares or the anticipated aggregate offering price of the Registrable Securities to be included in the registration does not equal or exceed the number of shares or the anticipated aggregate offering price required to originally trigger the Company&#146;s obligation to initiate such registration as specified in Section&nbsp;2.2 or Section&nbsp;2.4, whichever is applicable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.8</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Indemnification.&#160; </b>In the event any Registrable Securities are included in a registration statement under Sections&nbsp;2.2, 2.3 or 2.4:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; To the extent permitted by law, the Company will indemnify and hold harmless each Holder, the partners, members, officers and directors of each Holder; any underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any losses, claims, damages, or liabilities (joint or several) to which they may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively a &#147;<b><i style="font-weight:bold;">Violation</i></b>&#148;) by the Company: (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in such registration statement or incorporated reference therein, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii)&nbsp;the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii)&nbsp;any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or any rule&nbsp;or regulation promulgated under the Securities Act, the Exchange Act or any state securities law in connection with the offering covered by such registration statement; and the Company will reimburse each such Holder, partner, member, officer, director, underwriter or controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; <i>provided, however</i>, that the indemnity agreement contained in this Section&nbsp;2.8(a)&nbsp;shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with written information furnished expressly for use in connection with such registration by such Holder, partner, member, officer, director, underwriter or controlling person of such Holder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">12<a name="38204-3-KK-03_PB_12_085832_4688"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=331470,FOLIO='12',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-03_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 08:59 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; To the extent permitted by law, each Holder will, if Registrable Securities held by such Holder are included in the securities as to which such registration qualifications or compliance is being effected, indemnify and hold harmless the Company, each of its directors, its officers and each person, if any, who controls the Company within the meaning of the Securities Act, any underwriter and any other Holder selling securities under such registration statement or any of such other Holder&#146;s partners, directors or officers or any person who controls such Holder, against any losses, claims, damages or liabilities (joint or several) to which the Company or any such director, officer, controlling person, underwriter or other such Holder, or partner, director, officer or controlling person of such other Holder may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon any of the following statements: (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in such registration statement or incorporated reference therein, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii)&nbsp;the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii)&nbsp;any violation or alleged violation by the Company of the Securities Act (collectively, a &#147;<b><i style="font-weight:bold;">Holder Violation</i></b>&#148;), in each case to the extent (and only to the extent) that such Holder Violation occurs in reliance upon and in conformity with written information furnished by such Holder under an instrument duly executed by such Holder and stated to be specifically for use in connection with such registration; and each such Holder will reimburse any legal or other expenses reasonably incurred by the Company or any such director, officer, controlling person, underwriter or other Holder, or partner, officer, director or controlling person of such other Holder in connection with investigating or defending any such loss, claim, damage, liability or action if it is judicially determined that there was such a Holder Violation; <i>provided, however,</i> that the indemnity agreement contained in this Section&nbsp;2.8(b)&nbsp;shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; <i>provided further</i>, that in no event shall any indemnity under this Section&nbsp;2.8 exceed the net proceeds from the offering received by such Holder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Promptly after receipt by an indemnified party under this Section&nbsp;2.8 of notice of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section&nbsp;2.8, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; <i>provided, however,</i> that an indemnified party shall have the right to retain its own counsel, with the fees and expenses thereof to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding.&#160; The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Section&nbsp;2.8 to the extent, and only to the extent, prejudicial to its ability to defend such action, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section&nbsp;2.8.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">13<a name="38204-3-KK-03_PB_13_085836_2983"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=673700,FOLIO='13',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-03_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 08:59 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If the indemnification provided for in this Section&nbsp;2.8 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loses, claims, damages or liabilities referred to herein, the indemnifying party, in lieu of indemnifying such indemnified party thereunder, shall to the extent permitted by applicable law contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the Violation(s)&nbsp;or Holder Violation(s)&nbsp;that resulted in such loss, claim, damage or liability,as well as any other relevant equitable considerations.&#160; The relative fault of the indemnifying party and of the indemnified party shall be determined by a court of law by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission; <i>provided that</i> in no event shall any contribution by a Holder hereunder exceed the proceeds from the offering received by such Holder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(e)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The obligations of the Company and Holders under this Section&nbsp;2.8 shall survive completion of any offering of Registrable Securities in a registration statement and, with respect to liability arising from an offering to which this Section&nbsp;2.8 would apply that is covered by a registration filed before termination of this Agreement, such termination.&#160; No indemnifying party, in the defense of any such claim or litigation, shall, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.9</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Assignment of Registration Rights.&#160; </b>The rights to cause the Company to register Registrable Securities pursuant to this Section&nbsp;2 may be assigned by a Holder to a transferee or assignee of Registrable Securities (for so long as such shares remain Registrable Securities) that (a)&nbsp;is a subsidiary, parent, general partner, limited partner, retired partner, member or retired member, or stockholder of a Holder that is a corporation, partnership or limited liability company, (b)&nbsp;is a Holder&#146;s family member or trust for the benefit of an individual Holder, (c)&nbsp;acquires at least five hundred thousand (500,000) shares of Registrable Securities (as adjusted for stock splits and combinations), or (d)&nbsp;is an entity affiliated by common control (or other related entity) with such Holder; <i>provided, however,</i> (i)&nbsp;the transferor shall, within ten (10)&nbsp;days after such transfer, furnish to the Company written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being assigned and (ii)&nbsp;such transferee shall agree to be subject to all restrictions set forth in this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.10</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Limitation on Subsequent Registration Rights. </b>&#160;Other than as provided in Section&nbsp;5.10, after the date of this Agreement, the Company shall not enter into any agreement with any holder or prospective holder of any securities of the Company that would grant such holder rights to demand the registration of shares of the Company&#146;s capital stock, or to include such shares in a registration statement that would reduce the number of shares includable by the Holders.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.11</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><font style="font-weight:bold;">Market Stand-Off</font> Agreement.&#160; </b>To the extent required (and such requirement is made in writing to the Holders) by the Company or the underwriters, each Holder hereby agrees</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">14<a name="38204-3-KK-03_PB_14_085846_6228"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=14,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=360966,FOLIO='14',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-03_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 08:59 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">that such Holder shall not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any shares of Common Stock (or other securities) of the Company held by such Holder (other than those included in the registration) (i)&nbsp;during the 180-day period following the effective date of the Initial Offering (or such longer period, not to exceed 34 days after the expiration of the 180-day period, as the underwriters or the Company shall request in order to facilitate compliance with NASD Rule&nbsp;2711 or NYSE Member Rule&nbsp;472 or any successor or similar rule&nbsp;or regulation); provided that all officers and directors of the Company and holders of at least one percent (1%) of the Company&#146;s voting securities are bound by and have entered into similar agreements, and provided that, such agreements shall provide that any discretionary waiver or termination of the restrictions of such agreements by the Company or the underwriters shall apply to all Holders equally on a <i>pro rata </i>basis (as such term is defined in Section&nbsp;4.1).&#160; The foregoing provisions of this Section&nbsp;</font>2.11 shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.12</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Agreement to Furnish Information.</b>&#160; Each Holder agrees to execute and deliver such other agreements as may be reasonably requested by the Company or the managing underwriters that are consistent with the Holder&#146;s obligations under Section&nbsp;2.11 or that are necessary to give further effect thereto.&#160; In addition, if reasonably requested by the Company or the representative of the underwriters of Common Stock (or other securities) of the Company, each Holder shall provide, within ten (10)&nbsp;days of such request, such information as may be required by the Company or such representative in connection with the completion of any public offering of the Company&#146;s securities pursuant to a registration statement filed under the Securities Act.&#160; The obligations described in Section&nbsp;2.11 and this Section&nbsp;2.12 shall not apply to a Special Registration Statement.&#160; In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to such shares of Common Stock (or other securities) subject to the foregoing restriction until the end of such period.&#160; Each Holder agrees that any transferee of any shares of Registrable Securities shall be bound by Sections&nbsp;2.11 and 2.12.&#160; The underwriters of the Company&#146;s stock are intended third party beneficiaries of Sections 2.11 and 2.12 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.13</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Rule&nbsp;144 Reporting.&#160; </b>With a view to making available to the Holders the benefits of certain rules&nbsp;and regulations of the SEC which may permit the sale of the Registrable Securities to the public without registration, the Company agrees to use its best efforts to:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Make and keep public information available, as those terms are understood and defined in SEC Rule&nbsp;144 or any similar or analogous rule&nbsp;promulgated under the Securities Act, at all times after the effective date of the first registration filed by the Company for an offering of its securities to the general public;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; File with the SEC, in a timely manner, all reports and other documents required of the Company under the Exchange Act; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; So long as a Holder owns any Registrable Securities, furnish to such Holder forthwith upon request:&#160; a written statement by the Company as to its compliance with the reporting requirements of said Rule&nbsp;144 of the Securities Act, and of the Exchange Act (at any time after it has become subject to such reporting requirements); a copy of the most recent annual or quarterly</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">15<a name="38204-3-KK-03_PB_15_085855_2639"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=15,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=631062,FOLIO='15',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-03_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 08:59 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">report of the Company filed with the Commission; and such other reports and documents as a Holder may reasonably request in connection with availing itself of any rule&nbsp;or regulation of the SEC allowing it to sell any such securities without registration.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.14</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Termination of Registration Rights.</b>&#160; The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Section&nbsp;2.2, Section&nbsp;2.3, or Section&nbsp;2.4 hereof shall terminate upon the earlier of: (i)&nbsp;the date three (3)&nbsp;years following an initial public offering that results in the conversion of all outstanding shares of Preferred stock; or (ii)&nbsp;such time as such Holder, holds less than one percent (1%) of the Company&#146;s outstanding Common Stock (treating all shares of Preferred Stock on an as converted basis), the Company has completed its Initial Offering and all Registrable Securities of the Company issuable or issued upon conversion of the Shares held by and issuable to such Holder (and its Affiliates) may be sold pursuant to Rule&nbsp;144 during any ninety (90) day period.&#160; Upon such termination, such shares shall cease to be &#147;Registrable Securities&#148; hereunder for all purposes.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;3.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>COVENANTS OF THE COMPANY.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.1</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Basic Financial Information and Reporting.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company will maintain true books and records of account in which full and correct entries will be made of all its business transactions pursuant to a system of accounting established and administered in accordance with generally accepted accounting principles consistently applied (except as noted therein), and will set aside on its books all such proper accruals and reserves as shall be required under generally accepted accounting principles consistently applied.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; So long as an Investor (with its Affiliates) shall own not less than two hundred fifty thousand (250,000) shares of Preferred Stock (as adjusted for stock splits and combinations) (a &#147;<b><i style="font-weight:bold;">Major Investor</i></b>&#148;), the Company will furnish each Major Investor, as soon as practicable after the end of each fiscal year of the Company, and in any event within one hundred twenty (120) days thereafter, an unaudited balance sheet of the Company, as at the end of such fiscal year, and an unaudited statement of income and a statement of cash flows of the Company, for such year, all prepared in accordance with generally accepted accounting principles consistently applied (except as noted therein) and setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company will furnish each Major Investor, as soon as practicable after the end of the first, second and third quarterly accounting periods in each fiscal year of the Company, and in any event within forty-five (45) days thereafter, an unaudited balance sheet of the Company as of the end of each such quarterly period, and an unaudited statement of income and a statement of cash flows of the Company for such period and for the current fiscal year to date, prepared in accordance with generally accepted accounting principles consistently applied (except as noted therein), with the exception that no notes need be attached to such statements and year-end audit adjustments may not have been made, as well as an up-to-date capitalization table of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">16<a name="38204-3-KK-03_PB_16_085903_2794"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=16,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=752308,FOLIO='16',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-03_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 08:59 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company will furnish each Major Investor, as soon as practicable, but in any event within thirty (30) days of the end of each month, a balance sheet of the Company as of the end of each such month, and a statement of income and a statement of cash flows of the Company for such month and for the current fiscal year to date, including a comparison to plan figures for such period, prepared in accordance with generally accepted accounting principles consistently applied (except as noted thereon), with the exception that no notes need be attached to such statements and year-end audit adjustments may not have been made.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(e)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company will furnish each such Major Investor to the extent requested by such Major Investor no earlier than thirty (30) days after the beginning of each fiscal year an annual budget for such fiscal year (and as soon as available, any subsequent written revisions thereto).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.2</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Inspection Rights.&#160; </b>Each Major Investor shall have the right to visit and inspect any of the properties of the Company or any of its subsidiaries, and to discuss the affairs, finances and accounts of the Company or any of its subsidiaries with its officers, and to review such information as is reasonably requested all at such reasonable times and as often as may be reasonably requested; <i>provided, however,</i> that the Company shall not be obligated under this Section&nbsp;3.2 with respect to a competitor of the Company or with respect to information which the Board reasonably determines in good faith is confidential or attorney-client privileged and should not, therefore, be disclosed.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.3</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Confidentiality of Records.&#160; </b>Each Investor agrees to use the same degree of care as such Investor uses to protect its own confidential information to keep confidential any information furnished to such Investor hereof that the Company identifies as being confidential or proprietary (so long as such information is not in the public domain), except that such Investor may disclose such proprietary or confidential information (i)&nbsp;to any former partners who retained an economic interest in such Investor, current or prospective partner of the partnership or any subsequent partnership under common investment management, limited partner, general partner, member or management company of such Investor, employee or representative of such Investor having a need to know the contents of such information, such Investor&#146;s legal counsel, accountants or other professional advisors, subsidiary or parent of such Investor, in each case as long as such party is advised of and agrees or has agreed to be bound by the confidentiality provisions of this Section&nbsp;3.3 or comparable restrictions; (ii)&nbsp;at such time as it enters the public domain through no fault of such Investor; (iii)&nbsp;that is communicated to it free of any obligation of confidentiality; (iv)&nbsp;that is developed by such Investor or its agents independently of and without reference to any confidential information communicated by the Company; or (v)&nbsp;as required by applicable law.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.4</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Reservation of Common Stock.&#160; </b>The Company will at all times reserve and keep available, solely for issuance and delivery upon the conversion of the Preferred Stock, all Common Stock issuable from time to time upon such conversion.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.5</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Stock Vesting.&#160; </b>Unless otherwise approved by the Board (including a majority of the Preferred Directors, as defined in that certain Second Amended and Restated Voting Agreement dated as of the date hereof, as the same may be amended from time to time), all stock options and other stock equivalents issued after the date of this Agreement to employees, directors, consultants and other service providers (&#147;<b><i style="font-weight:bold;">Stock Awards</i></b>&#148;) shall be subject to vesting as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">17<a name="38204-3-KK-03_PB_17_085910_8299"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=17,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=46295,FOLIO='17',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-03_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 08:59 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&nbsp;twenty-five percent (25%) of such stock shall vest at the end of the first year following the earlier of the date of issuance or such person&#146;s services commencement date with the Company, and (b)&nbsp;the remaining seventy-five percent (75%) of such stock shall vest monthly over the remaining three (3)&nbsp;years.&#160; All unvested stock subject to such Stock Awards shall be subject to repurchase at cost by the Company upon termination of employment or service of such director, officer, employee or consultant for any reason.&#160; No transfer of unvested stock subject to such Stock Awards shall be allowed.&#160; The Company shall have a right of first refusal on all transfers of vested stock, which right of first refusal shall terminate upon a Qualified IPO (as defined in the Company&#146;s Amended and Restated Certificate of Incorporation (as may be amended from time to time, the &#147;<b><i style="font-weight:bold;">Charter</i></b>&#148;)).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.6</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><font style="font-weight:bold;">Directors&#146; Liability and Indemnification;</font> Director and Officer Insurance. </b>&#160;The Charter and bylaws shall provide (a)&nbsp;for elimination of the liability of directors to the maximum extent permitted by law and (b)&nbsp;for indemnification of directors for acts on behalf of the Company to the maximum extent permitted by law; provided that such insurance coverage shall be in an amount no less than $4,000,000 (inclusive of main and &#147;Side A&#148; policies).&#160; In addition, the Company shall enter into and use its best efforts to at all times maintain indemnification agreements with each of its directors to indemnify such directors to the maximum extent permissible under applicable law.&#160; Further, in the event the Company merges with another entity and is not the surviving corporation, or transfers all of its assets, the Company shall use its best effort to provide that successors of the Company shall assume the Company&#146;s obligations with respect to indemnification of the directors.&#160; The Company will use its best efforts to obtain promptly after the date hereof and maintain in full force and effect director and officer liability insurance in an amount to be determined and approved by the Board, including the Preferred Directors.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.7</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Observer Rights.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company shall allow (i)&nbsp;one (1)&nbsp;representative designated by New Enterprise Associates 15, L.P., or its Affiliates (&#147;<b><i style="font-weight:bold;">NEA</i></b>&#148;), who shall initially be Sara Nayeem, (ii)&nbsp;one (1)&nbsp;representative designated by Osage University Partners I, L.P., or its Affiliates (&#147;<b><i style="font-weight:bold;">Osage</i></b>&#148;), who shall initially be Bill Harrington, (iii)&nbsp;one (1)&nbsp;representative designated by Frazier Healthcare VI, L.P., or its Affiliates (&#147;<b><i style="font-weight:bold;">Frazier</i></b>&#148;), who shall initially be Dan Estes, (iv)&nbsp;one (1)&nbsp;representative designated by Altitude Life Science Ventures, or its Affiliates (&#147;<b><i style="font-weight:bold;">Altitude</i></b>&#148;), who shall initially be Dave Maki, (v)&nbsp;one (1)&nbsp;representative designated by Roche Finance Ltd., or its Affiliates (&#147;<b><i style="font-weight:bold;">Roche</i></b>&#148;), who shall initially be Carole Nuetcherlein, (vi)&nbsp;one (1)&nbsp;representative designated by Adams Street Partners, LLC, or its Affiliates (&#147;<b><i style="font-weight:bold;">Adams Street</i></b>&#148;), who shall initially be Elisha P. Gould III and (vii)&nbsp;one (1)&nbsp;representative from Longwood Fund III GP, LLC, or its Affiliates (&#147;<b><i style="font-weight:bold;">Longwood</i></b>&#148;), who shall initially be David Donabedian, to attend all meetings of the Board in a nonvoting capacity, so long such designating entity is a Major Investor.&#160; The Company shall give such representative copies of all notices, minutes, consents and other materials, financial or otherwise, which the Company provides to its Board; provided, however, that the Company reserves the right to exclude such representative from access to any material or meeting or portion thereof if the Company in good faith believes, with advice of counsel, that such exclusion is reasonably necessary to preserve the attorney-client privilege, to protect highly confidential information or for other similar reasons.&#160; The decision of the Board with respect to the privileged or confidential nature of such information shall be final and binding.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">18<a name="38204-3-KK-03_PB_18_085914_8247"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=18,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=433159,FOLIO='18',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-03_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 08:59 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company shall allow one (1)&nbsp;representative designated by AstraZeneca AB who shall initially be Kumar Srinivasan, to attend all meetings of the Board in a nonvoting capacity.&#160; The Company shall give such representative copies of all notices, minutes, consents and other materials, financial or otherwise, which the Company provides to its Board; provided, however, that the Company reserves the right to exclude such representative from access to any material or meeting or portion thereof if the Company in good faith believes, with advice of counsel, that such exclusion is reasonably necessary to preserve the attorney-client privilege, to protect highly confidential information or for other similar reasons (including actual or potential conflicts of interest).&#160; The decision of the Board with respect to the privileged or confidential nature of such information shall be final and binding.&#160; Notwithstanding any other provision contained herein, this Section&nbsp;3.7(b)&nbsp;shall expire and terminate as to AstraZeneca AB upon the earliest of (i)&nbsp;AstraZeneca AB&#146;s disposition of fifty percent (50%) or more of the Series&nbsp;B Preferred Stock issued to AstraZeneca AB pursuant to that certain License Agreement between the Company and AstraZeneca AB dated August&nbsp;25, 2015, (ii)&nbsp;the effective date of the Company&#146;s initial public offering of its Common Stock or any other transaction that results in the Company or any successor being a publicly traded company, (iii)&nbsp;upon an Acquisition (as defined in the Charter) or (iv)&nbsp;at such time AstraZeneca AB holds less than one percent (1%) of the Company&#146;s outstanding Common Stock (treating all shares of Convertible Stock on an as converted basis).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; For so long as any shares of New Preferred Stock remain outstanding, the Company shall allow two (2)&nbsp;representatives designated by the holders of a majority of shares of New Preferred Stock, who shall initially be Gilles Alberici and Olivier Martinez, to attend all meetings of the Board in a nonvoting capacity.&#160; The Company shall give such representative copies of all notices, minutes, consents and other materials, financial or otherwise, which the Company provides to its Board; provided, however, that the Company reserves the right to exclude such representative from access to any material or meeting or portion thereof if the Company in good faith believes, with advice of counsel, that such exclusion is reasonably necessary to preserve the attorney-client privilege, to protect highly confidential information or for other similar reasons (including actual or potential conflicts of interest).&#160; The decision of the Board with respect to the privileged or confidential nature of such information shall be final and binding.&#160; Notwithstanding any other provision contained herein, this Section&nbsp;3.7(c)&nbsp;shall expire and terminate as to the holders of New Preferred Stock upon the earliest of (i)&nbsp;at such time as the holders of New Preferred Stock collectively hold less than five percent (5%) of the Company&#146;s outstanding Common Stock (treating all shares of Convertible Stock on an as converted basis), (ii)&nbsp;the effective date of the Company&#146;s initial public offering of its Common Stock or any other transaction that results in the Company or any successor being a publicly traded company or (iii)&nbsp;upon an Acquisition (as defined in the Charter).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.8</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Board Meetings.</b>&#160; The Company will use its best efforts to hold at least four (4)&nbsp;meetings of the Board each year or as otherwise approved by the Board.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.9</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Compensation Committee.</b>&#160; The Company shall establish a compensation committee of the Board (&#147;<b><i style="font-weight:bold;">Compensation Committee</i></b>&#148;) consisting of at least two (2)&nbsp;directors designated by the holders of Preferred Stock, for the purpose of, among other things, reviewing and determining the compensation of the Company&#146;s executive officers.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">19<a name="38204-3-KK-03_PB_19_085924_5893"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=19,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=1027900,FOLIO='19',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-03_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 08:59 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.10</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Reimbursement of Expenses.</b>&#160; The Company shall reimburse each director of the Company for all reasonable travel or other out-of-pocket expenses incurred in connection with attending meetings of the Board.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.11</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Proprietary Information and Inventions Agreement. </b>&#160;The Company shall require all employees and consultants to execute and deliver a Proprietary Information and Inventions Agreement substantially in a form approved by the Board.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.12</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Qualified Small Business.&#160; </b>For so long as any of the Shares are held by an Investor (or a transferee in whose hands such Shares are eligible to qualify as &#147;Qualified Small Business Stock&#148; as defined in Section&nbsp;1202(c)&nbsp;of the Internal Revenue Code of 1986, as amended (the &#147;<b><i style="font-weight:bold;">Code</i></b>&#148;)), the Company will use its reasonable efforts to comply with the reporting and recordkeeping requirements of Section&nbsp;1202 of the Code, any regulations promulgated thereunder and any similar state laws and regulations.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.13</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Non-Competition and Non-Solicitation Agreement.</b>&#160; The Company shall require that all key employees and key consultants (as determined by the Board or the Compensation Committee) execute and deliver a Non-Competition and Non-Solicitation Agreement substantially in a form approved by the Board.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.14</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Investor Covenants on Anti Money Laundering and Anti-Corruption.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Each Investor represents and warrants, for purposes of all applicable Anti-Money Laundering Laws, that:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-9.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">i.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160; </font>the origin and source of the funds that it/he/she paid to the Company to acquire or subscribe for any Shares or make any shareholder&#146;s loan to the Company do not result from any activity in breach of any applicable Anti-Money Laundering Laws.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Until the consummation of a Qualified IPO, the Company will use its best efforts to inform the Investors of any new shareholder of the Company (with indication of its identity and, for closely-held legal entities, of its shareholders or beneficial owners) before the relevant individual or entity becomes a shareholder of the Company and to use its best efforts to cause any new shareholder of the Company to comply with the parties&#146; undertakings set forth in this Section.&#160; In particular, in the event of issuance of equity or other voting securities, the Company will use its best efforts to obtain appropriate representations and warranties or other reasonably sufficient evidence from the relevant subscribing third party that such third party complies with all applicable Anti-Money Laundering Laws.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.15</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Company Covenants on Anti Money Laundering and Anti-Corruption</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company represents and warrants that it does not participate and has never participated in any transactions in violation of applicable Anti-Money Laundering Laws.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company undertakes to comply with all applicable Anti-Corruption Laws and not to participate in any activities in violation of applicable Anti-Corruption Laws.&#160; The</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">20<a name="38204-3-KK-03_PB_20_085932_9862"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=20,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=785702,FOLIO='20',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-03_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 08:59 2018' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Company has adopted and implemented appropriate internal policies and/or rules&nbsp;in order to prevent the violation of applicable Anti-Corruption Laws.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.16</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Additional Undertakings and Acknowledgements on Anti Money Laundering and Anti-Corruption.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The parties hereto acknowledge that InnoBio and its management company (<i>soci&#233;t&#233; de gestion</i>), Bpifrance Investissement, are subject to certain filing and reporting obligations to prevent money laundering activities and financing of terrorism provided for in sections 2 to 7 of Chapter 1 of Title VI, Book V of the French Monetary and Financial Code and of the provisions of the General Rules&nbsp;(<i>R&#233;glement G&#233;n&#233;ral</i>) of the French Stock Market Regulator (<i>Autorit&#233; des March&#233;s Financiers</i>) and, in particular, are required to report to competent regulatory authorities: (i)&nbsp;any transaction involving money transfers which they are aware, assume or have good reasons to believe that: (a)&nbsp;relates to the commission of an crime or offence which can result in the imprisonment of its authors for a duration exceeding one year or (b)&nbsp;participates to the financing of terrorism, as well as (ii)&nbsp;any transaction for which the identity of the relevant instructing party, the effective beneficiary, the settlor in a trust or any other asset management vehicle involved in the relevant transaction remains unclear despite all investigations InnoBio and its management company have to carry out.&#160; Under applicable French laws,&nbsp;InnoBio and its management company also have to refrain from carrying out any operation they believe is linked to money laundering activities or financing of terrorism.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.17</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Termination of Covenants.&#160; </b>All covenants of the Company contained in Section&nbsp;3 of this Agreement (other than the provisions of Section&nbsp;3.3 and 3.6) shall expire and terminate as to each Investor upon the earlier of (i)&nbsp;the effective date of a Qualified IPO (as defined in the Charter) or (ii)&nbsp;upon an Acquisition (as defined in the Charter).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;4.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>RIGHTS OF FIRST REFUSAL.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.1</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Subsequent Offerings.&#160; </b>Subject to applicable securities laws, each Major Investor shall have a right of first refusal to purchase its <i>pro rata</i> share of all Equity Securities, as defined below, that the Company may, from time to time, propose to sell and issue after the date of this Agreement, other than the Equity Securities excluded by Section&nbsp;4.6 hereof.&#160; Each Major Investor&#146;s <i>pro rata</i> share is equal to the ratio of (a)&nbsp;the number of Common Shares (including all shares of Common Stock issuable or issued upon conversion of the Shares or upon the exercise of outstanding warrants or options) of which such Major Investor is deemed to be a holder immediately prior to the issuance of such Equity Securities to (b)&nbsp;the total number of the Company&#146;s outstanding Common Shares (including all shares of Common Stock issued or issuable upon conversion of the Shares or upon the exercise of any outstanding warrants or options) immediately prior to the issuance of the Equity Securities.&#160; The term &#147;<b><i style="font-weight:bold;">Equity Securities</i></b>&#148; shall mean (i)&nbsp;any Common Stock, Preferred Stock or other security of the Company, (ii)&nbsp;any security convertible into or exercisable or exchangeable for, with or without consideration, any Common Stock, Preferred Stock or other security (including any option to purchase such a convertible security), (iii)&nbsp;any security carrying any warrant or right to subscribe to or purchase any Common Stock, Preferred Stock or other security, or (iv)&nbsp;any such warrant or right.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">21<a name="38204-3-KK-05_PB_21_090104_7107"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=21,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=317671,FOLIO='21',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-05_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:26 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.2</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Exercise of Rights.&#160; </b>If the Company proposes to issue any Equity Securities, it shall give each Major Investor written notice of its intention, describing the Equity Securities, the price and the terms and conditions upon which the Company proposes to issue the same.&#160; Each Major Investor shall have fifteen (15) days from the giving of such notice to agree to purchase its <i>pro rata</i> share of the Equity Securities for the price and upon the terms and conditions specified in the notice by giving written notice to the Company and stating therein the quantity of Equity Securities to be purchased.&#160; Notwithstanding the foregoing, the Company shall not be required to offer or sell such Equity Securities to any Major Investor if such offer or sale would cause the Company to be in violation of applicable federal securities laws by virtue of such offer or sale.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.3</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Issuance of Equity Securities to Other Persons</b>.&#160; If not all of the Major Investors elect to purchase their <i>pro rata</i> share of the Equity Securities, then the Company shall promptly notify in writing the Major Investors who do so elect and shall offer such Major Investors the right to acquire such unsubscribed shares on a <i>pro rata</i> basis.&#160; The Major Investors shall have five (5)&nbsp;days after receipt of such notice to notify the Company of its election to purchase all or a portion thereof of the unsubscribed shares.&#160; The Company shall have ninety (90) days thereafter to sell the Equity Securities in respect of which the Major Investor&#146;s rights were not exercised, at a price not lower and upon general terms and conditions not materially more favorable to the purchasers thereof than specified in the Company&#146;s notice to the Major Investors pursuant to Section&nbsp;4.2 hereof.&#160; If the Company has not sold such Equity Securities within ninety (90) days of the notice provided pursuant to Section&nbsp;4.2, the Company shall not thereafter issue or sell any Equity Securities, without first offering such securities to the Major Investors in the manner provided above.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.4</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Termination of Rights of First Refusal.&#160; </b>The rights of first refusal established by this Section&nbsp;4 shall not apply to, and shall terminate upon the earlier of (i)&nbsp;the effective date of a Qualified IPO or (ii)&nbsp;upon a Liquidation Event (as defined in the Charter).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.5</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Assignment of Rights of First Refusal.&#160; </b>The rights of first refusal of each Major Investor under this Section&nbsp;4 may be assigned to the same parties, subject to the same restrictions as any transfer of registration rights pursuant to Section&nbsp;2.9; <i>provided further </i>that Regents of the University of Michigan shall also have the right to apportion its right of first refusal among itself and any Osage University Partners, including any investment fund managed by Osage University Partners that is an &#147;accredited investor&#148; with the meaning of Regulation D under the Securities Act.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.6</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Excluded Securities.&#160; </b>The rights of first refusal established by this Section&nbsp;4 shall have no application to any of the following Equity Securities:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; any Equity Securities that fall within one of the enumerated exceptions to the definition of Excluded Securities (as defined in the Charter);</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; any Equity Securities issued pursuant to the Share Contribution Agreement; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">22<a name="38204-3-KK-05_PB_22_090109_9111"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=22,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=559167,FOLIO='22',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-05_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:26 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; any Equity Securities that are specifically deemed not to be subject to the rights of first refusal in this Section&nbsp;4 by the written consent or affirmative vote of the Major Investors holding a majority of the Preferred Stock then held by all Major Investors.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;5.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>MISCELLANEOUS.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.1</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Governing Law.&#160; </b>This Agreement shall be governed by and construed under the laws of the State of Delaware in all respects as such laws are applied to agreements among Delaware residents entered into and performed entirely within Delaware, without giving effect to conflict of law principles thereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.2</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Successors and Assigns.&#160; </b>Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the parties hereto and their respective successors, assigns, heirs, executors, and administrators and shall inure to the benefit of and be enforceable by each person who shall be a holder of Registrable Securities from time to time; <i>provided, however</i>, that prior to the receipt by the Company of adequate written notice of the transfer of any Registrable Securities specifying the full name and address of the transferee, the Company may deem and treat the person listed as the holder of such shares in its records as the absolute owner and holder of such shares for all purposes, including the payment of dividends or any redemption price.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.3</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Entire Agreement.&#160; </b>This Agreement, the Exhibits and Schedules hereto, the Share Contribution Agreement and the other documents delivered pursuant thereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and no party shall be liable or bound to any other in any manner by any oral or written representations, warranties, covenants and agreements except as specifically set forth herein and therein.&#160; Each party expressly represents and warrants that it is not relying on any oral or written representations, warranties, covenants or agreements outside of this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.4</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Severability.&#160; </b>In the event one or more of the provisions of this Agreement should, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.5</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Amendment and Waiver.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Except as otherwise expressly provided, this Agreement may be amended or modified, and the obligations of the Company and the rights of the Holders under this Agreement may be waived, only upon the written consent of the Company and the holders of a majority of the then-outstanding Registrable Securities.&#160; Notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section&nbsp;4 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">23<a name="38204-3-KK-05_PB_23_090116_2270"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=23,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=635224,FOLIO='23',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-05_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:26 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">securities in such transaction).&#160; The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver.&#160; Any amendment, termination, or waiver effected in accordance with this Section&nbsp;</font>5.5 shall be binding on all parties hereto, regardless of whether any such party has consented thereto provided<i>, </i>however<i>, </i>that notwithstanding the foregoing, (i)&nbsp;Section&nbsp;3.7(a)&nbsp;of this Agreement shall not be amended or waived without the written consent of any of NEA, Osage, Frazier, Altitude, Roche, Longwood or Adams Street so long as such party is entitled to designate an observer pursuant to Section&nbsp;3.7(a), (ii)&nbsp;Section&nbsp;3.7(b)&nbsp;shall not be amended or waived without the written consent of AstraZeneca so long as such party is entitled to designate an observer pursuant to Section&nbsp;3.7(b)&nbsp;and (iii)&nbsp;Section&nbsp;3.7(c)&nbsp;shall not be amended or waived without the written consent of the holders of a majority of the shares of New Preferred Stock so long as such holders are entitled to designate an observer pursuant to Section&nbsp;3.7(c).&#160; No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; For the purposes of determining the number of Holders or Investors entitled to vote or exercise any rights hereunder, the Company shall be entitled to rely solely on the list of record holders of its stock as maintained by or on behalf of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.6</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Delays or Omissions.&#160; </b>It is agreed that no delay or omission to exercise any right, power, or remedy accruing to any party, upon any breach, default or noncompliance by another party under this Agreement shall impair any such right, power, or remedy, nor shall it be construed to be a waiver of any such breach, default or noncompliance, or any acquiescence therein, or of any similar breach, default or noncompliance thereafter occurring.&#160; It is further agreed that any waiver, permit, consent, or approval of any kind or character on any party&#146;s part of any breach, default or noncompliance under this Agreement or any waiver on such party&#146;s part of any provisions or conditions of this Agreement must be in writing and shall be effective only to the extent specifically set forth in such writing.&#160; All remedies, either under this Agreement, by law, or otherwise afforded to any party, shall be cumulative and not alternative.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.7</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Notices.&#160; </b>All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a)&nbsp;upon personal delivery to the party to be notified, (b)&nbsp;when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the next business day, (c)&nbsp;five (5)&nbsp;days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d)&nbsp;two (2)&nbsp;days after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.&#160; All communications shall be sent to the party to be notified at the address as set forth on the signature pages&nbsp;hereof or Exhibit&nbsp;A hereto or at such other address or electronic mail address as such party may designate by ten (10)&nbsp;days advance written notice to the other parties hereto.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.8</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Attorneys&#146; Fees.&#160; </b>In the event that any suit or action is instituted under or in relation to this Agreement, including without limitation to enforce any provision in this Agreement, the prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs and expenses of enforcing any right of such prevailing party under or with respect to this Agreement, including without limitation, such reasonable fees and expenses of attorneys and accountants, which shall include, without limitation, all fees, costs and expenses of appeals.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">24<a name="38204-3-KK-05_PB_24_090123_6952"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=24,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=584599,FOLIO='24',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-05_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:26 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.9</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Titles and Subtitles.&#160; </b>The titles of the sections and subsections of this Agreement are for convenience of reference only and are not to be considered in construing this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.10</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Additional Investors.</b>&#160; Notwithstanding anything to the contrary contained herein, if the Company shall issue additional shares of its Preferred Stock pursuant to the Share Contribution Agreement, any purchaser of such shares of Preferred Stock shall become a party to this Agreement by executing and delivering an additional counterpart signature page&nbsp;to this Agreement and shall be deemed an &#147;<b><i style="font-weight:bold;">Investor</i></b>,&#148; a &#147;<b><i style="font-weight:bold;">Holder</i></b>&#148; and a party hereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.11</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Counterparts.&#160; </b>This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.12</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Aggregation of Stock.&#160; </b>All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.13</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Pronouns.</b>&#160; All pronouns contained herein, and any variations thereof, shall be deemed to refer to the masculine, feminine or neutral, singular or plural, as to the identity of the parties hereto may require.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.14</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Termination.</b>&#160; This Agreement shall terminate and be of no further force or effect upon the earlier of (i)&nbsp;a Liquidation Event; or (ii)&nbsp;the date three (3)&nbsp;years following the effective date of a Qualified IPO.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.15</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Right to Conduct Activities.</b>&nbsp; The Company hereby agrees and acknowledges that NEA, 5AM Co-Investors III, L.P., 5AM Ventures III, L.P., Adams Street, Roche, Longwood, Frazier, Osage,Altitude, CEMA Inc. (&#147;<b><i style="font-weight:bold;">CEMA</i></b>&#148;), Otannale SAS (&#147;<b><i style="font-weight:bold;">Otannale</i></b>&#148;), SHAM Innovation Sante SAS (&#147;<b><i style="font-weight:bold;">SHAM</i></b>&#148;) and InnoBio FPCI (&#147;<b><i style="font-weight:bold;">InnoBio</i></b>&#148;) (such Investors, collectively, the &#147;<b><i style="font-weight:bold;">Fund Investors</i></b>&#148;) are professional investment funds, and as such invest in numerous portfolio companies, some of which may be deemed competitive with the Company&#146;s business (as currently conducted or as currently propose to be conducted).&nbsp; The Company hereby agrees that, to the extent permitted under applicable law, no Fund Investor shall be liable to the Company for any claim arising out of, or based upon, (i)&nbsp;the investment by such Fund Investor in any entity competitive with the Company, or (ii)&nbsp;actions taken by any partner, officer or other representative of such Fund Investor to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x)&nbsp;any of the Investors from liability associated with the unauthorized disclosure of the Company&#146;s confidential information obtained pursuant to this Agreement, or (y)&nbsp;any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.16</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Amendment of Prior Agreement.&#160; </b>The Prior Agreement is hereby amended and superseded in its entirety and restated herein.&#160; Such amendment and restatement is effective upon the execution of this Agreement by the Company and the parties required for an amendment pursuant to Section&nbsp;5.5 of the Prior Agreement.&#160; Upon such execution, all provisions of, rights</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">25<a name="38204-3-KK-05_PB_25_090130_9801"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=25,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=466174,FOLIO='25',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-05_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:26 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">granted and covenants made in the Prior Agreement are hereby waived, released and superseded in their entirety by the provisions hereof and shall have no further force or effect.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.17</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Dispute Resolution</b>.&#160; The parties (a)&nbsp;hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b)&nbsp;agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of Delaware or the United States District Court for the District of Delaware, and (c)&nbsp;hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF.&#160; THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY&nbsp;BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION,&nbsp;INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS.&#160; THIS SECTION&nbsp;HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS.&#160; EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.18</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Acknowledgment</b>.&#160; The Company acknowledges that the Investors are in the business of venture capital investing and therefore review the business plans and related proprietary information of many enterprises, including enterprises which may have products or services which compete directly or indirectly with those of the Company.&#160; Nothing in this Agreement shall preclude or in any way restrict the Investors from investing or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[<b>SIGNATURE PAGE FOLLOWS</b>]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">26<a name="38204-3-KK-05_PB_26_090136_2440"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=26,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=836297,FOLIO='26',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-05_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:26 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF, </font></b>the parties hereto have executed this <b>SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT </b>as of the date set forth in the first paragraph hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COMPANY:</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">MILLENDO   THERAPEUTICS,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Signature:</font></p>    </td>
<td width="39%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:39.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Julia Owens</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Print Name:</font></p>    </td>
<td width="39%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:39.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Julia Owens</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="39%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:39.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President and CEO</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=27,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=572584,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-05_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:26 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF, </font></b>the parties hereto have executed this <b>SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT </b>as of the date set forth in the first paragraph hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEW ENTERPRISE ASSOCIATES 15, L.P.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="39%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:39.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Louis Citron</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:43.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Louis Citron</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:43.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief Legal Officer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:43.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEA VENTURES 2015, L.P.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="39%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:39.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Louis Citron</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:43.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Louis Citron</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:43.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice President</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=28,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=810383,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-05_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:26 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF, </font></b>the parties hereto have executed this <b>SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT </b>as of the date set forth in the first paragraph hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:47.62%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="47%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:47.62%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:47.62%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FRAZIER   HEALTHCARE VI</font></b><b>, L.P.</b></p>    </td>   </tr>
<tr>
<td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:47.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BY: FHM VI, LP, its   general partner</font></p>    </td>   </tr>
<tr>
<td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:47.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BY: FHM VI, LLC, its   general partner</font></p>    </td>   </tr>
<tr>
<td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Signature:</font></p>    </td>
<td width="37%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:37.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ James Topper</font></p>    </td>   </tr>
<tr>
<td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Print Name:</font></p>    </td>
<td width="37%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:37.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">James Topper</font></p>    </td>   </tr>
<tr>
<td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="37%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:37.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Authorized   Representative</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=29,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=775574,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-05_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:26 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF, </font></b>the parties hereto have executed this <b>SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT </b>as of the date set forth in the first paragraph hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5AM   VENTURES III, L.P.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: 5AM Partners III,   LLC, its General Partner</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Andrew J. Schwab</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Andrew J. Schwab,</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Managing Member</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5AM CO-INVESTORS III, L.P.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: 5AM Partners III,   LLC, its General Partner</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Andrew J. Schwab</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Andrew J. Schwab,</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Managing Member</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=30,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=60955,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-05_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:26 2018' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF, </font></b>the parties hereto have executed this <b>SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT </b>as of the date set forth in the first paragraph hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">GALLAGHER REVOCABLE TRUST</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Carol Gallagher</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Carol Gallagher</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Trustee</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=31,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=191718,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-07_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:27 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF, </font></b>the parties hereto have executed this <b>SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT </b>as of the date set forth in the first paragraph hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OSAGE UNIVERSITY PARTNERS I,   L.P.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: Osage University   GP, LP, its general partner</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: Osage Partners,   LLC, its general partner</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ William Harrington</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">William Harrington</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Authorized Signer</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=32,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=798196,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-07_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:27 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF, </font></b>the parties hereto have executed this <b>SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT </b>as of the date set forth in the first paragraph hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ALTITUDE LIFE SCIENCE VENTURES</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Dave Maki</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dave Maki</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Managing Member</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=33,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=627873,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-07_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:27 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF, </font></b>the parties hereto have executed this <b>SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT </b>as of the date set forth in the first paragraph hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ASTRAZENECA AB</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Anders Holmen</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Anders Holmen</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">VP Pharm Sci</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=34,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=531464,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-07_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:27 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF, </font></b>the parties hereto have executed this <b>SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT </b>as of the date set forth in the first paragraph hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ADAMS   STREET 2012 DIRECT FUND LP</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: ASP 2012 Direct Management LP its   General Partner</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: ASP 2012 Direct Management LLC its   General Partner</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: Adams Street Partners, LLC its   Managing Member</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Terry P. Gould</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Elisha (Terry) P. Gould   III</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Partner</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ADAMS   STREET 2013 DIRECT FUND LP</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: ASP 2013 Direct Management LP its   General Partner</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: ASP 2013 Direct Management LLC its   General Partner</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: Adams Street Partners, LLC its   Managing Member</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Terry P. Gould</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Elisha (Terry) P. Gould   III</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Partner</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ADAMS   STREET 2014 DIRECT FUND LP</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: ASP 2014 Direct Management LP its   General Partner</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: ASP 2014 Direct Management LLC its   General Partner</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: Adams Street Partners, LLC its   Managing Member</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Terry P. Gould</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Elisha (Terry) P. Gould   III</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Partner</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ADAMS   STREET 2015 DIRECT VENTURE/GROWTH FUND LP</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: ASP 2015 Direct Management LP its   General Partner</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: ASP 2015 Direct Management LLC its   General Partner</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: Adams Street Partners, LLC its   Managing Member</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Terry P. Gould</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Elisha (Terry) P. Gould   III</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Partner</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ADAMS   STREET VENTURE/GROWTH FUND VI LP</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: ASP VG Management VI LP its General   Partner</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: ASP VG Management VI LLC its General   Partner</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: Adams Street Partners, LLC its Managing   Member</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Terry P. Gould</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Elisha (Terry) P. Gould   III</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Partner</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=35,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=238693,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-07_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:27 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF, </font></b>the parties hereto have executed this <b>SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT </b>as of the date set forth in the first paragraph hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RENAISSANCE VENTURE CAPITAL   FUND I, LP</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: Renaissance Venture   Partners GP, LLC</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Christopher Riznik</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Christopher Riznik</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CEO</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=36,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=608375,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-07_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:27 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF, </font></b>the parties hereto have executed this <b>SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT </b>as of the date set forth in the first paragraph hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RANDALL WHITCOMB</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Randall Whitcomb</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=37,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=486911,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-07_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:27 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF, </font></b>the parties hereto have executed this <b>SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT </b>as of the date set forth in the first paragraph hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Roche Finance Ltd</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Carole Nuechterlein</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Carole Nuechterlein</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Authorized Signatory</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Andreas Knierzinger</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Andreas Knierzinger</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Authorized Signatory</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=38,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=650493,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-07_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:27 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF, </font></b>the parties hereto have executed this <b>SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT </b>as of the date set forth in the first paragraph hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PURCHASERS:</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Longwood Fund III GP, LLC</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">General Partner of Longwood Fund III LP</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Rob Hadfield</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Rob Hadfield</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General Counsel and Partner</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=39,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=275658,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-07_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:27 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF, </font></b>the parties hereto have executed this <b>SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT </b>as of the date set forth in the first paragraph hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ANN ARBOR SPARK</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Skip Simms</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Skip Simms</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sr. Vice President</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=40,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=336739,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-07_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:27 2018' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF, </font></b>the parties hereto have executed this <b>SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT </b>as of the date set forth in the first paragraph hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OTONNALE SAS</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">represented by Mr.&nbsp;Thierry Abribat</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Thierry Abribat</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Thierry Abribat</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=41,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=36431,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-09_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:36 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF, </font></b>the parties hereto have executed this <b>SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT </b>as of the date set forth in the first paragraph hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CEMA Inc.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">represented by Mr.&nbsp;Thierry Abribat</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Thierry Abribat</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Thierry Abribat</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=42,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=584799,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-09_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:36 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF, </font></b>the parties hereto have executed this <b>SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT </b>as of the date set forth in the first paragraph hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SHAM INNOVATION SANT&#200; SAS</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">represented by </font>Mrs.&nbsp;Mounia   Chaoui</p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ </font>Mounia Chaoui</p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mounia   Chaoui</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=43,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=425783,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-09_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:36 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF, </font></b>the parties hereto have executed this <b>SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT </b>as of the date set forth in the first paragraph hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INNOBIO FPCI</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">represented   by Mr.&nbsp;Olivier Martinez</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Olivier Martinez</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Olivier Martinez</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=44,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=748437,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-09_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:36 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF, </font></b>the parties hereto have executed this <b>SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT </b>as of the date set forth in the first paragraph hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TAB CONSULTING SARL</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">represented   by its <i>G&#233;rant</i> Mr.&nbsp;Thierry   Abribat</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ </font>Thierry Abribat</p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Thierry   Abribat</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=45,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=508749,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-09_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:36 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF, </font></b>the parties hereto have executed this <b>SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT </b>as of the date set forth in the first paragraph hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EUMEDIX FR S.&#192;. R.L.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">represented   by Mr.&nbsp;Thierry Abribat</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ </font>Thierry Abribat</p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Thierry   Abribat</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=46,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=347772,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-09_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:36 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF, </font></b>the parties hereto have executed this <b>SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT </b>as of the date set forth in the first paragraph hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DR. EZIO GIACOMO GIOVANNI GHIGO</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">represented   by Mr.&nbsp;Thierry Abribat</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ </font>Thierry Abribat</p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Thierry   Abribat</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=47,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=80244,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-09_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:36 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF, </font></b>the parties hereto have executed this <b>SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT </b>as of the date set forth in the first paragraph hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DR. AART JOHANNES VAN DER LELIJ</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">represented   by Mr.&nbsp;Thierry Abribat</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ </font>Thierry Abribat</p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Thierry   Abribat</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=48,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=329673,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-09_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:36 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF, </font></b>the parties hereto have executed this <b>SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT </b>as of the date set forth in the first paragraph hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">LEERINK PARTNERS LLC</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.16%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ </font>Gabriel Cavazos</p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Gabriel   Cavazos</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Managing Director</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=49,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=718927,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-09_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:36 2018' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;A</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SCHEDULE OF INVESTORS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">New Enterprise Associates 15, L.P.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NEA Ventures 2015, L.P.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5AM Co-Investors III, L.P.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5AM Ventures III, L.P.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ann Arbor SPARK</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Frazier Healthcare VI, L.P.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Gallagher Revocable Trust</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Osage University Partners I, L.P.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Regents of the University of Michigan</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Altitude Life Science Ventures II, L.P.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Altitude Life Science Ventures Side Fund II, L.P.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AstraZeneca AB</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adams Street 2012 Direct Fund LP</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adams Street 2013 Direct Fund LP</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adams Street 2014 Direct Fund LP</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adams Street 2015 Direct Venture/Growth Fund LP</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adams Street Venture/Growth Fund VI LP</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Renaissance Venture Capital Fund I, LP</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Longwood Fund III, LP</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Randall Whitcomb</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Roche Finance Ltd.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Leerink Partners LLC</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">TAB Consulting SARL</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SHAM Innovation Sant&#233; SAS</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">InnoBio FPCI</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Otonnale SAS</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CEMA Inc.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Eumedix FR S.&#192; R.L.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dr.&nbsp;Ezio Giacomo Giovanni Ghigo</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dr.&nbsp;Aart Johannes Van Der Lelij</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=50,EFW="2237017",CP="OVASCIENCE",DN="2",CHK=310876,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KK-09_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 09:36 2018' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.7
<SEQUENCE>3
<FILENAME>a2237017zex-4_7.htm
<DESCRIPTION>EX-4.7
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;4.7</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">MILLENDO THERAPEUTICS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FIRST AMENDMENT TO</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECOND AMENDED AND RESTATED</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTOR RIGHTS AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 5.65pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This First Amendment to the Second Amended and Restated Investor Rights Agreement (the &#147;<u>Amendment</u>&#148;), dated as of October&nbsp;24, 2018 is by and between MILLENDO THERAPEUTICS,&nbsp;INC., a Delaware corporation (the &#147;<u>Company</u>&#148;) and the persons or entities listed on <u>Exhibit&nbsp;A</u> hereto, referred to hereinafter as the &#147;Investors&#148; and each individually as an &#147;Investor.&#148; The Company and the Investors are sometimes referred to herein as a &#147;<u>Party</u>&#148; and, collectively, as the &#147;<u>Parties</u>&#148;.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RECITALS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 5.65pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, the Parties have entered into a Shareholders and Option Agreement, dated as of December&nbsp;19, 2017 (the &#147;<u>Original Agreement</u>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 5.65pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, pursuant to Section&nbsp;5.5(a)&nbsp;of the Original Agreement, the Original Agreement may be amended by the written consent of the Company and the holders of a majority of the then-outstanding Registrable Securities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 5.65pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NOW, THEREFORE, in consideration of the foregoing, and the mutual agreements set forth herein and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Definitions</u>. Capitalized terms used and not defined in this&nbsp;Amendment&nbsp;have the respective meanings assigned to them in the Original&nbsp;Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Amendments&nbsp;to the Original&nbsp;Agreement</u>. As of the Effective Date (defined below), the Original&nbsp;Agreement is hereby amended or modified as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The following definitions are added to Section&nbsp;1.1 of the Original&nbsp;Agreement:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>Company Reverse Merger</u>&#148; means a merger of the Company with and into another Person, pursuant to which the Capital Stock is exchanged for stock in a publicly traded company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>Exchanged Stock</u>&#148; means the stock received by holders of the Capital Stock upon a reclassification, exchange, substitution or other event that results in a change of the number and/or class of the Capital Stock, including in the event of a Company Reverse Merger.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The following definitions appearing in Section&nbsp;1.1 of the Original Agreement are hereby deleted in their entirety and replaced with the following:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>Class&nbsp;Common-1 Stock</u>&#148; shall have the meaning ascribed to such term in the Charter, provided, however, that if the Company Reverse Merger has occurred, then &#147;Class&nbsp;Common-1 Stock&#148; shall mean the Exchanged Stock.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>Common Shares</u>&#148; shall have the meaning ascribed to such term in the Charter, provided, however, that if the Company Reverse Merger has occurred, then &#147;Common Shares&#148; shall mean the Exchanged Stock.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>Common Stock</u>&#148; shall have the meaning ascribed to such term in the Charter, provided, however, that if the Company Reverse Merger has occurred, then &#147;Common Stock&#148; shall mean the Exchanged Stock.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2237017",CP="OVASCIENCE",DN="3",CHK=773702,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KM_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:40 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>Convertible Stock</u>&#148; shall have the meaning ascribed to such term in the Charter, provided, however, that if the Company Reverse Merger has occurred, then &#147;Convertible Stock&#148; shall mean the Exchanged Stock.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>Initial Offering</u>&#148; means the first to occur of (1)&nbsp;Company&#146;s first firm commitment underwritten public offering of its Capital Stock registered under the Securities Act and (2)&nbsp;the Company Reverse Merger.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>New Preferred Stock</u>&#148; means, collectively, the Series&nbsp;A-1 Preferred Stock and the Series&nbsp;B-1 Preferred Stock, provided, however that if the Company Reverse Merger has occurred, then &#147;New Preferred Stock&#148; shall mean the Exchanged Stock.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>Preferred Stock</u>&#148; means, collectively, the Series&nbsp;A Preferred Stock, the Series&nbsp;A-1 Preferred Stock, the Series&nbsp;B Preferred Stock and the Series&nbsp;B-1 Preferred Stock, provided, however that if the Company Reverse Merger has occurred, then &#147;Preferred Stock&#148; shall mean the Exchanged Stock.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>Registrable Securities</u>&#148; means (a)&nbsp;(i)&nbsp;prior to the occurrence of the Company Reverse Merger, the Capital Stock of the Company issuable or issued upon conversion of the Shares and (ii)&nbsp;following the Company Reverse Merger, the Exchanged Stock and (b)&nbsp;any Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, such above-described securities. Notwithstanding the foregoing, Registrable Securities shall not include any securities (i)&nbsp;sold by a person to the public either pursuant to a registration statement or Rule&nbsp;144 or (ii)&nbsp;sold in a private transaction in which the transferor&#146;s rights under Section&nbsp;2 of this Agreement are not assigned.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Section&nbsp;2.14 of the Original&nbsp;Agreement&nbsp;is hereby amended by inserting immediately following the words &#147;(i)&nbsp;the date three (3)&nbsp;years following an initial public offering that results in the conversion of all outstanding shares of Preferred stock&#148; the words &#147;or the consummation of the Company Reverse Merger&#148;.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Section&nbsp;3.7(b)&nbsp;is hereby amended by inserting immediately following the words &#147;the effective date of the Company&#146;s initial public offering of its Common Stock&#148; the words &#147;or the consummation of the Company Reverse Merger&#148;.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Section&nbsp;3.7(c)&nbsp;is hereby amended by inserting immediately following the words &#147;the effective date of the Company&#146;s initial public offering of its Common Stock&#148; the words &#147;or the consummation of the Company Reverse Merger&#148;.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2.6</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Section&nbsp;3.14(b)&nbsp;is hereby amended by inserting immediately following the words &#147;Until the consummation of a Qualified IPO&#148; the words &#147;or the consummation of the Company Reverse Merger&#148;.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2.7</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Section&nbsp;3.17 is hereby amended by inserting immediately following the words &#147;(i)&nbsp;the effective date of a Qualified IPO (as defined in the Charter)&#148; the words &#147;or the consummation of the Company Reverse Merger&#148;.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2.8</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Section&nbsp;4.4 of the Original&nbsp;Agreement&nbsp;is hereby amended by inserting immediately following the words &#147;(i)&nbsp;the effective date of a Qualified IPO&#148; the words &#147;or the consummation of the Company Reverse Merger.&#148;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2.9</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Section&nbsp;5.14 of the Original&nbsp;Agreement&nbsp;is hereby amended by inserting immediately following the words &#147;(ii)&nbsp;the date three (3)&nbsp;years following the effective date of a Qualified IPO&#148; the words &#147;or the consummation of the Company Reverse Merger.&#148;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2.10</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This Amendment will become effective on the date first written above (the &#147;<u>Effective Date</u>&#148;). Except as expressly provided in this Amendment, all of the terms and provisions of each Original&nbsp;Agreement are and will remain in full force and effect and are hereby ratified and confirmed by</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2237017",CP="OVASCIENCE",DN="3",CHK=504944,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KM_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:40 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the Parties. Without limiting the generality of the foregoing, the amendments contained herein will not be construed as an amendment to or waiver of any other provision of each Original&nbsp;Agreement or as a waiver of or consent to any further or future action on the part of either Party that would require the waiver or consent of the other Party. On and after the Effective Date, each reference in the Original&nbsp;Agreement to &#147;this Agreement,&#148; &#147;the Agreement,&#148; &#147;hereunder,&#148; &#147;hereof,&#148; &#147;herein,&#148; or similar words will mean and be a reference to the Original&nbsp;Agreement as amended by this Amendment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Miscellaneous.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.3.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This Amendment shall be governed by and construed under the laws of the State of Delaware in all respects as such laws are applied to agreements among Delaware residents entered into and performed entirely within Delaware, without giving effect to conflict of law principles thereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.3.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This Amendment shall inure to the benefit of and be binding upon each of the Parties and each of their respective successors and assigns.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.3.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The headings in this Amendment are for reference only and do not affect the interpretation of this Amendment.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.3.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This Amendment may be executed in counterparts, each of which is deemed an original, but all of which constitute one and the same agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.3.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This Amendment constitutes the sole and entire agreement between the Parties with respect to the subject matter contained herein, and supersedes all prior and contemporaneous understandings, agreements, representations, and warranties, both written and oral, with respect to such subject matter.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[Signature pages&nbsp;follow.]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2237017",CP="OVASCIENCE",DN="3",CHK=1000515,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KM_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:40 2018' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:36.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, the Parties have executed this Amendment as of the date first written above.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COMPANY</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">MILLENDO THERAPEUTICS INC.</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Julia C.   Owens</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Julia C. Owens</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President and CEO</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Signature Page&nbsp;to First Amendment to Second Amended and Restated Investor Rights Agreement</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2237017",CP="OVASCIENCE",DN="3",CHK=302909,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KM_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:40 2018' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEW ENTERPRISE ASSOCIATES 15, L.P.</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="44%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:44.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Louis Citron</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.58%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Louis Citron</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.58%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief Legal Officer</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.58%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.42%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEA VENTURES 2015, L.P.</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.58%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.42%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.58%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.42%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="44%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:44.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Louis Citron</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.58%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Louis Citron</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.58%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice President</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Signature Page&nbsp;to First Amendment to Second Amended and Restated Investor Rights Agreement</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2237017",CP="OVASCIENCE",DN="3",CHK=291130,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KM_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:40 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FRAZIER HEALTHCARE VI</font></b><b>, L.P.</b><br>   BY: FHM VI, LP, its general partner<br>   BY: FHM VI, LLC, its general partner</p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Signature:</font></p>    </td>
<td width="38%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:38.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ James Topper</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="38%" valign="top" style="padding:0in 0in 0in 0in;width:38.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Print Name:</font></p>    </td>
<td width="38%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:38.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">James Topper</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="38%" valign="top" style="padding:0in 0in 0in 0in;width:38.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="38%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:38.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Authorized Representative</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Signature Page&nbsp;to First Amendment to Second Amended and Restated Investor Rights Agreement</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2237017",CP="OVASCIENCE",DN="3",CHK=516090,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KM_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:40 2018' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">GALLAGHER REVOCABLE TRUST</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Carol Gallagher</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.76%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Carol Gallagher</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Trustee</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Signature Page&nbsp;to First Amendment to Second Amended and Restated Investor Rights Agreement</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2237017",CP="OVASCIENCE",DN="3",CHK=589739,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KM_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:40 2018' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Roche Finance Ltd</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Carole Nuechterlein</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.76%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Carole   Nuechterlein</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Authorized   Signatory</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Andreas   Knierzinger</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.76%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Andreas   Knierzinger</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Authorized   Signatory</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Signature Page&nbsp;to First Amendment to Second Amended and Restated Investor Rights Agreement</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2237017",CP="OVASCIENCE",DN="3",CHK=45501,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KM_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:40 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OTONNALE SAS<br>    </font></b>represented by   Mr.&nbsp;Thierry Abribat</p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Thierry   Abribat</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.76%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Thierry Abribat</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Signature Page&nbsp;to First Amendment to Second Amended and Restated Investor Rights Agreement</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2237017",CP="OVASCIENCE",DN="3",CHK=471192,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KM_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:40 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FONDS INNOBIO FPCI</font></b><br> represented by its management   company, Bpifrance Invesstissement,<br> Itself represented by Olivier   Martinez</p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Olivier Martinez</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.76%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Olivier Martinez</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Signature Page&nbsp;to First Amendment to Second Amended and Restated Investor Rights Agreement</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2237017",CP="OVASCIENCE",DN="3",CHK=778252,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KM_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:40 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTORS:</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TAB CONSULTING SARL</font></b><br> represented by its <i>G&#233;rant</i> Mr.&nbsp;Thierry Abribat</p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.26%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ </font>Thierry Abribat</p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.76%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Thierry Abribat</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Signature Page&nbsp;to First Amendment to Second Amended and Restated Investor Rights Agreement</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2237017",CP="OVASCIENCE",DN="3",CHK=273011,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KM_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:40 2018' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.8
<SEQUENCE>4
<FILENAME>a2237017zex-4_8.htm
<DESCRIPTION>EX-4.8
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;4.8</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">&nbsp;</font></i></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Execution version</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SHAREHOLDERS AND OPTION AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OF</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ALIZ&#201; PHARMA SAS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">December&nbsp;19, 2017</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2237017",CP="OVASCIENCE",DN="4",CHK=637161,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KO-01_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:41 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ALIZ&#201; PHARMA SAS</font></b><b><br> SHAREHOLDERS AND OPTION AGREEMENT</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This SHAREHOLDERS AND OPTION AGREEMENT (the &#147;<u>Agreement</u>&#148;), dated as of December&nbsp;19, 2017 is by and between MILLENDO THERAPEUTICS,&nbsp;INC., a Delaware corporation(together with its successors or assigns that hold Shares, the &#147;<u>Majority Shareholder</u>&#148;), and OTONNALE SAS, a French <i>soci&#233;t&#233; par actions simplifi&#233;e</i>, whose registered office is located at 15 Chemin du Saquin, Espace Europen, B&#228;t G, 69130 Ecully, France, registered under number 539&nbsp;195&nbsp;438 with the Lyon Trade and Companies Register (together with its successors or assigns that hold Shares, the &#147;<u>Minority Shareholder</u>&#148;), in the presence of ALIZ&#201; PHARMA, a French <i>soci&#233;t&#233; par actions simplifi&#233;e</i>, whose registered office is located at 15, Chemin du Saquin, Espace Europ&#233;en, 69130 Ecully, France, registered under number 497 575 621 with the Lyon Trade and Companies Register (the &#147;<u>Company</u>&#148;).&#160; Each of the Majority Shareholder and the Minority Shareholder are sometimes referred to herein as a &#147;<u>Shareholder</u>&#148; and, collectively, as the &#147;<u>Shareholders</u>&#148;.&#160; The Company and the Shareholders are sometimes referred to herein as a &#147;<u>Party</u>&#148; and, collectively, as the &#147;<u>Parties</u>&#148;.&#160; The definitions of certain capitalized terms used herein are set forth in <u>Section&nbsp;8</u>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RECITALS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, as at the date hereof: (i)&nbsp;Majority Shareholder owns 184,648 Shares in the Company (the &#147;<u>Majority Shareholder Shares</u>&#148;) and (ii)&nbsp;Minority Shareholder owns 36,302 Shares in the Company (the &#147;<u>Minority Shareholder Shares</u>&#148;), the Majority Shareholder Shares and Minority Shareholder Shares represent, together, 100% of the share capital and voting right (on non-diluted basis) of the Company as at the date hereof.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, the Company and the Shareholders desire to enter into this Agreement to provide for certain matters with respect to the ownership and transfer by the Shareholders of Shares owned as of the date hereof or hereafter acquired by the Shareholders.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NOW, THEREFORE, in consideration of the foregoing, and the mutual agreements set forth herein and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;1.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>MANAGEMENT ARRANGEMENTS; AND APPROVAL FOR CERTAIN ACTIONS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>President</u>.&#160; The Shareholders (severally and not jointly (<i>conjointement et non solidairement</i>)), within their respective powers and capacity as holders of Shares and, as the case may be, officer (<i>mandataire social</i>) of the Company, and the Company shall take all Necessary Actions to cause:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 45.0pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the President of the Company to be designated among the candidate(s)&nbsp;selected by the Majority Shareholder; <u>provided</u> that the first President as from the date hereof shall be the Majority Shareholder represented by Ms Julia C. Owens; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 45.0pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the President of the Company to be appointed as may be required from time to time by the Majority Shareholder in compliance with this Section&nbsp;1(a)&nbsp;as well as applicable law and the Bylaws.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2237017",CP="OVASCIENCE",DN="4",CHK=871470,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KO-01_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:41 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Day-to-Day Management</u>.&#160; Subject to authority granted to the shareholders of the Company under mandatory French laws and the Bylaws, the President shall be responsible for the overall direction and control of the management of the Company and the formulation of the policies to be applied in the conduct of the Company&#146;s business in compliance with applicable laws and the Bylaws. Subject to mandatory applicable laws and the Bylaws Management of the Company will manage the day-to-day operations of the Company in accordance with the authority of the President.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;2.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>MINORITY SHAREHOLDER PROXY.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The shareholders undertake and agree that, until the Call Option Expiration Date:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Minority Shareholder and Majority Shareholder undertake to consult each other in order to find a mutual position prior to any shareholders&#146; meeting of the Company for all items on the agenda of the meeting and shall use their best efforts in order to reach a mutual position.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Notwithstanding the foregoing, the Minority Shareholder undertakes to vote in the same way as the Majority Shareholder as regards all items on the agenda of each shareholders&#146; meetings of the Company, except when the decision submitted to the shareholders&#146; meeting vote:<i> (i)&nbsp;</i>is related to the changing of the form of the Company into a partnership (French <i>soci&#233;t&#233; en nom collectif</i>) or transformation of the Company into a <i>soci&#233;t&#233; en commandite simple</i> or into a <i>soci&#233;t&#233; en commandite par actions</i>), <i>(ii)&nbsp;</i>is contrary to the best corporate interest (<i>int&#233;r&#234;t social</i>) of the Company, <i>(iii)</i>&nbsp;is related to the removal of a corporate officer of the Company, <i>(iv)</i>&nbsp;would result in a breach by Minority Shareholder of any applicable laws or the Bylaws, <i>(v)</i>&nbsp;would result in any increase of its commitments (<i>augmentation des engagements</i>) in the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>When unanimous consent of all shareholders of the Company is required at a shareholders&#146; meeting of the Company, Minority Shareholder moreover undertakes to attend such meeting or to grant appropriate voting power to Majority Shareholder, whatever the means used to convene such meeting (physical shareholders&#146; meeting, unanimous written deed or consultation in writing).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;3.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>TRANSFERS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Transfer Restrictions</u>.&#160; The Minority Shareholder shall not Transfer any Shares between the execution date hereof and the Call Option Expiration Date, except for Transfers approved in writing by the Majority Shareholder or for purposes of completion of the Put Option or Call Option set forth in Section&nbsp;4 below.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Other Restrictions on Transfers.</u>&#160; In addition to the restrictions set forth above, any Transfer of Shares by the Minority Shareholder to a transferee, other than pursuant to the Put Option or Call Option set forth in Section&nbsp;4 below or as otherwise permitted by the Majority Shareholder, shall be permitted only if the transferee shall agree in writing to be bound by, and comply with, the terms and conditions of this Agreement by executing an adherence act in the form attached as <u>Exhibit&nbsp;A</u> hereto.&#160; Upon the execution of the adherence act in the form attached as <u>Exhibit&nbsp;A</u> hereto, such transferee shall be deemed to be a Minority Shareholder pursuant to this Agreement and references to &#147;Minority Shareholder&#148; shall be deemed to be references to all &#147;Minority Shareholders&#148;.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="38204-3-KO-01_PB_2_092322_5224"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2237017",CP="OVASCIENCE",DN="4",CHK=659035,FOLIO='2',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KO-01_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:41 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;4.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>OPTIONS (<i>PROMESSES</i>)</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Shareholders undertake and agree that the exercise of the Put Option and Call Option pursuant to this Section&nbsp;4 shall be subject to Majority Shareholder having sufficient funding (by any means, including, but not limited to, as a result of one or more capital increases, shareholders&#146; loans or bank financing or reallocation of existing capital) representing an amount at least equal to the Cash Consideration by November&nbsp;30, 2018 at the latest (the &#147;<u>Financing Condition</u>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For purposes of this Section&nbsp;4, the Majority Shareholder shall notify to Minority Shareholder by November&nbsp;30, 2018 at the latest that it has satisfied the Financing Condition.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1. <u>Put Option</u></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to the terms and conditions set out in the Agreement and satisfaction of the Financing Condition, upon request by Minority Shareholder, Majority Shareholder hereby unconditionally and irrevocably undertakes to acquire from Minority Shareholder pursuant to Section&nbsp;4.4, the then all outstanding Shares held by the Minority Shareholder (the &#147;<u>Put Option</u>&#148;). The Put Option may only be exercised with respect to all (and not a portion of) the Shares.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Put Option may be exercised only once, by means of a notification (the &#147;<u>Put Option Exercise Notice</u>&#148;) sent by Minority Shareholder to Majority Shareholder, at any time during the Put Option Exercise Period.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Put Option will automatically become null and void as at the Put Option Expiration Date if Minority Shareholder does not exercise it during the Put Option Exercise Period.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Minority Shareholder accepts the benefit of the Put Option, as an option only, without however undertaking to sell the Shares, until Minority Shareholder serves the Put Option Exercise Notice within the Put Option Exercise Period.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2. <u>Call Option</u></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to the terms and conditions set out in the Agreement and satisfaction of the Financing Condition, if the Minority Shareholder does not deliver the Put Option Exercise Notice during the Put Option Exercise Period, upon request by Majority Shareholder, Minority Shareholder hereby unconditionally and irrevocably undertakes to sale or contribute, as applicable, to Majority Shareholder pursuant to Section&nbsp;4.4, all its then outstanding Shares (the &#147;<u>Call Option</u>&#148;). The Call Option may only be exercised with respect to all (and not a portion of) the Shares.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Call Option may be exercised only once, by means of a notification (the &#147;<u>Call Option Exercise Notice</u>&#148; and together with the Put Option Exercise Notice, the &#147;<u>Exercise Notice</u>&#148;)) sent by Majority Shareholder to Minority Shareholder, at any time during the Call Option Exercise Period.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Call Option will automatically become null and void as at the Call Option Expiration Date if Majority Shareholder does not exercise it during the Call Option Exercise Period.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Majority Shareholder accepts the benefit of the Call Option, as an option only, without however undertaking to acquire the Shares until Majority Shareholder serves the Call Option Exercise Notice within the Call Option Exercise Period.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="38204-3-KO-01_PB_3_092353_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2237017",CP="OVASCIENCE",DN="4",CHK=834648,FOLIO='3',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KO-01_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:41 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.3. <u>Accelerated of Call Option</u></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding the foregoing, in case of a Triggering Sale between the date of execution hereof and December&nbsp;31, 2018, the Call Option shall be accelerated so that Majority Shareholder may acquire all outstanding Shares of the Minority Shareholder immediately prior to completion of the relevant Triggering Sale and Sections 4.2 and 4.4 shall apply <i>mutatis mutandis</i> except for the Call Option Exercise Period which shall start on the execution date hereof and end on December&nbsp;31, 2018; <u>provided</u>, however, that, in case the relevant acquirer is a private company and the consideration to be paid by such acquirer to the Shareholders in the relevant Triggering Sale consists solely of new shares of such acquirer, then Majority Shareholder shall use its reasonable commercial efforts to postpone the completion date of the relevant Triggering Sale until after December&nbsp;1</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">st</font>, 2018.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.4. <u>Transfer of Shares in case of exercise of the Call or Put Option</u></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 7.1pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In case of exercise of the Put Option pursuant to the Section&nbsp;4.1 or of the Call Option pursuant to Section&nbsp;4.2 (or 4.3, as applicable), the Minority Shareholder shall: (i)&nbsp;sell (<i>c&#233;der</i>) 3,030 Shares (or in case Minority Shareholder has transferred or received any Shares after the execution date hereof, 9% of the Shares then held by the Minority Shareholder) (the &#147;<u>Otonnale Sale</u>&#148;) to Majority Shareholder which will pay in cash an amount equal to &#128;699,735.34 (or in case Minority Shareholder has transferred or received any Shares after the execution date hereof, &#128;230.93 per Share then held by the Minority Shareholder) (the &#147;<u>Cash Consideration</u>&#148;) to Minority Shareholder in remuneration therefor; and (ii)&nbsp;contribute in kind (<i>apporter en nature</i>) 33,272 Shares (or in case Minority Shareholder has transferred or received any Shares after the execution date hereof, 91% of the Shares then held by the Minority Shareholder) (the &#147;<u>Otonnale Contribution</u>&#148;) to Majority Shareholder in exchange for shares of Majority Shareholder Capital Stock equal to the amounts provided for in the Contribution Agreement and as set forth in the Consideration Certificate delivered pursuant thereto (the &#147;<u>Share Consideration</u>&#148;), or such corresponding aggregate number of shares of Majority Shareholder Common Stock in case of conversion of the Majority Shareholder Class&nbsp;Common-1 Stock, Majority Shareholder Series&nbsp;A-1 Preferred Stock and Majority Shareholder Series&nbsp;B-1 Preferred Stock into Majority Shareholder Common Stock before the Otonnale Closing pursuant to the Majority Shareholder Certificate of Incorporation. For the avoidance of doubt, the Share Consideration shall not be subject to adjustment for any dividends, splits, reverse splits, combinations, recapitalizations, and the like, in each case, of the Company, occurring after the date hereof;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .1in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Procedural Requirements</u>.&#160; In case of exercise of the Put Option pursuant to the Section&nbsp;4.1 or of the Call Option pursuant to Section&nbsp;4.2 (or 4.3, as applicable), the applicable Exercise Notice to be sent by the Minority Shareholder or Majority Shareholder shall specify the expected effective date (the &#147;<u>Effective Date</u>&#148;) of the contribution and sale of the Shares pursuant to this Section&nbsp;4; <u>provided</u>, that, in the case of the Put Option Exercise Notice, such date shall be at least five (5)&nbsp;Business Days after the date on which the Put Option Exercise Notice is sent and on or prior to December&nbsp;31, 2018.&#160; In the case of the Call Option Exercise Notice, the Effective Date should be within the Call Option Exercise Period. As at such Effective Date: (i)&nbsp;the Minority Shareholder and its transferees (if any) shall deliver to the Company, at the place designated in such notice, the duly executed stock transfer forms <i>(ordres de mouvement de titres)</i> reflecting the Otonnale Contribution and Otonnale Sale, and (ii)&nbsp;the Majority Shareholder shall (a)&nbsp;issue and deliver to such holder, or to his, her or its nominees, a certificate or certificates for the number of full shares of the Share Consideration issuable on such contribution in accordance with the provisions hereof, and pay cash as provided in Section&nbsp;1.11 of the Contribution Agreement in lieu of any fraction of a share of Share Consideration otherwise issuable upon such contribution, and (b)&nbsp;pay the Cash Consideration by wire transfer in immediately available funds to the bank account so notified by Minority Shareholders. The Company shall update the stock</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="38204-3-KO-01_PB_4_092441_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2237017",CP="OVASCIENCE",DN="4",CHK=307165,FOLIO='4',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KO-01_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:41 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 7.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">transfer books as soon as the Otonnale Contribution and Otonnale Sale are completed, to reflect such completion in favor of the Majority Shareholder.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .1in;text-indent:.35in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In a situation where Majority Shareholder has validly exercised its Call Option on the Shares pursuant to the provisions of Section&nbsp;4.2 or 4.3, as applicable, yet where Minority Shareholder has defaulted in the execution of his obligations hereunder, the Majority Shareholder shall (a)&nbsp;issue and deliver to Minority Shareholder or to his, her or its nominees, a certificate or certificates for the number of full shares of the Share Consideration issuable on such contribution in accordance with the provisions hereof and (b)&nbsp;deposit in escrow at the Escrow: (x)&nbsp;the cash amount as provided in Section&nbsp;1.11 of the Contribution Agreement in lieu of any fraction of a share of Share Consideration otherwise issuable upon such contribution, (y)&nbsp;the certificate or certificates for the number of full shares of the Share Consideration issued on such contribution in accordance with the provisions hereof and (z)&nbsp;the Cash Consideration; and remittance to the Company of a copy of the above certificate and of the exercise notice specified in Section&nbsp;4.2(b), together with a receipt from the Escrow, shall be deemed a duly executed transfer order and shall cause the Company, which the Company hereby accepts, to register the corresponding transfer of Shares in the shareholders registry (<i>registre des mouvements de titres</i>) and the relevant individual shareholders&#146; accounts. As per article R. 228-10 of the French commercial code, the date of transfer of ownership of the Shares would be deemed set by the Shareholders on the date of receipt by the Company of a copy of the Call Option Exercise Notice.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;5.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>OTHER COVENANTS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .2in;text-indent:42.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160; </font><u>Dividends</u>. In case of exercise of the Put Option pursuant to the Section&nbsp;4.1 or of the Call Option pursuant to Section&nbsp;4.2 (or 4.3, as applicable), Minority Shareholder hereby expressly and irrevocably waives any and all rights it may have to receive any dividend or distribution of any sort from the Company with regard to the financial year which will end on December&nbsp;31, 2018. The Minority Shareholder acknowledges the fact that such waiver is limited in time. The Majority Shareholder acknowledges the fact that such waiver is subject to exercise of the Put Option pursuant to the Section&nbsp;4.1 or of the Call Option pursuant to Section&nbsp;4.2 (or 4.3, as applicable).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 14.2pt;text-indent:42.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&nbsp;<u>Majority Shareholder Investment Documents</u>.&#160; The Minority Shareholder acknowledges and agrees that following the Otonnale Contribution and Otonnale Sale, the Majority Shareholder Capital Stock received in exchange therefor shall be subject to the rights and obligations of the Minority Shareholder under the Majority Shareholder Investors&#146; Rights Agreement, the Majority Shareholder Voting Agreement and the Majority Shareholder ROFR Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;6.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>MISCELLANEOUS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 14.2pt;text-indent:35.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Successors, Assigns and Transferees</u>.&#160; Except as otherwise permitted by the provisions on Transfer in <u>Section&nbsp;3</u>, neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any Party, in whole or in part (whether by operation of law, stock sale, merger, consolidation or otherwise), without the prior written consent of the Parties, and any attempt to make such assignment without such written consent shall be null and void; <u>provided</u>, that the Majority Shareholder may assign the rights, interests and obligations hereunder in connection with any Transfer of Shares by the Majority Shareholder without the consent of any other Parties.&#160; This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives, heirs, legatees, successors, and permitted assigns and shall also apply to any Shares acquired by Shareholders after the date hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .2in;text-indent:35.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Competitive Opportunity</u>.&#160; Notwithstanding anything to the contrary in this Agreement, the Company and each Party (other than the Majority Shareholder) (i)&nbsp;acknowledges and affirms that</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="38204-3-KO-01_PB_5_092554_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2237017",CP="OVASCIENCE",DN="4",CHK=109304,FOLIO='5',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KO-01_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:41 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 14.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the Majority Shareholder and its Affiliates, employees, directors, partners and members, including, as the case may be, any member of the Board appointed by the Majority Shareholder and, as the case may be, any Board observer (collectively, the &#147;<u>Majority Group</u>&#148;) (x)&nbsp;have participated (directly or indirectly) and will continue to participate (directly or indirectly) in various other business activities (&#147;<u>Other Majority Business Activities</u>&#148;), including Other Majority Business Activities engaged in various aspects of businesses similar to those engaged in by the Company and its Subsidiaries that may, are or will be competitive with the Company&#146;s or any of its Subsidiaries&#146; businesses or that could be suitable for the Company&#146;s or any of its Subsidiaries&#146; interests, (y)&nbsp;may develop or become aware of business opportunities for Other Majority Business Activities; and (z)&nbsp;may or will, as a result of the nature of the Majority Group&#146;s businesses and other factors, have conflicts of interest or potential conflicts of interest, (ii)&nbsp;hereby renounces and disclaims any interest or expectancy in any business opportunity (including any Other Majority Business Activities or any other opportunities that may arise in connection with the circumstances described in the foregoing clauses (x)&nbsp;&#151; (z)&nbsp;(collectively, the &#147;<u>Renounced Majority Business Opportunities</u>&#148;)), and (iii)&nbsp;acknowledges and affirms that no member of Majority Group, including any member of the Board appointed by the Majority Shareholder or any Board observer, shall have any obligation to communicate or offer any Renounced Majority Business Opportunity to the Company or any of its Subsidiaries or any other Party, and any member of Majority Group may pursue any Renounced Majority Business Opportunity.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .2in;text-indent:35.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Specific Performance</u>.&#160; The Parties acknowledge that, pursuant to the terms of this Agreement, they are bound by certain undertakings to Transfer Shares. As a consequence, and in accordance with article&nbsp;1124 of the French civil code, each Party acknowledges that in case of any withdrawal or non-performance of a Transfer subsequent to the exercise of an option or an undertaking to Transfer Shares, it will not prevent the underlying agreement to be valid.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 14.2pt;text-indent:49.6pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each Party acknowledges that, accordingly, (i)&nbsp;the beneficiary of any option or right shall, in any case, be entitled to pursue specific performance (<i>ex&#233;cution forc&#233;e</i>) without prejudice to any additional compensation (<i>dommages et int&#233;r&#234;t compl&#233;mentaires</i>) and (ii)&nbsp;by exception to article&nbsp;1221 of the French civil code, there exists no physical, legal nor moral obstacle that would prevent such specific performance (<i>ex&#233;cution forc&#233;e</i>) to take place and (iii)&nbsp;each Party may in any case be entitled to pursue specific performance (<i>ex&#233;cution forc&#233;e</i>) even if an obvious disproportion between the cost of the performance of its obligation for the debtor and the interest of the beneficiary (for the purpose of article 1221 of the French civil code) would result from such specific performance (<i>ex&#233;cution forc&#233;e</i>).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .2in;text-indent:35.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Hardship</u>. Each Party agrees, in accordance with article 1195 of the French Civil Code, to assume the risk of a change of circumstances unforeseeable at the date hereof rendering the performance of the obligations stipulated therein excessively onerous, and irrevocably waives the benefit of the aforementioned article 1195 and all rights provided for in that article. Consequently, each Party agrees to bear all the consequences which would arise from a <i>situation d&#146;impr&#233;vision</i> within the meaning of that article.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 14.2pt;text-indent:35.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Governing Law</u>.&#160; This Agreement (and any claim or controversy arising out of or relating to Agreement) shall be governed by and construed in accordance with the laws of France, excluding its conflicts of law principles.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 14.2pt;text-indent:35.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Dispute Resolution</u>.&#160; All disputes arising out of or relating to this Agreement, including any question regarding its existence, validity or termination, shall be finally settled under the Rules&nbsp;of Arbitration of the International Chamber of Commerce (the &#147;<u>ICC Arbitration Rules</u>&#148;).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .2in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The seat, or legal place, of arbitration shall be London, United Kingdom, and the language of the arbitration shall be English. The arbitral tribunal shall be comprised of three</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="38204-3-KO-01_PB_6_092633_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2237017",CP="OVASCIENCE",DN="4",CHK=59753,FOLIO='6',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KO-01_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:41 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 14.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">arbitrators; each party shall nominate one arbitrator and the two party-nominated arbitrators shall jointly nominate the third arbitrator, who shall serve as the presiding arbitrator, within 30 days of the second arbitrator&#146;s appointment.&#160;&#160; Judgment on the award may be entered in any court of competent jurisdiction.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .2in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The existence and content of the arbitral proceedings and any rulings or award, including but not limited to testimony and documents exchanged, produced, or created by the Parties shall be confidential and shall not be disclosed to third parties except for (a)&nbsp;a Party&#146;s direct and indirect parents and their direct and indirect subsidiaries, (b)&nbsp;third parties who have a need to know (e.g., legal counsel, accountants, witnesses, experts,&nbsp;etc.), and (c)&nbsp;third parties to whom disclosure is legally required (e.g., governmental authorities,&nbsp;etc.), or (d)&nbsp;to the extent that disclosure is required to protect or pursue a legal right, or to enforce or challenge an award in <i>bona fide </i>legal proceedings before a state court or other judicial authority.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 14.2pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Notwithstanding anything to the contrary in this Agreement, either Party may apply to any court having jurisdiction for interim injunctive relief (including a temporary restraining order or preliminary injunction) or any other provisional or interim measure to protect a Party&#146;s interests or preserve the <i>status quo</i> during the pendency of a dispute between the Parties.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 14.2pt;text-indent:35.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Descriptive Headings</u>. The descriptive headings of this Agreement are</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">inserted for convenience only and do not constitute a part of this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 14.2pt;text-indent:35.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Notices</u>. All notices and other communications hereunder shall be in writing and shall be deemed given (a)&nbsp;upon receipt if delivered personally, (b)&nbsp;when transmitted if telecopied or via electronic mail if the sender on the same day sends a confirming copy of such notice by a recognized overnight delivery service (charges prepaid) or (c)&nbsp;on the first Business Day following dispatch if sent by an internationally recognized overnight courier service, such as Federal Express, to the Parties at the following addresses (or at such other address for a Party as shall be specified by like notice):</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 45.0pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">if to the Company, addressed to it at:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">ALIZ&#201; PHARMA SAS</font><br>  </font>15, Chemin du Saquin<br>  Espace Europ&#233;en<br>  69130 Ecully<br> France<br> Attn: Julia Owens | Jeff Brinza<br>  E-Mail: owens@millendo.com | brinza@millendo.com</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">with a copy (which shall not constitute notice) to:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cooley LLP<br> 500 Boylston Street<br> Boston, MA 02116<br> Email: mvega@cooley.com | dbartholomew@cooley.com<br> Attn:&nbsp;Miguel Vega | David Bartholomew</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="38204-3-KO-01_PB_7_092748_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2237017",CP="OVASCIENCE",DN="4",CHK=769015,FOLIO='7',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KO-01_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:41 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">if to the Majority Shareholder, addressed as follows:</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Millendo Therapeutics,&nbsp;Inc.<br> 301 N. Main St, Suite&nbsp;100<br> Ann Arbor, MI 48104<br> Attn: Julia Owens | Jeff Brinza<br>  </font>E-Mail: owens@millendo.com | brinza@millendo.com</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">with a copy (which shall not constitute notice) to:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cooley LLP<br> 500 Boylston Street<br> Boston, MA 02116<br> Email: mvega@cooley.com | dbartholomew@cooley.com<br> Fax: (617) 937-2400<br> Attn:&nbsp;Miguel Vega | David Bartholomew</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">if to the Minority Shareholder:</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">OTONNALE SAS</font><br>  </font>15 Chemin du Saquin<br>  Espace Europen<br> B&#228;t G, 69130 Ecully<br> France<br> Telephone: +33.4.37.49.87.20<br> Email: gilles.alberici@octalfa.eu</p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attn:&nbsp;Gilles Alberici</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">with a copy (which shall not constitute notice) to:</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">Jones Day</font><br>  </font>2 Rue Saint-Florentin,<br>  75001 Paris, France<br>  Attn: Geoffroy Pineau-Valencienne<br>  Telephone: +33.1.56.59.39.39<br>  Fax: +33.1.56.59.39.38<br>  E-Mail: gpineauvalencienne@jonesday.com</p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">Akl&#233;a</font><br>  </font>29 rue de Bonnel<br>  69442 Lyon Cedex 3 - France<br>  Attn: Gilles BAZAILLE<br>  Telephone: +33 4 72 44 44 44<br>  Fax: +33 4 72 44 44 45<br>  E-Mail: GBazaille@aklea.fr</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 14.2pt;text-indent:28.35pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Recapitalization, Exchange, Etc. Affecting the Company&#146;s Shares</u>.&#160; The provisions of this Agreement shall apply, to the full extent set forth herein, with respect to any and all Shares of the Company or any successor or assign of the Company (whether by merger, consolidation, sale of</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="38204-3-KO-01_PB_8_092936_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2237017",CP="OVASCIENCE",DN="4",CHK=715215,FOLIO='8',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KO-01_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:41 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 14.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">assets, conversion to a corporation or otherwise) that may be issued in respect of, in exchange for, or in substitution of, the Shares and, other than with respect to the Share Consideration, shall be appropriately adjusted for any dividends, splits, reverse splits, combinations, recapitalizations, and the like occurring after the date hereof.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 14.2pt;text-indent:28.35pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Severability</u>.&#160; Any term or provision of this Agreement that is held by a court of competent jurisdiction or other authority to be invalid, void or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the invalid, void or unenforceable term or provision in any other situation or in any other jurisdiction. If the final judgment of a court of competent jurisdiction or other authority declares that any term or provision hereof is invalid, void or unenforceable, the Parties agree that the court making such determination shall have the power to and shall, subject to the discretion of such court, reduce the scope, duration, area or applicability of the term or provision, to delete specific words or phrases, or to replace any invalid, void or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 7.1pt;text-indent:28.35pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(k)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Amendment</u>.&#160; This Agreement may be amended, modified or extended, and the terms, conditions and provisions hereof may be waived, only by a written agreement approved by each Party.&#160; At any time hereafter, Persons acquiring Shares in compliance with the provisions of this Agreement may be made Parties hereto by executing a signature page&nbsp;in the form attached as <u>Exhibit&nbsp;A</u> hereto, which signature page&nbsp;shall be countersigned by the Company and each other Party hereto and shall be attached to this Agreement and become a part hereof without any further action of any other Party hereto.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 7.1pt;text-indent:28.35pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(l)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Tax Withholding</u>.&#160; The Company or the Majority Shareholder, as applicable, shall be entitled to require payment in cash or deduction from any amounts payable to any Shareholder of any sums required by federal, state, local or non-U.S. tax law to be withheld with respect to the contribution, issuance, vesting, exercise, repurchase or cancellation of any Shares or with respect to any distribution made with respect to any Shares.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 7.1pt;text-indent:28.35pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(m)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Transfer Taxes</u><i>.&#160; </i>Majority Shareholder shall bear and pay, and shall reimburse any relevant party hereto for, any sales taxes, transfer taxes, stamp taxes, excise taxes, documentary charges, or similar taxes or duties (if any) that may become payable in connection with the contribution and sale of Shares by Minority Shareholder as contemplated herein (including, the French registration duties (<i>droits d&#146;enregistrement</i>) due as a result of the Otonnale Sale).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 7.1pt;text-indent:28.35pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(n)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Integration</u>.&#160; This Agreement, the Bylaws and the Contribution Agreement constitute the entire agreement among the Parties hereto pertaining to the subject matter hereof and supersedes all prior agreements and understandings pertaining thereto.&#160; To the extent of any conflict between the terms of this Agreement and the Contribution Agreement, the Contribution Agreement will control.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 7.1pt;text-indent:28.35pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(o)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Further Assurances</u>.&#160; In connection with this Agreement and the transactions contemplated thereby, each Shareholder shall execute and deliver any additional documents and instruments and perform any additional acts that may be necessary or appropriate to effectuate and perform the provisions of this Agreement and such transactions.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="38204-3-KO-01_PB_9_092948_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2237017",CP="OVASCIENCE",DN="4",CHK=30521,FOLIO='9',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KO-01_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:41 2018' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt 7.1pt;text-indent:28.35pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 7.1pt;text-indent:28.35pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(p)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No Strict Construction</u>.&#160; This Agreement shall be deemed to be collectively prepared by the Parties, and no ambiguity herein shall be construed for or against any Party based upon the identity of the author of this Agreement or any provision hereof.</p>
<p style="margin:0in 0in .0001pt 7.1pt;text-indent:28.35pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 7.1pt;text-indent:28.35pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(q)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No Third Party Beneficiaries</u>.&#160; Neither this Agreement, nor any provision contained herein, shall create a third-party beneficiary relationship or otherwise confer any right, entitlement or benefit upon any Person other than the Parties to this Agreement and their permitted assigns.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 7.1pt;text-indent:28.35pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(r)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No Recourse</u>.&#160; Notwithstanding anything that may be expressed or implied in this Agreement, the Company and each Shareholder covenant, agree and acknowledge that no recourse under this Agreement or any document or instrument delivered in connection with this Agreement shall be had against any current or future director, officer, employee, agent, general or limited partner or member of any Shareholder or any Affiliate or assignee thereof, as such, whether by the enforcement of any assessment or by any legal or equitable proceeding, or by virtue of any statute, regulation or other applicable law, it being expressly acknowledged that no personal liability whatsoever shall attach to, be imposed upon or otherwise be incurred by any current or future director, officer, employee, agent, general or limited partner or member of any Shareholder or any Affiliate or assignee thereof, as such, for any obligation of any Shareholder under this Agreement or any documents or instruments delivered in connection with this Agreement for any claim based on, in respect of or by reason of such obligations or their creation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 7.1pt;text-indent:28.35pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(s)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Duration</u>. This Agreement shall be effective as from its execution date and terminate and be of no further force or effect, except with respect to the provisions set forth in <u>Sections 5</u> and <u>6</u>, upon the earlier to occur of (a)&nbsp;the unanimous agreement of the Majority Shareholder and the Minority Shareholder, (b)&nbsp;the contribution of the Shares held by the Minority Shareholder pursuant to Section&nbsp;4, (c)&nbsp;upon the Minority Shareholder (or its transferees) ceasing to hold Shares and (d)&nbsp;December&nbsp;19, 2022.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 7.1pt;text-indent:28.35pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(t)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Construction</u>.&#160; Unless the context of this Agreement otherwise requires, (i)&nbsp;words of any gender include each other gender; (ii)&nbsp;words using the singular or plural number also include the plural or singular number, respectively; (iii)&nbsp;the terms &#147;hereof,&#148; &#147;herein,&#148; &#147;hereby&#148; and derivative or similar words refer to this entire Agreement; (iv)&nbsp;the terms &#147;Article&#148; or &#147;Section&#148; refer to the specified Article&nbsp;or Section&nbsp;of this Agreement; (v)&nbsp;the word &#147;including&#148; shall mean &#147;including, without limitation&#148;, (vi)&nbsp;each defined term has its defined meaning throughout this Agreement, whether the definition of such term appears before or after such term is used, and (vii)&nbsp;the word &#147;or&#148; shall be disjunctive but not exclusive.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 45.0pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>References to agreements and other documents shall be deemed to include all subsequent amendments and other modifications thereto.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 45.0pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>References to statutes shall include all regulations promulgated thereunder and references to statutes or regulations shall be construed as including all statutory and regulatory provisions consolidating, amending or replacing the statute or regulation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 45.0pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All references to &#147;$&#148; or &#147;dollars&#148; shall be to the lawful currency of the United States.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 45.0pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All references to &#147;&#128;&#148; or &#147;Euros&#148; shall be to the lawful currency of European Union.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">10<a name="38204-3-KO-03_PB_10_101605_2206"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2237017",CP="OVASCIENCE",DN="4",CHK=20617,FOLIO='10',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KO-03_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:41 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECTION&nbsp;7.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>DEFINITIONS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As used in this Agreement, the following terms have the following meanings:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Affiliate</u>&#148; means with respect to a specified Person, any Person that directly or indirectly controls, is controlled by, or is under common control with, the specified Person.&#160; As used in this definition, the term &#147;control&#148; means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting securities, by contract or otherwise.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Bylaws</u>&#148; means the by-laws (<i>statuts</i>) of the Company, as amended from time to time.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Business Day</u>&#148; means any day other than a Saturday, a Sunday or a day on which commercial banks in Paris, France are permitted or obligated by applicable Legal Requirement to be closed.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Call Option Exercise Period</u>&#148; means the period starting on December&nbsp;16</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>, 2018 (included) to December&nbsp;31<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">st</font>, 2018 (included).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Call Option Expiration Date</u>&#148; means December&nbsp;31</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">st</font>, 2018 at 11:59pm (Paris, time).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Cash Consideration</u> has the meaning ascribed to it in Section&nbsp;4.4.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Company Charter</u>&#148; means the certificate of incorporation (<i>extrait K-bis</i>) of the Company as amended from time to time.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Company Sale</u>&#148; means (i)&nbsp;a transaction or series of related transactions in which a Person, or a group of related Persons, acquires from the Shareholders shares representing more than fifty percent (50%) of the outstanding voting power of the Company; or (ii)&nbsp;a merger or consolidation in which the Company is a constituent party or a subsidiary of the Company is a constituent party and the Company issues shares of its capital stock pursuant to such merger or consolidation, except any such merger or consolidation involving the Company or a subsidiary in which the shares of capital stock of the Company outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or consolidation, at least a majority, by voting power, of the capital stock of (1)&nbsp;the surviving or resulting corporation; or (2)&nbsp;if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately following such merger or consolidation, the parent corporation of such surviving or resulting corporation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u> Consideration Certificate</u>&#148; as the meaning ascribed to it in the Contribution Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Company Constitutional Documents</u>&#148; means the Company Charter and the Bylaws, as amended from time to time.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:42.6pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Contribution Agreement</u>&#148; means that Share Sale and Contribution Agreement by and among the Majority Shareholder, the Company, the shareholders of the Company listed therein, the Manager (as defined therein), the Contributing Holder Representative (as defined therein) and Eumedix (as defined therein) dated as of December&nbsp;19, 2017.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Escrow</u>&#148; means the Company or any bank of national standing who would accept to receive the relevant funds in escrow in accordance with the terms hereof.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Financing Condition</u>&#148; has the meaning ascribed to it in Section&nbsp;4.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">11<a name="38204-3-KO-03_PB_11_101620_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2237017",CP="OVASCIENCE",DN="4",CHK=644850,FOLIO='11',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KO-03_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:41 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Majority Shareholder Capital Stock</u>&#148; means the Majority Shareholder Common Shares and the Majority Shareholder Preferred Stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Majority Shareholder Certificate of Incorporation</u>&#148; means that certain Amended and Restated Certificate of Incorporation of Majority Shareholder filed with the Secretary of State of the State of Delaware, as may be amended from time to time.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Majority Shareholder Common Shares</u>&#148; means the Majority Shareholder Common Stock and the Majority Shareholder Class&nbsp;Common-1 Stock.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Majority Shareholder Common Stock</u>&#148; means the Common Stock of Majority Shareholder, $0.001 per share.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Majority Shareholder Investors&#146; Rights Agreement</u>&#148; means that certain Second Amended and Restated Investors&#146; Rights Agreement dated as of the closing date of the Share Purchase by and among Majority Shareholder and the holders of Majority Shareholder Capital Stock party thereto, as amended.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Majority Shareholder Preferred Stock</u>&#148; means the Majority Shareholder Series&nbsp;A Preferred Stock, the Majority Shareholder Series&nbsp;A-1 Preferred Stock, the Majority Shareholder Series&nbsp;B Preferred Stock, and the Majority Shareholder Series&nbsp;B-1 Preferred Stock.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Majority Shareholder ROFR Agreement</u>&#148; means that certain Second Amended and Restated Right of First Refusal and Co-Sale Agreement dated as of the closing date of the Share Purchase by and among Majority Shareholder and the holders of Majority Shareholder Capital Stock party thereto, as amended.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Majority Shareholder Sale</u>&#148; means (i)&nbsp;a transaction or series of related transactions in which a Person, or a group of related Persons, acquires from the shareholders of the Majority Shareholder shares representing more than fifty percent (50%) of the outstanding voting power of the Majority Shareholder; or (ii)&nbsp;a merger or consolidation in which the Majority Shareholder is a constituent party or a subsidiary of the Majority Shareholder is a constituent party and the Majority Shareholder issues shares of its capital stock pursuant to such merger or consolidation, except any such merger or consolidation involving the Majority Shareholder or a subsidiary in which the shares of capital stock of the Majority Shareholder outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or consolidation, at least a majority, by voting power, of the capital stock of (1)&nbsp;the surviving or resulting corporation; or (2)&nbsp;if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately following such merger or consolidation, the parent corporation of such surviving or resulting corporation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:38.6pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Majority Shareholder Series&nbsp;A Preferred Stock</u>&#148; means the Series&nbsp;A Preferred Stock of Majority Shareholder, par value $0.001 per share.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Majority Shareholder Series&nbsp;A-1 Preferred Stock</u>&#148; means the Series&nbsp;A-1 Preferred Stock of Majority Shareholder, par value $0.001 per share.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Majority Shareholder Series&nbsp;B Preferred Stock</u>&#148; means the Series&nbsp;B Preferred Stock of Majority Shareholder, par value $0.001 per share.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Majority Shareholder Series&nbsp;B-1 Preferred Stock</u>&#148; means the Series&nbsp;B-1 Preferred Stock of Majority Shareholder, par value $0.001 per share.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">12<a name="38204-3-KO-03_PB_12_101626_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2237017",CP="OVASCIENCE",DN="4",CHK=643238,FOLIO='12',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KO-03_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:41 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:38.6pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Majority Shareholder Voting Agreement</u>&#148; means that certain Second Amended and Voting Agreement dated as of the closing date of the Share Purchase by and among Majority Shareholder and the holders of Majority Shareholder Capital Stock party thereto, as amended.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:38.6pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:38.6pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Necessary Action</u>&#148; means, with respect to a specified result, all actions (to the extent permitted by applicable law) necessary to cause such result, including (i)&nbsp;voting or providing written consent or proxy with respect to any Shares, (ii)&nbsp;calling and attending meetings in person or by proxy for purposes of obtaining a quorum and causing the adoption of Shareholders&#146; resolutions and amendments to the Company Constitutional Documents, (iii)&nbsp;executing agreements and instruments and (iv)&nbsp;making, or causing to be made, all filings, registrations or similar actions that are required to achieve such result.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Person</u>&#148; includes any individual, corporation, association, partnership (general or limited), joint venture, trust, estate, limited liability company, or other legal entity or organization.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Put Option Exercise Period</u>&#148; means the period starting on December&nbsp;1</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">st</font>, 2018 (included) to December&nbsp;15<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>, 2018 (included).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Put Option Expiration Date</u>&#148; means December&nbsp;15</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>, 2018 at 11:59pm (Paris, time).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Securities Act</u>&#148; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations in effect thereunder.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Shares</u>&#148; means the shares (<i>actions</i>) issued or to be issued by the Company irrespective of their class or category.&#160; For the avoidance of doubt, &#147;Shares&#148; shall include all Shares issued to a Shareholder on or after the date hereof, which such Shares shall be subject to the rights and restrictions set forth in this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Share Consideration</u> has the meaning ascribed to it in Section&nbsp;4.4.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Subsidiary</u>&#148; or &#147;<u>Subsidiaries</u>&#148; of any Person means any corporation, partnership, joint venture or other legal entity of which such Person (either alone or through or together with any other Person), owns, directly or indirectly, 50% or more of the stock or other equity interests which are generally entitled to vote for the election of the board of directors or other governing body of such corporation or other legal entity.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Transfer</u>&#148; any transaction resulting or which may result at a later date (e.g., the granting of a put or call option or a pledge) in a transfer of ownership of Shares (<i>propri&#233;t&#233;, nue-propri&#233;t&#233; ou usufruit</i>) for any reason whatsoever (including but not limited to sales, gratuities, contributions, partial contributions of assets, mergers, de-mergers, transfers as a result of death or any combination of these methods of transfer of ownership).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Triggering Sale</u>&#148; means the Company Sale or the Majority Shareholder Sale.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[Signature pages&nbsp;follow]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">13<a name="38204-3-KO-03_PB_13_101643_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=14,EFW="2237017",CP="OVASCIENCE",DN="4",CHK=721161,FOLIO='13',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KO-03_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:41 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, the Parties have executed this Shareholders Agreement as of the date first above written.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COMPANY<br>    </font></b>represented by:</p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Julia C. Owens</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:&nbsp;&nbsp;Millendo Therapeutics Inc.,</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">itself represented by:</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:&nbsp;&nbsp;Julia C. Owens</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:&nbsp;&nbsp;CEO</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[Signature Page&nbsp;to Shareholders Agreement]</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=15,EFW="2237017",CP="OVASCIENCE",DN="4",CHK=600824,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KO-03_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:41 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">MAJORITY SHAREHOLDER<br>    </font></b>represented by:</p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Julia C. Owens</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.08%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:&nbsp;&nbsp;Julia Owens</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.08%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:&nbsp;&nbsp;President&nbsp;&amp; CEO</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[Signature Page&nbsp;to Shareholders Agreement]</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=16,EFW="2237017",CP="OVASCIENCE",DN="4",CHK=502663,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KO-03_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:41 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">MINORITY SHAREHOLDER<br>    </font></b>represented by:</p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Thierry Abribat</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:&nbsp;&nbsp;Thierry Abribat</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[Signature Page&nbsp;to Shareholders Agreement]</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=17,EFW="2237017",CP="OVASCIENCE",DN="4",CHK=1015034,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KO-03_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:41 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;A</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ADHERENCE ACT<br> TO THE<br> SHAREHOLDERS AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:40.25pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By execution of this signature page, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hereby agrees, effective as of</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>, to become a party to, be bound by the obligations of and receive the benefits of that certain Shareholders Agreement, dated as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, as amended from time to time, by and among [Company Name], a [state] [corporation] and the other Parties named therein and shall be deemed to be a &#147;[Shareholder / Minority Shareholder]&#148; for all purposes thereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.92%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>   </tr>
<tr>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>   </tr>
<tr>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notice Address:</font></p>    </td>   </tr>
<tr>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accepted:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[COMPANY NAME]</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[SHAREHOLDER   NAME]</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[SHAREHOLDER   NAME]</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=18,EFW="2237017",CP="OVASCIENCE",DN="4",CHK=826036,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KO-03_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 10:41 2018' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.9
<SEQUENCE>5
<FILENAME>a2237017zex-4_9.htm
<DESCRIPTION>EX-4.9
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;4.9</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">MILLENDO THERAPEUTICS SAS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FIRST AMENDMENT TO</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SHAREHOLDERS AND OPTION AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 5.65pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This First Amendment to the Shareholders and Option Agreement (the &#147;<u>Amendment</u>&#148;), dated as of September&nbsp;28, 2018 is by and between MILLENDO THERAPEUTICS,&nbsp;INC., a Delaware corporation(together with its successors or assigns that hold Shares, the &#147;<u>Majority Shareholder</u>&#148;), and OTONNALE SAS, a French <i>soci&#233;t&#233; par actions simplifi&#233;e</i>, whose registered office is located at 15&#160; Chemin du Saquin, Espace Europen, B&#228;t G, 69130 Ecully, France, registered under number 539 195 438 with the Lyon Trade and Companies Register (together with its successors or assigns that hold Shares, the &#147;Minority Shareholder&#148;), in the presence of MILLENDO THERAPEUTICS SAS (formerly known as ALIZ&#201; PHARMA SAS), a French soci&#233;t&#233; par actions simplifi&#233;e with a share capital of EUR 220,950, whose registered office is located at Espace europ&#233;en - 15, Chemin du Saquin, 69130 Ecully, registered at the Lyon Trade and Companies register under number 497 575 621 (the &#147;<u>Company</u>&#148;). Each of the Majority Shareholder and the Minority Shareholder are sometimes referred to herein as a &#147;<u>Shareholder</u>&#148; and, collectively, as the &#147;<u>Shareholders</u>&#148;.&#160; The Company and the Shareholders are sometimes referred to herein as a &#147;<u>Party</u>&#148; and, collectively, as the &#147;<u>Parties</u>&#148;.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RECITALS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 5.65pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, the Parties have entered into a Shareholders and Option Agreement, dated as of December&nbsp;19, 2017 (the &#147;<u>Original Agreement</u>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 5.65pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, pursuant to Section&nbsp;6(k)&nbsp;of the Original Agreement, the Original Agreement may be amended by the written agreement of each Party.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 5.65pt;text-indent:40.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NOW, THEREFORE, in consideration of the foregoing, and the mutual agreements set forth herein and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Definitions</u>. Capitalized terms used and not defined in this&nbsp;Amendment&nbsp;have the respective meanings assigned to them in the Original&nbsp;Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Amendments&nbsp;to the Original&nbsp;Agreement</u>. As of the Effective Date (defined below), the Original&nbsp;Agreement&nbsp;is hereby amended or modified as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The following definitions of &#147;<u>Contribution Agreement</u>&#148; appearing in Section&nbsp;7 of the Original&nbsp;Agreement&nbsp;is hereby deleted in their entirety and replaced with the following:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>Contribution Agreement</u>&#148; means that Share Sale and Contribution Agreement by and among the Majority Shareholder, the Company, the shareholders of the Company listed therein, the Manager (as defined therein), the Contributing Holder Representative (as defined therein) and Eumedix (as defined therein) originally dated as of December&nbsp;19, 2017, and as may be amended from time to time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Section&nbsp;4.4(a)&nbsp;of the Original&nbsp;Agreement&nbsp;is hereby amended by inserting immediately following the words &#147;before the Otonnale Closing pursuant to the Majority Shareholder Certificate of Incorporation.&#148; the words &#147;Upon any reclassification, exchange, substitution, or other event that results in a change of the number and/or class of the Majority Shareholder Capital Stock issuable upon exercise of the Put Option pursuant to Section&nbsp;4.1 or the Call Option pursuant to Section&nbsp;4.2 (or 4.3, as applicable), the Minority Shareholder shall be entitled to receive, upon exercise of such option, the number and kind of securities and property that Minority Shareholder would have received if such exercise had been made immediately before such reclassification, exchange, substitution or other event.&#160; Such an event shall include</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2237017",CP="OVASCIENCE",DN="5",CHK=563252,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KQ_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 11:40 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">any automatic conversion and/or exchange of the Majority Shareholder Capital Stock pursuant to a merger of the Majority Shareholder with and into another Person or the acquisition of the Majority Shareholder by another Person.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This Amendment will become effective on the date first written above (the &#147;<u>Effective Date</u>&#148;). Except as expressly provided in this Amendment, all of the terms and provisions of the Original&nbsp;Agreement are and will remain in full force and effect and are hereby ratified and confirmed by the Parties. Without limiting the generality of the foregoing, the amendments contained herein will not be construed as an amendment to or waiver of any other provision of the Original&nbsp;Agreement or as a waiver of or consent to any further or future action on the part of either Party that would require the waiver or consent of the other Party. On and after the Effective Date, each reference in the Original&nbsp;Agreement to &#147;this Agreement,&#148; &#147;the Agreement,&#148; &#147;hereunder,&#148; &#147;hereof,&#148; &#147;herein,&#148; or similar words will mean and be a reference to the Original&nbsp;Agreement as amended by this Amendment.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Miscellaneous.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This Amendment is governed by and construed in accordance with, the laws of France, excluding its conflict of laws provisions.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This Amendment shall inure to the benefit of and be binding upon each of the Parties and each of their respective successors and assigns.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The headings in this Amendment are for reference only and do not affect the interpretation of this Amendment.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This Amendment may be executed in counterparts, each of which is deemed an original, but all of which constitute one and the same agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This Amendment constitutes the sole and entire agreement between the Parties with respect to the subject matter contained herein, and supersedes all prior and contemporaneous understandings, agreements, representations, and warranties, both written and oral, with respect to such subject matter.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[Signature pages&nbsp;follow.]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2237017",CP="OVASCIENCE",DN="5",CHK=648595,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KQ_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 11:40 2018' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:36.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, the Parties have executed this Amendment as of the date first written above.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COMPANY</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">MILLENDO THERAPEUTICS SAS<br>   represented by MILLENDO THERAPEUTICS INC.,<br>   itself represented by Ms.&nbsp;Julia C. Owens</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Julia C. Owens</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Julia C. Owens</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">MAJORITY SHAREHOLDER</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">MILLENDO THERAPEUTICS   INC.</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Julia C. Owens</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Julia C. Owens</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President and CEO</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">MINORITY SHAREHOLDER</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">OTONNALE SAS</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">represented by   Mr.&nbsp;Gilles Alberici</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Gilles Alberici</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Gilles Alberici</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Signature Page&nbsp;to First Amendment to Shareholders and Option Agreement</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2237017",CP="OVASCIENCE",DN="5",CHK=878461,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-KQ_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 11:40 2018' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>6
<FILENAME>a2237017zex-5_1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#18ZEU10401_6">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="kc10401_exhibit_5.1"> </A>
<A NAME="toc_kc10401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;5.1    <BR>    </B></FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g425336.jpg" ALT="GRAPHIC" WIDTH="399" HEIGHT="124">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>November&nbsp;6,
2018 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>OvaScience,&nbsp;Inc.<BR>
9 Fourth Avenue<BR>
Waltham, MA 02451 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Ladies
and Gentlemen: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have acted as counsel to OvaScience,&nbsp;Inc. (the "Company"), in connection with the filing by the Company of a Registration Statement on Form&nbsp;S-3 (the "Registration
Statement") with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Securities Act"). The Registration Statement relates to the registration
for resale by the selling stockholders named in the Registration Statement (the "Selling Stockholders") of up to an aggregate of 1,886,574 shares of the Company's common stock, $0.001 par value per
share (the "Shares"). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Shares being registered for resale on the Registration Statement will be issued to the Selling Stockholders pursuant to a Stock Purchase Agreement, dated November&nbsp;1, 2018 (as
amended from time to time, the "Purchase Agreement"), by and among the Company, Millendo Therapeutics,&nbsp;Inc. ("Millendo") and the Selling Stockholders. After the closing of the merger (the
"Merger") of Orion Merger Sub,&nbsp;Inc., a Delaware corporation and a direct, wholly-owned subsidiary of the Company ("Orion Merger Sub"), with and into Millendo, pursuant to the Agreement and Plan
of Merger and Reorganization, dated August&nbsp;8, 2018, as amended on September&nbsp;25, 2018 and on November&nbsp;1, 2018, by and among the Company, Orion Merger Sub and Millendo (the "Merger
Agreement"), and upon the satisfaction or waiver of the conditions set forth in the Purchase Agreement, the Shares purchased by the Selling Stockholders pursuant to the Purchase Agreement will be
issued, and such Shares are being registered for resale on the Registration Statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with this opinion, we have examined and relied upon the Certificate of Incorporation and Bylaws of the Company, each as restated and/or amended to date, and such other
documents as we have deemed necessary for purposes of rendering this opinion. In our examination, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the
authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified or photostatic copies and the authenticity of the
originals of such copies. As to questions of fact material to this opinion, we have relied upon certificates or comparable documents of public officials and of officers and representatives of the
Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
opinion is limited to the federal laws of the United States and the General Corporation Law of the State of Delaware and we express no opinion with respect to the laws of any other
jurisdiction. No opinion is expressed herein with respect to the qualification of the Shares under the securities or blue sky laws of any state or any foreign jurisdiction. </FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g924698.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="30">
  </B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2237017",CP="OVASCIENCE",DN="6",CHK=575719,FOLIO='blank',FILE='DISK121:[18ZEU1.18ZEU10401]KC10401A.;16',USER='HYUNG',CD=';6-NOV-2018;15:20' -->
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g80173.jpg" ALT="GRAPHIC" WIDTH="45" HEIGHT="12">
 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g744458.jpg" ALT="GRAPHIC" WIDTH="48" HEIGHT="61">
 </B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>November&nbsp;6,
2018<BR>
Page 2 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon currently
existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments
which might affect any matters or opinions set forth herein. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
upon and subject to the foregoing, it is our opinion that the Shares are validly issued, fully paid and non-assessable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
understand that you wish to file this opinion with the Commission as an exhibit to the Registration Statement in accordance with the requirements of Item&nbsp;601(b)(5) of
Regulation&nbsp;S-K promulgated under the Securities Act and to reference the firm's name under the caption "Legal Matters" in the prospectus which forms part of the Registration Statement, and we
hereby consent thereto. In giving this consent, we do not admit that we are within the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and
regulations of the Commission promulgated thereunder. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="233pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Very truly yours,</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>/s/ Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=2,EFW="2237017",CP="OVASCIENCE",DN="6",CHK=701836,FOLIO='blank',FILE='DISK121:[18ZEU1.18ZEU10401]KC10401A.;16',USER='HYUNG',CD=';6-NOV-2018;15:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="18ZEU10401_6">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kc10401_1">Exhibit 5.1</A></FONT><BR>
</UL>
<!-- SEQ=,FILE='QUICKLINK',USER=HYUNG,SEQ=,EFW="2237017",CP="OVASCIENCE",DN="6" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>7
<FILENAME>a2237017zex-10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;10.1</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Lease Agreement</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="53%" valign="top" style="padding:0in 0in 0in 0in;width:53.7%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Landlord&#146;s Name <i>I </i>Address:</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">301 N. Main Street, L.L.C.</font></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" style="padding:0in 0in 0in 0in;width:53.7%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c/o Forge Property Management</font></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" style="padding:0in 0in 0in 0in;width:53.7%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15 Research Drive, Suite&nbsp;A</font></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" style="padding:0in 0in 0in 0in;width:53.7%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ann Arbor, MI. 48103</font></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" style="padding:0in 0in 0in 0in;width:53.7%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" style="padding:0in 0in 0in 0in;width:53.7%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tenant&#146;s Name <i>I </i>Address:</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Millendo Therapeutics,&nbsp;Inc.</font></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" style="padding:0in 0in 0in 0in;width:53.7%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">301 N. Main Street,   Suite&nbsp;100</font></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" style="padding:0in 0in 0in 0in;width:53.7%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ann Arbor, Ml. 48104</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Lease Agreement (&#147;Lease&#148;) is made as of the 31st day of December, 2015, by and between Millendo Therapeutics,&nbsp;Inc., a Delaware corporation as &#147;Tenant&#148; and 301 N. Main Street, L.L.C., a Michigan limited liability company as &#147;Landlord&#148;:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Premises. Landlord leases to the Tenant and Tenant leases from Landlord office space located on the First Floor of the office building located at 301 N. Main Street, in the City of Ann Arbor County of Washtenaw, State of Michigan, and commonly known as 301 N. Main Street, Suite&nbsp;100 (the &#147;Premises&#148;). The Premises includes the exclusive use of the areas formerly known as Suite&nbsp;100, Suite&nbsp;102, the two bathrooms at the west end of the hallway, and the hallway from the Main Street entrance to the west stairway door. Tenant shall also have the shared use of all common areas within the building located at 301 N. Main Street in the City of Ann Arbor, County of Washtenaw, State of Michigan (the &#147;301 N, Main Building&#148;).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Term; Commencement Date. The term (the &#147;Term&#146;&#146;) of this lease (&#147;Lease&#148;) shall be 24 months, commencing on January&nbsp;1, 2016 (the &#147;Commencement Date&#148;). This Lease shall expire December&nbsp;31, 2017, subject to the terms and condition of this Lease including Tenant&#146;s options to renew or extend the term of this Lease.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Rent. Tenant shall pay the Landlord for the term of 24 months for rent for said Leased Premises the base sum of $285,216. Base Rent shall be payable in monthly installments in advance on the first day of each month as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Year 1: $ 11 ,723 per month, $ 140,676 annually</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Year 2: $ 12,045 per month, $ 144,540 annually</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Payment received by the Landlord after the fifth day of the month is subject to a 5% late charge.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Renewal. Provided Tenant is not in default, Tenant shall have the option to renew this Lease for one additional 12 month term at a Base Rent of $11,377 per month, $136,524 annually. Tenant must notify Landlord in writing by way of electronic mail, hand delivery or US mail, not less than 90 days prior to the expiration of the existing term or option may be voidable by Landlord. During the renewal term, if any, the terms and conditions of this Lease shall remain in full force and effect. Landlord also grants to Tenant a right of first negotiation on any rentable space on the second floor of the Building that becomes available for rent at any time during the Term (the &#147;Available Second Floor Space&#148;). Landlord shall provide Tenant with written notice of the availability of Available Second Floor Space (the &#147;Availability Notice&#148;) promptly upon becoming aware of such availability. Landlord and Tenant shall negotiate exclusively and in good faith for the leasing of such Available Second Floor Space for a period of 60 days from the date of the Availability Notice. If Landlord and Tenant are unable to agree on lease terms for the Available Second Floor Space, within such 60 day period, then</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">1<a name="38204-3-LA_PB_1_105020_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2237017",CP="OVASCIENCE",DN="7",CHK=293336,FOLIO='1',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-LA_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 11:43 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .6in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Landlord shall be free to negotiate a lease for such Available Second Floor Space with a third party on terms no more favorable than those offered by Tenant during such 60 day period .</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Holdover. Landlord may allow Tenant to continue in possession after the expiration or sooner termination of this Lease. If the Tenant continues in possession with the consent of the Landlord, but without having renewed this Lease with some written instrument, then the tenancy shall continue for month to month, and may be terminated by either party by giving notice no less than 15 days prior to the end of the monthly period. Jn the event of a holdover by Tenant, for the period that Tenant continues in possession of the premises Tenant shall pay a rent amount equal to 125% of the rent at the time of the expiration or sooner termination of this Lease.</p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Utilities and Other Tenant Costs. Tenant shall be responsible for the payment of a prorated share of the gas, electric, water and sewer utilities cost at 301 N. Main Street and the parking lot at 400 N.1st Street. Landlord will bill Tenant monthly based on Tenant&#146;s pro rata share of 35%. Tenant shall also be responsible for Tenant&#146;s phone, internet, data and cable television, alarm systems, business insurance and janitorial services for the Premises.</p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Condition of Premises. Tenant acknowledges that it has examined the Premises prior to executing this Lease, and knows conditions thereof, and that no representations as to the conditions or state of repairs therefor have been made by Landlord, or its agents, which are herein not expressed, and Tenant accepts the Premises in their present condition at the date of the execution of this Lease, except a otherwise stated herein. Landlord represents and warrants that the Premises (including the heating, air conditioning, ventilation , electrical, plumbing, and sewage systems) are in good working order and in a habitable condition. Tenant shall accept Premises on an &#147;as is&#148; basis with no additional improvements or modifications by Landlord other than those described in Exhibit&nbsp;A and as represented in the previous sentence.</p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Use of Premises. Tenant shall use the Premises as office purposes and for no other use without the prior written authorization of the Landlord .</p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Maintenance, Repairs, and Alterations.&#160; Upon 24 hours prior notice (except in case of an emergency where no notice shall be required), Landlord shall have the right to enter the Premises at al l reasonable hours to inspect the Premises and to install or repair pipes, wires, and other appliances or to make any other installations or repairs deemed by Landlord to be necessary to the use and occupancy of the Premises and other parts of the building. Landlord shall be responsible for keeping the following in good condition and repair: (a)&nbsp;roof, foundation, structural portion of the building, exterior walls and exterior windows and doors; (b)&nbsp;building systems, including mechanical, heating, air conditioning, ventilation, electrical, plumbing and lifo safety; and (c)&nbsp;Building common areas, exterior grounds and parking lots (adjacent and surface), including snow removal and lawn care.</p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tenant shall not make any alterations, additions, or improvements to the premises without the prior written consent of Landlord, which will not be unreasonably withheld. Upon expiration or termination of this Lease, Tenant shall deliver up the premises in the same condition as existed on the Commencement Date at the commencement of this Lease, subject to ordinary wear and tear and damage by the elements.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Signs. Tenant shall be permitted to have a sign with Tenant&#146;s name placed at a location mutually agreed upon by Landlord and Tenant and in compliance with all local ordinances and regulations. Tenant shall be responsible for the cost and installation of any approved sign. Tenant shall remove such sign(s)&nbsp;upon termination or expiration of this Lease. Landlord, at its cost and expense, shall include Tenant&#146;s name on the building&#146;s directory.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="38204-3-LA_PB_2_105113_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2237017",CP="OVASCIENCE",DN="7",CHK=61325,FOLIO='2',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-LA_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 11:43 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Damage to Premises. If the Premises are damaged by fire or other casualty, then Landlord shall repair the Premises as speedily as possible, and the rent shall be abated in whole or in part, according to the portion of the Premises which is rendered unusable. If the Premises cannot be repaired within one hundred eighty days (180), then Tenant may terminate this Lease by giving notice to Landlord within ten (10)&nbsp;days after the Land lord has notified Tenant of the time required to repair the Premises. Landlord shall, in its sole judgment, reasonably exercised, determine the length of time required to repair the Premises, and shall notify Tenant of such determination within ten (10)&nbsp;days after the occurrence of the fire or other casualty. Notwithstanding the foregoing, if the Premises are so damaged by fire or other casualty that demolition or substantial reconstruction is required, then Landlord may terminate this Lease by giving notice to Tenant within thirty (30) days after the date of such damage. If Landlord fails to restore the Premises (including reasonable means of access thereto) within a period which is thirty days longer than the period stated in Landlord&#146;s notice to Tenant as the estimated rebuilding period, Tenant, at any time thereafter until such rebuilding is completed, may terminate this Lease by delivering written notice to Landlord of such termination, in which event this Lease shall terminate as of the date of the giving of such notice.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Eminent Domain. If any part of the Premises is taken by public authority under the power of eminent domain then this Lease shall terminate on the part so taken on the date possession of the Premises is required for public use, and any pre-paid rent shall be refunded to the Tenant. ln such a circumstance, Landlord and Tenant shall also each have the right to terminate this Lease for any remaining portion of the Premises upon written notice to the other, which notice shall be delivered within thirty (30) days following the date notice is received of such taking. If neither party terminates this Lease, Landlord shall make all necessary repairs to the Premises and the building and the improvements in which the Premises are located to render and restore it to a complete architectural unit, and Tenant shall continue in possession of the portion of the Premises not taken under the power of eminent domain, under the terms and conditions provided in this Lease, except that the monthly rent shall be reduced in direct proportion to the amount of the Premises so taken. All damages awarded for such taking shall belong to and shall be property of the Landlord, whether such damages arc awarded as compensation for diminution in value of the leasehold or to the fee of the Premises.</p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Liability</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Indemnity. To the maximum extent this Lease may be made effective according to law, Tenant and Landlord agree to indemnify and save harmless each other from and against all claims of whatever nature arising from any act, omission, or negligence of the respective parties, or their respective contractors, licensees, invitees, agents, servants, or employees. This indemnity and hold harmless provision shall include indemnity against all costs, expense, and liabilities incurred in or in connection with any such claim or proceeding brought thereon, and the defense thereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Tenant&#146;s Risk. To the maximum extent this Lease may be made effective according to law, Tenant agrees to use and occupy the Premises and to use such other portions of the building as Tenant is given the right to use at Tenant&#146;s own risk; and Landlord shall have no responsibility or liability for any loss of or damage to fixtures or other personal property of Tenant or Tenant&#146;s agents, employees, independent contractors, or invitees for any other reason than the intentionally wrongful or negligent acts or omissions of Landlord or Landlord&#146;s agents, employees, independent contractors, or invitees or Landlord&#146;s breach of this Lease. The provisions of this section shall be applicable from and after the execution of this Lease and until the end of the Lease term, and during such further period as Tenant may use or be in possession of any part of the Premises or the building.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="38204-3-LA_PB_3_105134_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2237017",CP="OVASCIENCE",DN="7",CHK=1046265,FOLIO='3',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-LA_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 11:43 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Injury Caused by Third Parties. To the maximum extent this Lease may be made effective according to the law, Tenant agrees that Landlord shall not be responsible or liable to Tenant, or those claiming by, through, or under Tenant, for any loss or damage that may be occasioned by or through the acts or omissions of persons occupying adjoining Premises or any part of the Premises adjacent to or connecting with the Premises or any part of the building, or otherwise or for any loss or damage resulting to Tenant or those claiming by, through, or under Tenant, or its or their property, from breaking, bursting, stopping, or leaking of electric cables and wires, water, gas, ewer, or steam pipes, from roof leaks, fire, or any other like causes unless caused by Landlord&#146;&#160; willful negligence.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Insurance. Land lord will obtain and maintain, at all times until termination of this Lease and surrender of the Premises to Landlord, fire and extended insurance covering the building and the Premises, including common areas, and all other improvements to the building made by Landlord but specifically excluding Tenant betterments installed by Tenant and providing the insurance protection to Landlord described in this Lease. Landlord will retain in its possession the original policy and al l endorsements, renewal certificates and new policies, if any, issued during the Term but will provide Tenant, upon request, with copies of said policy.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Landlord will also maintain comprehensive general liability insurance coverage against claims for, or arising out of, bodily i1tjury, death or property damage occurring in, on or about the building and the Premises or property in, on or about the street, sidewalks or prope1ties adjacent to the building and the Premises. The policy shall carry limits, including coverage under umbrella policies of not less than $1,000,000 per occurrence and $2,000,000 aggregate.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition to the above, and not by the way of substitution thereof, Tenant shall obtain, at its own expense, comprehensive general liability insurance with both 301 N. Main Street , L.L.C. and Forge Property Management named as additionally insured, against claims for, or arising out of, bodily injury, death or property damage occurring on the Premises and shall have minimum limits of coverage of $1,000,000 per occurrence and $2,000,000 annual aggregate. Tenant will deliver a letter to Landlord confirming Tenant&#146;s required insurance coverage upon written request from Landlord.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Bankruptcy and Insolvency. If the leasehold estate hereby created shall be taken in execution, or by other process of law or if Tenant shall be declared bankrupt or insolvent, according to law, or any receiver be appointed for the business and property of Tenant, or if any assignment shall be made of the Tenant&#146;s property for the benefit of creditors, then in such event this Lease may be canceled at the option of the Land lord. If the Landlord chooses to cancel this Lease, Landlord must give notice to Tenant i n writing in accordance with Section&nbsp;17.0 contained herein.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subordination of Lease. Tenant agrees that Landlord may subordinate this Lease to its present or any subsequent mortgage on the leased premises, provided that such subordination shall not interfere with Tenant&#146;s continued occupancy of the premises pursuant to the Term of this Lease and provided that Landlord provides to Tenant a commercially reasonable non-disturbance agreement. Tenant agrees to execute any and all instruments as may be reasonably requested from time to time by Landlord in order to widence the above described subordination of this Lease to any mortgage. Tenant agree to execute, acknowledge and deliver to Landlord written request from Landlord within thirty (30) days of a statement in writing certifying this Lease is unmodified and in full force and effect (or ifthere have been modifications , that the same ,is in ful1 force and effect as modified, and stating said modifications), and the dates to which the rent and other charges have been paid in advance, if any, it being intended that any such statement delivered pursuant to this paragraph may be relied upon by any prospective purchaser, mortgagee, or assignee.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="38204-3-LA_PB_4_105414_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2237017",CP="OVASCIENCE",DN="7",CHK=553237,FOLIO='4',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-LA_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 11:43 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Landlord&#146;s Remedies.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In the event Tenant shall fail to pay the rent or any other obligation involving the payment of money reserved herein when due, Landlord shall give Tenant written notice of such default and if Tenant shall fail to cure such default within thirty (30) days after receipt of such notice, Landlord shall, in addition to its other remedies provided by law, and in this Lease, have the remedies set forth in subparagraph (c)&nbsp;below.</p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><font style="height:22px;left:0px;margin-left:229px;margin-top:59px;position:absolute;width:3px;z-index:-1895823360;"><img width="3" height="22" src="g382043lai001.gif"></font><font size="2" face="Times New Roman">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If Tenant shall be in default in performing any of the terms of this Lease other than the payment of rent or any obligation involving the payment of money, Landlord shall give tenant written notice of such default, and if Tenant shall fail to cure such default within forty-five (45) days after receipt of such notice, or if the default is of such a character as to require more than forty-five (45) days to cure, then if Tenant shall fail within said forty-five (45) day period to commence and thereafter proceed diligently to cure such default, then in either of such events, Landlord may (at its option and in addition to other legal remedies) cure such default for the account of Tenant and be reimbursed by Tenant for such care. Such reimbursement shall be additional rent for all purposes hereunder, including subparagraph (a)&nbsp;above and shall be paid by Tenant with the next monthly installment of rent.</p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If any rent or any other obligation involving the payment of money shall be due and unpaid or Tenant shall be in default upon any of the terms of this Lease, and such default has not been cured after notice and within U1e time provided in subparagraphs (a)&nbsp;and (b)&nbsp;above, then Landlord, may seek to take possession pursuant to legal proceedings or any notice provided for by law. Landlord may either terminate this Lease from time to time, without terminating this Lease, relet the Premises or any part thereof on such terms and conditions as Landlord shall in its sole discretion deem advisable. Any payments as result of such reletting be applied; first, to the payment of any indebtedness of Tenant to Landlord other than rent due hereunder; second, to the payment of any reasonable costs incurred by Landlord i n obtaining possession and reletting the Premises, including, without limitation, legal fees, brokerage commissions and tJ1e cost of any reasonable alterations, and repairs to the Premises; third to the payment of rent due and unpaid hereunder; and the residue, if any shall be held by Landlord and applied in payment of future rent as the same may become due and payable hereunder. Tenant shall be liable to Land lord for any deficiency. Both parties shall use their best efforts to mitigate its damages under this Lease.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All rights and remedies of Landlord hereunder shall be cumulative and none shall be exclusive of any other rights and remedies allowed by law.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Notices. Any notice that either party desires or is required to give under this Lease to the other party or to any other person shall be in writing and either personally served or sent by prepaid, certified, or registered mail. Notice shall be deemed communicated 48 hours from the time of mailing if mailed as provided in this paragraph.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notices for the Tenant should be sent to:<br>  </font></u>Millendo Therapeutics,&nbsp;Inc.<br> 301 N. Main Street, Suite&nbsp;#100<br> Ann Arbor, MI 48104<u><br>  </u>Attn: President and CEO<u><br>  </u>With a copy to: SVP Administration and General Counsel</p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notices for the Landlord should be sent to:<br>  </font></u>30 l N. Main Street, LLC<u><br> </u>c/o Forge Property Management<br> 15 Research Drive, Suite&nbsp;A<br> Ann Arbor, Ml. 48103</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="38204-3-LA_PB_5_105520_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2237017",CP="OVASCIENCE",DN="7",CHK=209531,FOLIO='5',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-LA_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 11:43 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt 114.65pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Assignment. The Tenant covenants not to assign or transfer this Lease or mortgage the same or sublet said Premises or any part thereof without the prior written consent of the Landlord, which consent shall not be unreasonably withheld or delayed. Any assignment, transfer, hypothecation, mortgage or subletting without said written prior consent shall give the Landlord the right to terminate this Lease and to re-enter and repossess the Premises. Notwithstanding the foregoing, Tenant shall have the right to assign or sublease the Premises, or a portion thereof, to any parent or affiliate or any entity resulting from a merger with tenant or the sale of all substantially all of the tenant&#146;s assets.</p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Successors. This Lease shall be binding on and inure to the benefit of the parties and their successors.</p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Severability. The unenforceability, invalidity, or illegality of any provision of this Lease shall not render the other provisions unenforceable, illegal, or invalid.</p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Law of Michigan. This Lease shall be construed and interpreted in accordance with the laws of the State of Michigan. Landlord, its successors and assigns, consents to the jurisdiction of the appropriate courts of the State of Michigan with respect to any other claims arising under this Agreement.</p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Environmental Matters. Landlord represents and warrants to Tenant that (a)&nbsp;Landlord has no notice or knowledge of any violation of any laws or regulations affecting the real property on which the Premises is located or the Premises itself, including any laws, ordinances, or regulations relating to the soil, surface water and ground water of or on the property; and to the Landlord&#146;s best knowledge the real property and Premises are free of and do not contain any pollution, contamination, or other environment.al hazards which shall include, but not limited to, those identified under federal, state, or local statute, ordinance, or regulation; and (b)&nbsp;Landlord has not received any notice of or have any knowledge of any existing or threatened condemnation or other litigation, administrative proceeding, or action of any kind involving this real property or the Premises.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Both parties shall comply with all applicable laws and regulations relating to the Premises, including environmental laws and regulations; provided that Tenant shall have no financial responsibility for hazardous materials which were not introduced into the Premises by Tenant or anyone under its control, and Landlord shall be responsible for the costs of compliance with all laws unless such compliance costs are triggered specifically by Tenant&#146;s particular use or as a result of Tenant&#146;s performance of alterations to the Premises after the Commencement Date. Each party shall give immediate notice to the other of the release or the threatened release of any hazardous material or any violation of any applicable environmental law or regulation at or affecting the real property or the Premises, and such party shall promptly undertake all obligations imposed upon it under applicable environmental law or regulation as a result of such event.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Quiet Enjoyment. So long as Tenant pays the rent and otherwise complies with this Lease, Tenant&#146;s possession of the Premises will not be disturbed by Landlord, its successors or assigns, and Tenant shall be entitled to quiet enjoyment of the Premises.</p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Security Deposit. The Landlord herewith acknowledges the receipt of $4,313.75 for the Premises covered by this Lease Agreement, which the Landlord shall retain as security for the faithful performance of all the covenants, conditions, and agreements of this Lease, but in no event shall the Landlord be obliged to apply the same upon rents or other charges in arrears or upon damages for the Tenant&#146;s failure to perform the said covenants, conditions, and agreements; the Landlord may so apply the security at its option; and the Landlord&#146;s right to the possession of the Premises for non-payment of rent or for any other reason shall not in any event be affected by reason of the fact that the Landlord holds the security. The said sum if not applied toward the payment of rent in arrears or toward the</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="38204-3-LA_PB_6_105606_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2237017",CP="OVASCIENCE",DN="7",CHK=509595,FOLIO='6',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-LA_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 11:43 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">payment of damage suffered by the Landlord by reason of the Tenant&#146;s breach of covenants, conditions, and agreements of this Lease is to be returned to the to the Tenant within 30 days after termination of this Lease Agreement. In no event is the Landlord obligated to return the security deposit until the Tenant has vacated the Premises and delivered possession to the Landlord. In the event that the Landlord repossesses himself of the said Premises because of the Tenant&#146;s default or because of the Tenant&#146;s failure to carry out the covenants, conditions, and agreements of this Lease, the Landlord may apply the said security upon all damages as may be suffered to the date of said repossession and may retain the said security to apply upon such damages as may be suffered or shall accnie thereafter by reason of the Tenant&#146;s default or breach. The Landlord shall not be obliged to keep the said security as a separate fund, but may mix the said security with its own funds.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Parking. Tenant shall have one parking space in the lot adjacent to the 301 N. Main Building and 11 parking spaces in the 400 North First parking lot. Landlord shall provide a sign designating the spots reserved for Tenant in the respective parking lots.</p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Amendments. Any amendments to this Lease must be in writing and signed by both Landlord and Tenant.</p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28.0</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Build-out. Landlord agrees to complete the work described in Exhibit&nbsp;A in a good and workmanlike manner and in compliance with all applicable laws. The work shall be substantially complete prior to January&nbsp;31, 2016. In addition, Landlord will make best efforts to modify Main Street entry door. Landlord will supervise construction nod bears the risk of cost overruns related to improvements made. Landlord will own improvements and Tenant will have no obligation to remove improvements at the end of the lease term.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The parties hereby execute this Lease Modification Agreement on this 30th day of November, 2017.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt .5in;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:45.58%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">301 N. Main Street, LLC<br>    </font></b>a Michigan limited liability company</p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:45.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Millendo   Therapeutics,&nbsp;Inc.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a Delaware corporation</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:45.58%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:45.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:45.58%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:45.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="40%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:40.82%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Eric Kchikian</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="39%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:39.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Julia C. Owens</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.82%;">
<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Eric Kchikian</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.84%;">
<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Julia C. Owens</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Its:</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.82%;">
<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Manager</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Its:</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.84%;">
<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President and CEO</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="38204-3-LA_PB_7_105946_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2237017",CP="OVASCIENCE",DN="7",CHK=77413,FOLIO='7',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-LA_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 11:43 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;A</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Landlord agrees to complete the work described below and in the final drawings dated 12/23/15, provided by Landlord to Tenant.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Add lockable door with glass window (similar to existing door at west end of hall) at west end of hall between the two lavatories. A drywall partition will be installed between the two lavatories and only the door will have glass.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Remove Suite&nbsp;102 entry door/demising wall to rafters</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Remove Suite&nbsp;102 break area demising wall to wood trim, provided that, promptly after the removal and before any trim work is added to finish the newly created opening, Tenant may request that the demising wall be removed to the rafters.</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Remove Suite&nbsp;100 entry door/demising wall to rafters</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Remove Suite&nbsp;JOO closet wall/door on north side of hall to rafters.</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Remove drywall from north side of Suite&nbsp;l 00 closet to rafters; remove drywall and shelves in the closet area in order to expose brick</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Add drywall to opening east of bath, move trim as needed .</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Add drywall wall to rafters - extending east wall of Suite&nbsp;102 break area</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Replace wood flooring (Suite&nbsp;100 reception) with vinyl plank flooring</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font>Overlay tile flooring in kitchen area and work room of Suite&nbsp;100 with vinyl plank flooring</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font>Replace carpet in Suite&nbsp;102 reception area and kitchenette with vinyl plank flooring</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font>Replace carpet in main hallway</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font>Paint new walls and existing walls as required</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font>Use existing lighting fixtures <i>I </i>doors <i>I </i>windows when available</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font>Install electrical outlets for new reception area and for cubicle areas.</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font>Update east bathroom: including vinyl plank flooring, pedestal sink, paint walls</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font>Install any fire/life safety system changes as required by Ann Arbor</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font>Install additional overhead light in largest office in Suite&nbsp;102</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="38204-3-LA_PB_8_110026_8146"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2237017",CP="OVASCIENCE",DN="7",CHK=607478,FOLIO='8',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-LA_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 11:43 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font>Install electrical outlet in closet on south side of main hall below stairwell</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="38204-3-LA_PB_9_110447_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2237017",CP="OVASCIENCE",DN="7",CHK=674747,FOLIO='9',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-LA_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 11:43 2018' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="720" height="948" src="g382043lai002.gif"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2237017",CP="OVASCIENCE",DN="7",CHK=486450,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-LA_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 11:43 2018' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="720" height="939" src="g382043lai003.jpg"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2237017",CP="OVASCIENCE",DN="7",CHK=851849,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-LA_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 11:43 2018' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="720" height="960" src="g382043lai004.jpg"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2237017",CP="OVASCIENCE",DN="7",CHK=871543,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-LA_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 11:43 2018' -->

<BR>
<!-- SEQ=,FILE='QUICKLINK',USER=HYUNG,SEQ=,EFW="2237017",CP="OVASCIENCE",DN="7" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>8
<FILENAME>a2237017zex-10_2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;10.2</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Lease Extension and Modification Agreement</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="34%" valign="top" style="padding:0in 0in 0in 0in;width:34.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Landlord&#146;s Name / Address:</font></b></p>    </td>
<td width="66%" valign="top" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">301 N. Main Street, LLC</font></p>    </td>   </tr>
<tr>
<td width="34%" valign="top" style="padding:0in 0in 0in 0in;width:34.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="66%" valign="top" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5 Research Dr.,   Suite&nbsp;B</font></p>    </td>   </tr>
<tr>
<td width="34%" valign="top" style="padding:0in 0in 0in 0in;width:34.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="66%" valign="top" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ann Arbor, Michigan   48103</font></p>    </td>   </tr>
<tr>
<td width="34%" valign="top" style="padding:0in 0in 0in 0in;width:34.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="66%" valign="top" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="34%" valign="top" style="padding:0in 0in 0in 0in;width:34.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Tenant&#146;s Name / Address:</font></b></p>    </td>
<td width="66%" valign="top" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Millendo   Therapeutics,&nbsp;Inc.</font></p>    </td>   </tr>
<tr>
<td width="34%" valign="top" style="padding:0in 0in 0in 0in;width:34.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="66%" valign="top" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">301 N. Main Street,   Suite&nbsp;100</font></p>    </td>   </tr>
<tr>
<td width="34%" valign="top" style="padding:0in 0in 0in 0in;width:34.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="66%" valign="top" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ann Arbor, Michigan   48104</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, the parties entered into a Lease Agreement for office space located in the City of Ann Arbor, County of Washtenaw, State of Michigan, and commonly known as 301 N. Main Street, Suite&nbsp;100 (&#147;Leased Premises&#148;), dated December&nbsp;31, 2015, but commencing as of January&nbsp;1, 2016 (&#147;Lease&#148;); and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, the parties desire to modify certain terms and extend the Lease as set forth herein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NOW, THEREFORE, in consideration of the terms and conditions of this Lease Extension and Modification Agreement, the parties agree as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Tenant hereby exercises its option to extend the Lease, commencing January&nbsp;1, 2018, through December&nbsp;31, 2018, at a </font>Base Rent of $11,377 per month, $136,524 annually, and Landlord hereby acknowledges and accepts such extension of the Lease.&#160; It is acknowledged and agreed that by letter dated September&nbsp;13, 2017, Tenant delivered timely notice of the exercise of Tenant&#146;s right to renew the Lease for an additional twelve month period expiring December&nbsp;31, 2018, and this Lease Extension and Modification Agreement does not supersede, modify, replace or act as a substitute for such notice of renewal by Tenant and the Lease was effectively renewed by such notice of renewal.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Except as expressly modified herein, all other terms and conditions of the Lease shall remain in full force and effect.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The parties hereby execute this Lease Modification Agreement on this 30th day of November, 2017.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">301 N. Main Street, LLC</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Millendo   Therapeutics,&nbsp;Inc.</font></b></p>    </td>   </tr>
<tr>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a Michigan limited   liability company</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a Delaware corporation</font></p>    </td>   </tr>
<tr>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Eric Kchikian</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Julia C. Owens</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Eric Kchikian</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Julia C. Owens</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Its:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Manager</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Its:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President   and CEO</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2237017",CP="OVASCIENCE",DN="8",CHK=541707,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-LC_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 11:44 2018' -->

<BR>
<!-- SEQ=,FILE='QUICKLINK',USER=HYUNG,SEQ=,EFW="2237017",CP="OVASCIENCE",DN="8" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>9
<FILENAME>a2237017zex-10_3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;10.3</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Lease Extension and Modification Agreement</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Landlord&#146;s Name / Address:</font></b></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">301 N. Main Street, LLC</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5 Research Dr.,   Suite&nbsp;B</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ann Arbor, Michigan   48103</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Tenant&#146;s Name / Address:</font></b></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Millendo   Therapeutics,&nbsp;Inc.</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">301 N. Main Street,   Suite&nbsp;100</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ann Arbor, Michigan   48104</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, the parties entered into a Lease Agreement for office space located in the City of Ann Arbor, County of Washtenaw, State of Michigan, and commonly known as 301 N. Main Street, Suite&nbsp;100 (&#147;Leased Premises&#148;), dated December&nbsp;31, 2017 (&#147;Lease&#148;); and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, the parties desire to modify certain terms and extend the Lease as set forth herein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NOW, THEREFORE, in consideration of the terms and conditions of this Lease Extension and Modification Agreement, the parties agree as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.&#160;&#160;&#160;&#160; </font><b>Term.</b>&#160; The term of this Lease Agreement shall be extended for six (6)&nbsp;months from December&nbsp;31, 2018 through the Lease Expiration Date of June&nbsp;30, 2019</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">2.&#160;&#160;&#160;&#160; </font><b>Rent.</b>&#160; Tenant shall pay Landlord Base Rent of $ 11,720 for each month of the </font>six (6)&nbsp;month term extension with payments due in advance on the first day of each month.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">3.&#160;&#160;&#160;&#160; </font><b>Option to Renew.</b>&#160;&#160; Tenant shall, provided the Lease is in full force and effect and Tenant is not in default under any of the terms and conditions of the Lease at the time of notification or commencement, have the option to extend this Lease on a month-to-month at the Base Rent of $11,720 for each month, on the same terms and conditions set forth in the Lease.&#160; If Tenant elects to exercise said option, then Tenant shall provide Landlord with written notice not less than thirty (30) days prior to the expiration of the term of the Lease, as extended, or Tenant shall have no further or additional right to extend or renew the term of the Lease.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">4.&#160;&#160;&#160;&#160; </font>Except as expressly modified herein, all other terms and conditions of the Lease shall remain in full force and effect.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The parties hereby execute this Lease Modification Agreement as of this 22nd day of October, 2018.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">301 N. Main Street, LLC</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">301 N. Main Street, LLC</font></b></p>    </td>   </tr>
<tr>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a Michigan limited   liability company</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a Michigan limited   liability company</font></p>    </td>   </tr>
<tr>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Eric Kchikian</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Eric Kchikian</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Eric Kchikian</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Eric Kchikian</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Its:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Manager</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Its:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Manager</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2237017",CP="OVASCIENCE",DN="9",CHK=420102,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-LE_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 11:44 2018' -->

<BR>
<!-- SEQ=,FILE='QUICKLINK',USER=HYUNG,SEQ=,EFW="2237017",CP="OVASCIENCE",DN="9" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>10
<FILENAME>a2237017zex-10_4.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;10.4</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AMENDMENT NO. 1 TO THE<br> ATTEROCOR,&nbsp;INC.</font></b><br>  <b>2012 STOCK PLAN</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Millendo Therapeutics,&nbsp;Inc., a Delaware corporation (formerly known as Atterocor,&nbsp;Inc.) (the &#147;<u>Company</u>&#148;), previously adopted the Atterocor,&nbsp;Inc. 2012 Stock Plan (as amended, the &#147;<u>Plan</u>&#148;). Unless otherwise defined herein, all capitalized terms shall have the meaning set forth in the Plan.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;2, Paragraph (h)&nbsp;of the Plan shall be amended in its entirety to read as follows:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.75in;text-indent:-.75in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(h)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>&#147;Company&#148; </b>means Millendo Therapeutics, Inc., a Delaware corporation (formerly known as Atterocor,&nbsp;Inc.).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">Section 3, Paragraph (a)&nbsp;of the Plan shall be amended in its entirety to read as</font>  </font>follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.75in;text-indent:-.75in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;Subject to the provisions of Section&nbsp;13 of the Plan, the maximum aggregate number of Shares that may be subject to option and sold under the Plan is 12,086,451 Shares. In no event shall the number of Shares issued pursuant to Incentive Stock Options exceed 12,086,451 Shares. The Shares may be authorized but unissued, or reacquired Common Stock.&#148;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except as expressly amended hereby, the Plan shall remain unchanged and in full force and effect and is hereby ratified and confirmed.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adopted   by the Company&#146;s Board of Directors:</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;17,   2015</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adopted   by the Company&#146;s Stockholders:</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;17,   2015</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2237017",CP="OVASCIENCE",DN="10",CHK=152612,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-LG_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 11:44 2018' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 5.7pt;text-indent:68.6pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, the undersigned has acknowledged this Amendment to the Plan this 17</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>&#160;day of December, 2015.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">MILLENDO THERAPEUTICS,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Signature:</font></p>    </td>
<td width="38%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:38.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Julia Owens</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="38%" valign="top" style="padding:0in 0in 0in 0in;width:38.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Print Name:</font></p>    </td>
<td width="38%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:38.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Julia Owens</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="38%" valign="top" style="padding:0in 0in 0in 0in;width:38.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title: </font></p>    </td>
<td width="38%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:38.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President and CEO</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2237017",CP="OVASCIENCE",DN="10",CHK=938710,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-LG_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 11:44 2018' -->

<BR>
<!-- SEQ=,FILE='QUICKLINK',USER=HYUNG,SEQ=,EFW="2237017",CP="OVASCIENCE",DN="10" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>11
<FILENAME>a2237017zex-10_5.htm
<DESCRIPTION>EX-10.5
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;10.5</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">MILLENDO THERAPEUTICS,&nbsp;INC.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AMENDMENT TO 2012 STOCK PLAN</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Millendo Therapeutics,&nbsp;Inc., a Delaware corporation (the &#147;<b><i style="font-weight:bold;">Company</i></b>&#148;), previously adopted the Atterocor,&nbsp;Inc. 2012 Stock Plan (as amended, the &#147;<b><i style="font-weight:bold;">Plan</i></b>&#148;). Unless otherwise defined herein, all capitalized terms shall have the meaning set forth in the Plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Section&nbsp;3, Paragraph (a)&nbsp;of the Plan is hereby deleted in its entirety and replaced with the following:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>&#147;</b>Subject to the provisions of Section&nbsp;13 of the Plan, the maximum aggregate number of Shares that may be subject to option and sold under the Plan is 20,086,451 Shares. In no event shall the number of Shares issued pursuant to Incentive Stock Options exceed 20,086,451 Shares. The Shares may be authorized but unissued, or reacquired Common Stock.&#148;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Except as set forth in this amendment, the Plan shall be unaffected hereby and shall remain in full force and effect.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adopted: June&nbsp;21, 2018</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Approved by Stockholders: June&nbsp;21, 2018</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2237017",CP="OVASCIENCE",DN="11",CHK=425743,FOLIO='',FILE="DISK121:[18ZEU3.18ZEU10403]38204-3-LI_ZEU10403.CHC",USER="HYUNG",CD='Nov  6 11:45 2018' -->

<BR>
<!-- SEQ=,FILE='QUICKLINK',USER=HYUNG,SEQ=,EFW="2237017",CP="OVASCIENCE",DN="11" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>12
<FILENAME>a2237017zex-23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#18ZEU10401_12">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="ke10401_exhibit_23.1"> </A>
<A NAME="toc_ke10401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;23.1    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ke10401_consent_of_independent__ke102306"> </A>
<A NAME="toc_ke10401_2"> </A></FONT> <FONT SIZE=2><B>  Consent of Independent Registered Public Accounting Firm    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We consent to the reference to our firm under the caption "Experts" in the Registration Statement (Form&nbsp;S-3) and related Prospectus of
OvaScience,&nbsp;Inc. for the registration of 1,886,574 shares of its common stock and to the incorporation by reference therein of our reports dated March&nbsp;15, 2018, with respect to the
consolidated financial statements of OvaScience,&nbsp;Inc. and the effectiveness of internal control over financial reporting of OvaScience&nbsp;Inc. included in its Annual Report
(Form&nbsp;10-K) for the year ended December&nbsp;31, 2017, filed with the Securities and Exchange Commission. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>/s/ Ernst&nbsp;&amp; Young&nbsp;LLP</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> Boston, Massachusetts</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> November&nbsp;6, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2237017",CP="OVASCIENCE",DN="12",CHK=139149,FOLIO='blank',FILE='DISK121:[18ZEU1.18ZEU10401]KE10401A.;4',USER='HYUNG',CD=';6-NOV-2018;14:16' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="18ZEU10401_12">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ke10401_1">Exhibit 23.1</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ke10401_2">Consent of Independent Registered Public Accounting Firm</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=HYUNG,SEQ=,EFW="2237017",CP="OVASCIENCE",DN="12" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>13
<FILENAME>a2237017zex-23_2.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#18ZEU10401_13">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="kg10401_exhibit_23.2"> </A>
<A NAME="toc_kg10401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;23.2    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="kg10401_consent_of_independent_auditors"> </A>
<A NAME="toc_kg10401_2"> </A></FONT> <FONT SIZE=2><B>  Consent of Independent Auditors    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We consent to the reference to our firm under the caption "Experts" and to the use of our report dated May&nbsp;4, 2018, with respect to the
consolidated financial statements of Millendo Therapeutics,&nbsp;Inc. included in the Registration Statement (Form&nbsp;S-3) and related Proxy Statement of OvaScience,&nbsp;Inc. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>/s/ Ernst&nbsp;&amp; Young&nbsp;LLP</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> Grand Rapids, Michigan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> November&nbsp;5, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2237017",CP="OVASCIENCE",DN="13",CHK=137977,FOLIO='blank',FILE='DISK121:[18ZEU1.18ZEU10401]KG10401A.;9',USER='CHE106204',CD=';6-NOV-2018;00:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="18ZEU10401_13">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kg10401_1">Exhibit 23.2</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kg10401_2">Consent of Independent Auditors</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=HYUNG,SEQ=,EFW="2237017",CP="OVASCIENCE",DN="13" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>14
<FILENAME>a2237017zex-23_3.htm
<DESCRIPTION>EX-23.3
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#18ZEU10401_14">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="ki10401_exhibit_23.3"> </A>
<A NAME="toc_ki10401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;23.3    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ki10401_consent_of_independent_auditor"> </A>
<A NAME="toc_ki10401_2"> </A></FONT> <FONT SIZE=2><B>  Consent of Independent Auditor    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We consent to the incorporation by reference in this Registration Statement on Form&nbsp;S-3 of Ovascience,&nbsp;Inc. of our report dated
May&nbsp;4, 2018, relating to the financial statements of Millendo Therapeutics SAS (formerly named Aliz&eacute; Pharma), appearing in the proxy statement filed on Schedule&nbsp;14A, which
is incorporated by reference in this Registration Statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also consent to the reference to our firm under the heading "Experts" in such Registration Statement. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Lyon, November&nbsp;6, 2018</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Le Commissaire aux comptes<BR>
/s/ RSM Rh&ocirc;ne-Alpes</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ga&euml;l Dhalluin<BR>
Partner<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2237017",CP="OVASCIENCE",DN="14",CHK=54433,FOLIO='blank',FILE='DISK121:[18ZEU1.18ZEU10401]KI10401A.;14',USER='CHE106204',CD=';6-NOV-2018;00:31' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="18ZEU10401_14">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ki10401_1">Exhibit 23.3</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ki10401_2">Consent of Independent Auditor</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=HYUNG,SEQ=,EFW="2237017",CP="OVASCIENCE",DN="14" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g352623.jpg
<DESCRIPTION>G352623.JPG
<TEXT>
begin 644 g352623.jpg
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M(+EPX8.@)2XI8!*6E(&NK$)/.EQD3G+&(QT*B F$H(-QD78$'D>3KNP%#DH
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M@?DQ0X491RI131* B19V51P/4"+80D7EVW*4VDR+YHIX<H_,G$11@$ .F[?
M<IW) YY$S-J1P[*(<@"B) -V'50&?LL$Q%CU_-M#D/9I=0\%4T%1 YAEW*)U
M%)14@B)E4(1H!Y)8! 2K.2LVR@AYK6OO75$HMT3*X*XF=),!,C8$R5>0'!-<
MV^T+M,ST:P>:<>++#-LJ\ZBXGWA;I)#=ND#*EOK21W8A2R6FQ(=(.F=SNY5>
MHJNL;8]?>%:3I@E9[$V,45*RDLF!@B8Q0 ,!+$NB<IW;ON,(@H1-+B36 [*$
MF'<76G-&1JWCNJ)>8GK1(BF9XZ\99M&LR 9W,V"54#K6,RC&A5G[Q03&6=J
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M$/)3=&DS1TA,P#]1,&B;^#E5G1)15M%GCP<OH[SL)25$)2))P!XGP$\G@<G
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M:4IIIKKI6680K-1_(KE003[!SW454'GH103^\JLH(<%(7\3&$I"F,$$@"20
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M0A&+X#?\7QU3@(@'.O4!J#&\O;DEE6GR$Y M2>_X\I9,Y$R )C/8]$Y4)$H
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MY2%!:9E++&I+(B"%+<5)=CB-29R FME7S)2UA(>%A#+-X43"1TY, IN94I1
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MI!C/U]>D'SK\&S9%JV0:-D4V[9LDDW003+TI)-D"E212(0. *0B!"$*4.Q0
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M::4IIIII2G'^?YZ:P>TXVH%T*<;53JY/*&  \S(1315Z4 Z0#PWX)%>I]BE
M?#<%Y  #T[:::I4E*P4K2E23NE0"@?4$$5:>89N$%JX9:?:5[S;S:'4'U0L*
M2?B*TY);0\&OS];>O2D.(F,8Q8BQ3**8]0\]/A.G3Q,A2C]PJ92 4.P  <!K
MK4]FN&4Q[)VLP!QV-9'''8>?4J!3#^HC^_?336H=M+76!]VMX)$CN6\[?TUX
MF\Z+T9%U">D],2-2<)L+4#\/ :%9G#[9\*09DE$J4UD5B"0/&FWTG+]0E'J
MQV[UXHS$PB =7^[ !@^$0Z>0UNF+AXF$;%90T9'Q+,G'2UC639BW+P'2'"+5
M))/L4. 'IYX^>FFMBQ;L,I26F&6B4B2VVA!.!N4I$UZRPL;*T:0;6SM;8J0-
M1M[=EDJQR6T)GXUV.FFFLBL^FFFFE*::::4IIIII2FFFFE*::::4IIIII2FF
CFFE*::::4IIIII2FFFFE*::::4IIIII2FFFFE*::::4K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g425336.jpg
<DESCRIPTION>G425336.JPG
<TEXT>
begin 644 g425336.jpg
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M(R0X6'%TDI>SU_ G5Z'1TB4F*#="1D=2:'FUP>'_Q  5 0$!
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M_+X:W_FS6_?2=>X1=%=LD\Y1IQ"=7G(;:MB"P)1QAR=XN*6IFMUL%PT$ 0$
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MN@>;[0?CJWD<2E\$Z2[[N/HJ\=.<8$B4PRGYM129H9HZRNI\L+/%+6^SX)#
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M="VK0;9TC6+%3O4$8KUJ@SJFMR$QQ.^,S4X-3U,&)W>ZOL(F&2B1P R<PU2
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M&ACT5A<$A[,C9HZRI +5>S3W5V=W9T='52IP,$OZ6/\ A%JT_FI0']H%E?\
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MH9@];7VLB<\LAV=D3P_R"PXLLF9S/.]R,]O1HWY%*4[FB<F9.4PFDZ9BBT0
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MK>@[T'XZ\[WK6M_'6\V:OHN<:AXF]/&A*M?8^6Q6=(F8VVK@)$4:0NU9-C[
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MV!]OR<0C:Q;WPZ1I(U]S8GD43!HIY/-6?:I;&%Z'[?N#'$2?02M7"X$ O4H
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/!C&,!C&,!C&,!C&,#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g924698.jpg
<DESCRIPTION>G924698.JPG
<TEXT>
begin 644 g924698.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ R35),3%]'4D%02$E#4SI;3U9!4T-)
M14Y#15U-24Y46E],159)3E]+7T9/3U0N15!3_]L 0P ! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$!_\  "P@ '@*L 0$1 /_$ !X   (" @,! 0             '!@@%
M"0($"@$#_\0 -1   00# 0$  00! 04'!0  !@,$!0<! @@) !02$Q46$1<9
M(3%1D0H8(B1A<H$E,Z&QL__:  @! 0  /P#">4DE?%/UOXU=7OZBN.LA:_\
MIZ"I&[.S]>X#&YXGHN&MPIN.JP2H+ XM,)K2,%FQ+9*8(P86 ,:OE*Y2!LGC
MM!7:3=X2VAM*S@^F./.]_3?H'IN[ZI[.Y_MGNF/ 2H7OHT$!3@UQR98=BBU/
M4O'4\,SS6J"6,D8(5%22PH6PPTM(;C2M&0U4D%L3\)NW7_0K2_\ M.;'KN+@
MT^Z=7"//KDHUL[G_ )I[/(>/>D/-N_;2JZ;N0QO 5J-[-B-3WM.'3=]!2@:W
M.C[1S$;U>H%MHI^VRNV>NSK+G7F?JBMO'WJ[<GO"TIWKN\N':BL:V)&U[PI2
M<N>D22@[9)GBA;55:V4/  "4&<I"Q! 5.P:'C9)O+)*M(@B4B,Z;.70ARK47
M0/>I]YSVR17&.<E\8<7<T'W-?-$!T3<H;M;DK;1A=<19-YFIW!G49=UI+5,\
M&16MH+:;/I@8%'Y*\?23%2<FV*Z>L<MLSMT[FN'*BY<Z*G3RP>=_5;TMI?EV
MTK3G',PVZ6JGD_FHEL<(JVZ#%JNQ96&P(G$67\Q3-KNM%UEMHI,]444G6*\A
M]N:\BNM(OM#HSTCNP85+HH5F2SCEGBLS->1TGJ5/HKE:!AK@I\BA7VJ*<"9U
M]9L61#)JS:-D6[N?BUY1'=TV>M72V]KX^X;_ /#'_O3_ /Z:_:<O)@T-%^)K
MT)]E)HZ*H/LWTPQ ,91X_EWTEN,]=7AH-#3=5TYRXPTUPQ8PL:Q3<(HMFO[+
M-I^.DFGC33:^@EA+R0JWVI$.G[M-/2(E%:AMIR>N;M,GP':]IV%9 V,E?":_
M.RTK_HFG7J4G+S-%P=?#%=QI@)D TQ(6\NX(HJ0=O_PZ7Z@Z'Y7/O<6S2T[G
MYSBZX[+O+DO"^CJ6T>\B]/)^=M)%7/\ 9L:_:[.G,965[$1VYILE<M-&#(/M
M>/JN=W6;)DTFZ6LY27*E6=E]56&ZZ',;PA7E(^7WE275P=5_T9<E*3-4%1_
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MWJQ:(<5<*KC;:&8UDK QNL+#[5PN-;0LB!ZL(37$(@D)OH='^&_^DJ)J1_\
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MG5U?77/=:4(RJ>U9.?A*ZL'6QQ]Z+&,R*).EBN(@I6.<O$'DH*ZL7VI/'_\
M@>#RS)VA,(,EVRR>G$[]&N%*TDP*(-NL*+@W]HA(K9-<HJ6!#/=#:OCE^]BP
MPV&',6J_:3 J52$<_:#\ZS75CI99DZU9.%L(*YUG,GV?R;"WVRY<ENC:9CNB
M)%9@S94T\L$<0L)>2EH9<CB87 YN^P]T()8=;+D$4.JZISLG!);S#".<1WZ7
M.SGL6Q@2HP0ML^S2V!!*]!("2*3(R*))O$#HR.0[?9W*34S)NMM6[&.8-M-E
MW+E;;":2>N=ML_X^7M#=.\]=0CTT5<\W-7-QP0W-Y&R1]7Q3&$7]<(/PV\EI
M"D+5FML^@Y1>,=LY-JRE6K1=W&NVL@UT69N45]XY6O9W)UQVN847571=-V%<
M(#K.;%U;B%@#D\7PFHO+-Q\JV<PT>^6<K:BD^[:0)5LRPZU&IMTVB9S,?(+I
M-M[,_'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\
M?'Q\?'Q\?'Q]IF]@.-K*Z]9\BJ5<5B0<5\^WC8?08K.%,D0Q^D;:->\UV_)T
M9*--1^"F5GC2+NM #=EJ"^['.H-J2KQ_\G+)L8:0H+SAYG]!UO8L*:&-A5F1
ME)3W!;'75H3+$@--U9<^Z(\<SNH[24@6[T*0U9MM.DK)G)08B]UVK1E3S&*?
M[+H%">XAK8/S?\X[6XTZ/YJ=,CT%?\VCGGT1Q[*J(UP2*R57]-VDZY)QT&O5
MZK^#;,%Z(L\CI?%L-8J0=04N,V:7FR\6-(PI9NTA%B0T9TA2GEQQ#QS_ # .
MZ Y+!.)]B/PZTC<#*CBH&A 23RM25*8MZKF)&%86Y($$8'VF8.XX;(X.M?[7
M$A6N9XB9SL'M\Y7Z C3@@6H2%I\;J6%JKFKF6RH"(#B-&3$84>M2:N<*AJX&
MH9N#A:$1"U\PHU)O$N6S1NU?1TRT8H04'I#?YD-.>M>77.^<9OQ2X8B@P5<X
MV935CM[,![I*X20(6(-WO"71*X&Y?>CUI*MRS4/C-TAB>UC35!B9?BI.6>(Q
M#>749!72'1%R<@ ]H<_V+(#76'-5]G6*ML_I2[2J]'JX3?($K3UJP$X?Q-0
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=F1^/CX^/CX^/CX^/CX^/CX^/CX^/CX^/CX^__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g80173.jpg
<DESCRIPTION>G80173.JPG
<TEXT>
begin 644 g80173.jpg
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MX-,95$)(RK3"%.$AQF27"./6 $^]RBD@D#+DP@#D(\N%;X]/"-D6/XVL;/\
M?0-=G_<_]^OQCODG7A9L"XX<9:@C$G6MM:7+3]9NMK1%.8-,@GP*HU^HIYA;
M-(E",:9S4Q]O=Y(X.QS.0N3I5;H2U.1P<KV5J4)%%5KY5?52O(='J\@ ]7H3
M X,Q-$7AD.B^N\<9H[%XTSI?L+0Q,C6C<RTZ%L;41!*5&F*#@)91>/7(AB&,
#7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g744458.jpg
<DESCRIPTION>G744458.JPG
<TEXT>
begin 644 g744458.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ R35),3%]'4D%02$E#4SI;3U9!4T-)
M14Y#15U-24Y46E]334%,3%]+7TQ/1T\N15!3_]L 0P ! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ /0 P P$B  (1
M 0,1 ?_$ !T   (" P #              @+"0H"!@<! P7_Q  \$   !P !
M @(&! P'       ! @,$!08'" D1 "$*$A,4%5$6,4%Q%Q@R-G)U@9.SM-+P
M)DETD92AP?_$ !4! 0$                    !_\0 'A$!  $#!0$
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MCXZIW4+.UKIQY19H?3&LNY=M7J;AHMN>LOJ#0'!%B.$)2/XZ7]L=)".F$BO
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M3J;7+3>Y:-C86*,U,2G#\1#GOU=Q#MW_  \\4.PB'< '\13#@ 1 ! 1 !\Q
M!#O]7</K\02K]7E&!Z@7*?:]2X].M;M> ZOL?#SCE&.=@1K52Q/-*#.0L1IE
IBK,".4V$'>F[_:HM":T"\/W9I%C3H:GYC7R,H&$F7MJ&GWG>?>MG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g382043lai001.gif
<DESCRIPTION>G382043LAI001.GIF
<TEXT>
begin 644 g382043lai001.gif
M1TE&.#EA P 6 '< ,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "'Y
M! $     +    0 # !0 @@   .KJZNOKZ^SL[.;FY@$" P$" P$" P,1"! @
0(ZZ]Z."0%M-YZ\[>Q20 .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g382043lai002.gif
<DESCRIPTION>G382043LAI002.GIF
<TEXT>
begin 644 g382043lai002.gif
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M!R @("0D)"XN+B,C(RHJ*C$Q,1L;&QX>'B<G)QT='1P<'"LK*R$A(2TM+0
M  $" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$"
M P$" P$" P$" P$" P$" P$" P$" P$" PC_  $('$BPH,&#"!,J7,BPH<.'
M$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7,&/*G$FSILV;
M.'/JW,FSI\^?0(,*'4JTJ-&C2),J7<JTJ=.G4*-*G4JUJM6K6+-JW<JUJ]>O
M7"& '4NVK-FS:"V*3<NVK=NW<./*=;AVKMV[>/-JA"!V;5\ =0G^Y3LPL$##
M!P<75(R8)&/ D#L&;JRWLN7+>0D7ADR9LV8(0?@2[GR8L^?1IA>*7LTZLNNZ
MDTTKQDR[MNW;"O\*# T@M&C!"H>4#N*#H._-L <&&1)DH P/D64T/QQ$AM_#
MUH=([^NH>-\AL'EO_][M0P9D[:5]"(<<1+QFP.@)#Q%N?H@'\X#=_X[L=WY?
M"/?UMMMUCWT'6E\^_-9>7>T=]A]?Q $FE@\)BN9!A1-.=^!HVHGF0WN\5=>;
M6 W*QMI:ZN77FWDA$EB:@X!)5YB,$FJ(W(N@\<:7=:=1]]MJI2EH'@0L-M?@
M9[*!-YIW"$HH(9"#V0B < WJV)>&!:YVW(B#_>?:8KC=!@%Z#NKVHFLR),C>
MAT^:*1ALY:TE@R.:+1CD>P!XD*-[,H#GW&A (E<=?@#TV9Q8:?JUW7B]=;B;
MC(A^^"!IA<WG()M]64<I>8?VABF$GXE7F%@=$I;B>?B1B.=:RR&JIYJDPO]:
MJ*BO\;@CG8=9RAF/9QHDPZ)CTGC@J K]&J('TZTHGIT&$<GKE&K"MUY^G1ID
M*8*#89K?=<9!ZFQICFBZ+:,'M4J=G]0F%UN8ECUXJ'JBT;I0FIW2ZQF8J?56
MW97KJ0H;GHX<REQD9(Y;)D+$^16$GN>RNF5!Q T)7[:%,8OC>/XAZ.>>_/7*
MZ9J'@NI@LM;V.V6J )P*(<D,SA>$([TAZUQYU(D:WK1$"D?BIX'FEJ:#0["I
M(F+)-<KKG$?SNN%B.]=;H4#P[N;>G2GNZ('.H*EIY-1_!:VAKGQ=.+*4#,+F
MZ)0#2TTTONSJ!:) SQ&*YWC7%8SVJ-PF1*1XI<K_IO9  9,8GZ=ROR=OQ1*/
MJ3-\^B$I)YE\/5UHVF_G=MC5<@JM+V6*]4G0M4\*=KA @Q-'I:>=VIDWO3"O
MZ&30T>EXIK I$YIFXG,CY.S7:0<ZM\*+0JOAP\,"=W)=I\:,\^'O=LTPJ<L3
MNAC8$- <*8,EJOO>[;NY7/.F;>NUH^J2@\;0XYKU^=ZZS;X=Z[^37KYLVI.'
M_&/HY6)8**S.^I7[H^)1'V_4,[R>!49'OR+,<FPEH+P93WW.01?^[H<<]!BI
M=$)K3;,\$+"K48A$^QN-[)P$'UOM;2WVP=)^7B.8!&)'6-4J&G_H5QWWV% _
M3DJ8:!(H,*7%,$@23-1 __SCH\=,SB_P,E*XRL0YTQCJA2':$K<<&+ZW&&9@
M?<&<DZB8G" DXC_F@M&;RG6Z0K6N>#X22. BHZV7$4J*PRH:<4(V1PFI#$HJ
M @R;I@.=0M7O>\WJ6,J,I$:Y]2IO)$I$LL*X(5:YB3<6A)IY6!0G,>*M-Y.@
MT'V&D(A$)!%9BFK6A'!F/4E6['\D--IY-K8YO1&$3=FAH:@LYK\II:=3_<LC
M<+B3.$6.R(L,>A9U)C>B*36'1^'Z%]V,5\-<H2M'X*MB7G[E')FA)DC!(8@U
M!^0Q@T1H.I[+5)W6LL;^6.=0UO32N&J9'UE9:CHT4\[_:DB8X!WO2K);GV<@
M5_]'WY LD,C[#1:E]CH;U>6)HDF$Q(#))08:YT)7@UN"*!0T%A%T/P@25\H6
M!P%'</29G ,-CYH3($<Z9%\15) -&[,C/[4G1>>DF6^05#&&D0Y7[1R;P3(U
MI.9DL'HYW-C_6+6="17G8(*49F8<1,U<X1*5W#(77V 7KQ$:SXX"E=RS"!,P
M:]UG4,3YT *-]:M?:6=09)V/=GY%H>K,QP/W*2M:RVJL^4B'.7!=#EX_)!VZ
MSM58-6S/[:13G3@)]K" 75!H%DLO(@%(3SG2%(A M#+?I$E)UDGF@O;XL.%<
MS9>1TB.%M&:PQ7@.,M2,UY#<]"71'0E:%4MJN5*+NBO_^=!FNQ)J/%4I,DN2
M"H35^XL0KR3#7,:(<C)KDVKRHS1#@9&+2G4;<\Q7/9SI4W=U/"YU'!K(1PV'
ME5($P!K3TYWR,&=ADS5=7_MT5KJ:%7-]\D' %F@?P@Y6KMJ9CP^0Q9SGK+5Z
MFV2K>MQKU@*_53WW\4$B$DQ1[:A'K>Q]L%WA>EE'*/0YZAEMT"Z4X:!!.!$>
M]3"(@Z:>22#+ Z#=C'\O!"?\#,'$N_$COO0ZHY9=9W1?$FEIGN/(ZPKRB1^C
M5L7^R9F!GHR-<AO=5!>'7@G9!X3"A VD2D@0G.XT,4.4WG(T!*SH+O4UTY6H
M"MEW18FE#'Y7M=:6SNJP*ELU_Z_/VK(\TRS*5P:&1JU=S%'A5BU=,?>D*"7<
MC^!W(K@I22"8J^IJ7-B:A9UN8>><$K*\N-H=C_8^FJ'00.2;K.)-9DRIPR)H
M!K;855V52,693C*YB<I16?2(RM'/U B2P"R*"T#^.]S[4$4PCN)X;TYR8<JB
M5=IN&FTT0"8LV[QL%Z)N,5IH))=P5ZLX8G57,->*'+4_TU7!B$U].SPT-)_;
M(U37J&HOO?4*^R/N),9LI;.AFV.7-#P3L@Q&.M3C,[=DL<W(67"I8^NA9+?B
MP@:[=WDE+DL=A>IDV4NYNJL4RH2]0BQW+WV]\W2U7O1OWC9*A!L?#"N)2+I]
MHV;:=?]R:<KHA$^6<CP^.[(W:YEM1>3TQ9>'PK-LC3?J[UK;. Y<3G061\+Q
M0@:N)'K>_A"8Y)G#NE'3RFYG4]E'1$T+;;RB5:']DF)<Q]I++@>J<O9LOAJK
MRY2N2AP'MR9<!%,RU"52,-#-9+[!#1+)HU+RG6$5,?\5;5U/;([W()ZO%RD]
M3W^1L]JT!R Z/@\T-H5F8I9XF%("B#]ZC_%&:2W!$M&9YFB9>6JG2DB,JB9[
M%*\XV^B9'Z$2!I0D5*3#A@<Y4X,)X'*:<NKG24-Q0U"=#1D]J.\5[=G2,<PY
M&HYNI,Q124&&%*GZS9R\QEPZ:O3%RV+907%9JLBM%)N)"1[_J#_3ZA8&<*!P
MI.D+.:2DG 7<@:,>'H9R)D*:YEZ@ :QD;UW.7.E'/Y^@%Q=K4TJ0]B2ZQBC#
MI3A=4GZ5EW*1T1S=IAF30"NB9DS$PDZ^551HDWR4US,0,SCA5'(-5'P) 3K5
MQ1^.M6R&)GW)M2.B@U0B*!]8TU:;8R0>E"H+DRU=\T5IQ$*%(CT_4WF5]D^=
M(6Q'UH/GTR''1&S7E$K&43#5UC1 9TE0XW"X8H/A(4, P(/P9"<RD&*T9'$H
M=3WLH7H!&'H^:"2E]'!F6&<B<EQ-!SXB4D^LU%$%M(4;]QR+M%6-4URGM3(.
M EDUPEJ[@UI7)T3;0HC*H4>1QH; _]808V)IG*%U3I=QW38)>KB(CK9;\5<C
M)@-[9L@J]#-\%R=/Q04QM*6 CT)!" %D^\,T,.@K$E0P-(8_HI1!B&AN$&<8
MU?-&=1AYS$)D^P&%VT2"9\@6:Q,L[ %2ZI=CRK)^A+<04J6*:J1" #"!@,(X
MJ!4\#]-9P),LTR4X*'---B:*R-8[Q]$9WY$XO:>%P-%,*_@]#Y(8R@@AZ"%[
M3X,HY24]SVAHG8)T-7,CTL)NHA@RM>9*,2(WN[<NGZ9[829&'BB*[68K?9)D
M1%A]*<4OG89#N/<H1U-)K70^X.8I'!5-QQ@6>49"XJ<YX",?S650@F1JHW=$
M8C%>:S&!C/^2@N)87&VX@:+1-V7E=XG1*KQQD(48C?(&-Y\!BL*T3$79?D=8
M(SWB;Z339WFRA!(S)_LE/8*C&1E3*)DDE$335#%'5%;2:N\1CJ2C-#WY&OKC
MBJGD:1RG4<)T-H&&375D=;_Q04QT>_"BE^;39(2'2,XA+G-T=B>9%E,T'3;H
M)%$3<>"7*<IQ=9!Y,*<%->L!>P3A2R^87<'R:4442&^H;6,W9N0B=(:H(F=C
M0+2F>:V#E9JGCD"4'OLA)5.GAJ4G ]A8*'IB@Q1B9IQ!;$+7',- "BBXF%58
M&-Y!.I(3DU?U,MQGFI8#6Y"Q6Q,T=1*"'[BI')A&+23C>!*W8Y7_5GP>PGU!
MPH10E4>6YU$8F)AE,46Z\Y#_)C*;PBS.!4@^V"V,Z1_=%C(>U5W-)(6']&O[
M\AV'=I@"B8K_82S.-#).-SWVLT<>J! !VHN)9WM?<I]B 7U%=DQ7$R 72(HB
M)1J3\)40@C :^(@-=TGDTD)R(RG$Y8S>1)9 MC2 Z(2?"8?G@COP=T(MM1JK
MZ8ZSPBK.URAG246+,8?Z1I7N"18Q&HO*R60T<TX8>D U.IJL.91F]BL*=:*A
MT:5%.!BRAU2@\G?[,AT*I1R45VS8YG!$!Y*ZI!H1A4X'ZGGS(CE^YCN--#TS
MF$X PAR.<#4:]29O26H>M:4SEWPK2*3!_^1COB(L$16:*3F960EMS**HS0*%
M+"E3ZS0><Q)LT"$B\I6%UH9K"J0_$>(P0IH^U:)_33H69IF@V*8S2TAN*H@=
MR\) QAB79!DSE_4KW<%ROR-1BH*.:,8HE0,U034\PA@C6W*9?WI)O#@<2X=:
M()I\[%-!CEF29<.*@)%<F(@N$8-A?;-+1!)C9/)%J64_UL9Z'+.6R":D#TA;
MW*-<TQHDC-8H-79**$I[3&93_=9"O1-/1))<I75 X&4R01,EA#D9VC(F\OJJ
M6B%2Z>ATD6B.TGIZ6<=H/ZE6'FM7:K5?^34$@6IB%#)?6R20870\<]:73/-:
M$4.I3$0TK:*1S/\E+-D8<3J).C,[J>QQ:X.W;O<Z:N8Q7QFWE8;U/[_WBD:K
MJXX#0+GW-7AF>F=RCC/"E@]:CNU42PIC>_,&AZ?*K(1IE.5J>9?ZA/4R>M37
M?[DACNRA.A)+%D*[;JM(I/=F<8J2>+TS)9XT6GY+4105J"36':0@*6:6I=T3
M<%9B4,T(;(*G@8/2E[QXKN!T?5-;?N9HMWB3K0339QK5A$3X'5?)LZ3C20%B
MIS 2@L$B7U4YE;WRALZZ75D'56DI<EM%&@S")"S+'D/FAX%Q:.\FCV/$2"SF
MD?%S(XE"A]('O+LZ.]4"07';%<L'NW'DJ5"Y90MH;%*#@\+V8E5U3H+_15@Y
M Q[2P9?C4R:A2[I'>;XP,I8ELD#_ 7/%E!H4"S+8D7'N:"/_%AHPUUO=92 1
MA$L&)263B),YPR//@6(#1[7?H2/500KF$X10HB[<J($CB:V):D?I2#WWTX:*
MYWYOV[7+EU%^@6E6UW3YTHFX]Z,A'!OUR#CU!*-Q^9PEQ"%$%KU9\;N^QCE-
MI2P]=CXYFI#ZV"!XY6!W93NR$HD/Z* (XWF1NT5="X/ HHSO4B1VQ9C\DD0%
MJRH\5B.+2[5KR24$.VCS(FK5\U2@23>)T"\5:48DJYURB3@.;,#4V).8>I=*
M#'^WYX_W.SP U6@V4X<F::>>![$"4DQ-F#/9__F=W]>*0=1I&73(5!@>;(G#
M7Y$MB]2&]\FS_JL:G"A37T1Z,D *2OB?YT(P(TQN%6?(I0A._+J+,J(IHWAU
MVF<<)"-!,D:%22I<YR5FKJN],WF9^A(D=[N%&_-2H&&Z6H.IKZ%XQEP[/I!)
M@K56!;9>OUE6>=5?AWI>"6)6U&Q6#]@W ,)W 02__N0L'I8C<,9><D58X4M9
MM],@]"+/4S::J?0<)X-AT*0YXD="IBHX!Q=L0IF@@VK)TGM"C$BFS0PL@>8[
MX#<C5C)=8'I6X1(G/Z6O/^D=N!2-"F.7)O0:<52;;X-A(ILFW:%?"*9?(\M!
M<%51CN!1#_;2@*M)^_]U(6H54>S7H5 :<5)%D_:Z-*81+O3#5BJ=Q+.VC:_W
MTFX55N<57_8%6/91'H,2+H:"8OAU-0N$5J&Z7<<!O^DR1_U5S=3\F_DU:8-"
MS1!&5\P1LGKEM_ Q?^GG(![E5A<282SM81J&UUYSTAYTTA^B8!D67QD&I\U\
MU 9=%2V#,LPKA@_IB$,E&VV4(!P$(;PBO^O3+UES)Z]\G0&T3?Y<R+"!.1^T
M1.OX.8PK,*'F66\DM"P6,A^G,:=TKWDG*ZDZ3$^:+%TEU2C2080S9/VZ40]I
M7-&&/9TVU(?8&/RS:<_[3,0TLY,!7C:%HYRSFIP4&:T#-[>[:7CZ3/3CA 7_
MT<.%\KMEPYQ$<[R'O153I2#!S3:2MR+0MBFV52=],@F+B"](LE429"9A&&LZ
MHC)<,HA4&#$I8E>JY:90@D!%IAM1 ]3*N9P<DCXMB&-C1%L62*;5*Q XUS<O
M!E=O72=*UBIO3$TLPG#$4S'&S4:+)61!;55W&;,2!1V4\BT6(JZ7&EX82SK#
M0# ^U)2DHID6.E5_B58G$AK[M2#5PU=&Y4]G536PB(3G;15F4R\#!7PME#[
M>3&:_8,.+ /.T%,5^[^UMF0#_=]O4K^MAR6-?"9N=86D-CFX,Z_FN" 9$QH]
M3%E.PN$YQKR?XL^[](3_ 9((G8B0$<I&BBB=A%,?_[RSAK,<R82S=7ZV/]O5
M4/E!,5H7'A0O]EA4V L@^)QGAL&@)8=/&VDSBF(KDX"-2S9392=]77IKX,:^
MZ9(8I:-[J/K$B6KG3SZQ,FYU.ZT<>!9.KEV9*_),"Z;0/A-]*3@TO:XO <26
MG>;IWPHSI6UU3[6O-]L?3+4\!1&H3>P>!*NDMSJ?J*DJ+&J'L193!"0U\;1Q
M&Q0U)"=846Q\17:>43)T)@97^(YB"[9?\K5@B4 *$>*S<DP=/S7FS5)K7V1B
M),M!@8KO#<;OW<%G3"4])55LP81+/W54*&)(>VR2N<X4 &>_4'I_'S./GV='
M6>G9#.AD(B>=NCR9I2["F_^K9SRX,\;AX&F^/Y6=.A=MZ7UT$*Z80NDBVP5A
M=]:9/0_2;9>36<@BH0M[R/J$(&+S1TYFC91A9D96.M6R,*3PTEYO88DP"6#/
M09U$"@!_5#\TH"-7."#]G VB)\7I"), 8I- "H=N88$:]G.O*9]9GJCUL% U
MA$1G]"9S;0+_\4F1A=.N1XVCI?V!QH<?NU!#Z'R.M]GV+=QT,&:*>ECKLB\R
MJA!>)_EX)&1C0=##(9V?)\OYLO7,C BYC$]"<B<:.AVU?/T5EM#[<:4J.B4Z
M= O:A^T*E42T:^3^6/.57N@,2H45KL UJ?%MB'YG\*XV)]!'LG;EU&ZE5HS.
M@ZK_5(HA;]Y^3H<S]632$OF(3Q7!I-BN;:PR"H_-/9A8EC CTO4CJ+VH.)D<
MJ=#R39&@G;$H1"< X2$( ((R'$$ @##(D"$$$28,\O"A#(H. 03Q87%(Q(00
M.'KPD)"@Q9%!3#[$.+ C!)8B1[Y<V7"DC(PE'SH,DNCF2Q\>6@81>/&B!QDX
M6R(\.D3@0*8^!K(<4G0D2Z0=":8L*1.A#*U" 02%N?.BRH0^ACA=*19F5J10
M;[9T6%4DQR R$G&$X.,F0[(R5 9Q=+6@C*,>&CXU/!5N7*1H%3J^J!< 0ZHO
MU:[%G%GS9LZ=/7\&'5KT:-*E39]>B[0NU;R$'4IVF;J@_V26J^.23"UQ8]E)
M'!ESGFC2853%$A>[5.@Z(<6G5AG+[7F18<>%S1?*K:L2J=_L#BFRCBHQ(DC-
MJOV*S$OV:'F<KEER1>_Q94[U#X<X\KW0/4WM>$G2A*"HB#QR+\ "C[,HP &E
M:XXK__*2JZJW*AK.I[1D"RM B;ZS"BZUX JB-Y3TVFXWB)C:B#4(*$,JO!:+
M:NO#Y?+S:Z*-B//HLK=0X[%''W\$,D@AA\SJI;-XDNHWL32<:4$ SK/,L@U=
M&V*2BXR;BK/L6H+ON=_"2LC$BY2#Z"WU? CL*N4@\""CI_"[<D6FYD)1J@!E
M(F@ZH=C,Z#*8IJN-J+$J0V\SV/\FTXE.B1)IZ#C  G1IMX<DXVC-K1SQP)'
MY%NHI_LP]:$GD-J<I"=10=+T/A\22214PQ(Q#*3[$L7M0@51FL0PF4YMTZQ0
M?PWUK#9I6I71LT+E2MB-N/*!(HJ4XA"A@_[J<[L VS3IV;/JBLHP;F5HDR&_
MFJWK.XRXTK"QDYX,5K4=LR0R7GGGI;=>>W'"R\ RFXT/-]5\RZM1UMCS3CC
M&OUKIR7QE2JB&K\L%#.3%NS2.:,F37-&JAP4"=WAU!M+XYD$7C%)-D/RK-R9
M8!L8S-BDLV@AP?*%<RUP 4"K(]A,&@*E*RV+*CJ4SF7N+.Z>Q>_H<BG;*"4%
MC<Z.N%K_%R.P.5$;=81<9\OUJVMFPS5K"$:9/?8LALP&%J1T'ZL*OJ.X9<C5
M4\_"=!)8,_5@DJPS5:I-D$)M=6_M5DP03H40O#=QQ1=G7/$EOVNQY^3L1+RD
MAU6VC*S-%+RHU7P)E0BS6W6VU$,$43)Q]"]K*PME-9/4;RX3A8-+ZC$'-%"B
M4!\B#][,Y)3=N,JC?/+A)WM.BR7\/,PSI.X@PO%."4&^ZB#"6G+$Y/!&N@_Q
MZU!Z.$ 2.R(S0I>R;<N@A!R1?#W?H;^)XQ.G$DYB#H_7#?FMG(2)PN5@+$MS
M!M:V@1C/0;P;GXI\YZ?&-="!#X2@Z*Y2%_3PJT6:JXQ8JL.]_^NMY&6_^XX,
M2J6Y^[G,2':*W6V,(J6J"&PR4,J1>! B--2I)WLCBD@.M8,C-?D&4&&2B=J&
M9S/E (5ROMG<9/17LN) X" AFPG*@'<5,=$$@#FZS<V4<A6SK(DY!$'3>FZ"
M$2R"*RDN[&"MPF(\".@D8/S[W7M2Q))0]<>.N"/4!K=R*,H\A78JHF.?RB*Y
MR;3I)^%#B&$\XA0ND>A:A!Q4!"4Y24HV\$/;@1%"),42"U$'0Q5I#)[D0SR)
M(0\P3U1(_3JCK^34IU\+PQ\5 :9*E:!)A6:<RUVF$I7![8]07=)D5Y#7$SPJ
M#%YNFXT=,;0CF7$P/FUT5Q3;0\ASB?_D/OT1R\VDAS/Y>61[VB1E7N93$TUF
M,F)@BA]LP.47HK0E2Z&+'Y[&-!\3OM-XDZE)GG8&I=3P"S$ !(HKD<1%Z]2D
M6>*,D?L86$F&-M2AJ(%*@7*V2)#!TC9C*A^&G/.> @[K+<,+W99>)\.X4(\Z
MFRPAH5H'INO(SCI28QT,AU.@[5%T=RHM#X%B9BDU1JDV^EN(/$68T#QM2I;4
M<8PW/]HVUU6$1)";T9-\XL[_@%(ZX%EB!NOY) I"R"[N(>4[U02>\U2-.JH,
MJ2/%=Q0 72QY&$5=![^7O('PJX<=NU%1/%:FA_;5KW\-3>6:F2<!'JIE,'E>
M\<3XF0TB:AC_J?0*P5BY%9-EZ"FA$]EDFO,DF#@B$0G23</8Q)0 )4*O&[58
M2[<B5$8)!8D+3:S,('62A?(DGE8Q+?WTZKJ"626?";$229_T1.H0]X<& DIM
M,)N5.5$HF#]!X@<M<YZ00( 4!3*8"M?RO+R@,K%0Q-)7-%>MLIPONO1#7IY<
MR+Z?N>Z@&\JA=,SRF)_1=KF Q6]^&WH9D4:$AQO,(2P] C"SO/)WNGT*3=(+
M2)#J:RR0]*G[7()(0)%V))KZW;H4HC\EQBR]84&B2#OG.IR&=<![R>J[WC=/
MH5#((.4KRI$6@Y6.;.H]-<'C9#(&D7Q>E*NV+/'YP.I<)0KW@SO)_TYU2;%$
M,DGPK%49K'\B6:LOSJ9MU0HRZ=K224YJ3B7;LYQ<LH?7F%%-OV=&,P3OBTFJ
M=$>3X_/@.T_LG0XJ4*-FS5.N0%G;T+8Y=5B,\Y(N6JZWM22,N)O8>\RU(DEU
MRC5!!60.*8-1Y7BVE\?1T6I>A)<%27B-19SC) 8\$WR>4X^YF\NA*I4QI/0J
M:,$BE@=HI5(DI^Y^=6$9'#,-&(),HFGN"B]_TPCFEJW+?CM<(DPO1!)&NS0N
M$Y5T= ETE-UUQ$5V3G.VM7TO=RY)I_8A2TLAYIP2IDB[TIU/^):&IBYJ9X%Y
M,ADB/PHP<F]VCO.3]<10=&)BU<B*!A*;</\<1-OL+.UV704)!9^L&!#F9Z(,
MA&?Q*CB01.6GD)J15)%',E\/TN1E1 '4G6!D1)30FBTVBA3EAABQ3>GD426!
M(RG+M2"P'';4Z!03B\ XRX^^Q*H!VY,_QY2SV'C\QN8^GH&WO72F#RF\L1DU
M59QG97Q!O6"L(;K%-,K57;IJ6$WV5Y/P>FF8@_8UHOSA@"R=QP09I#(8&12
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M_S.)Q=3("6<HBK\1&[P$CN$@!>WP&.ALL\K)P W%F!?\"BC=C1#]3I73S9*
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MOB4GR-JY<U]A;4^_3J=RZ7D*FTS</QV+6%;BV7'GS1"QQPZ_1-D1&0,('S(
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MS19O.);^:'GYRF'S3VM.C8TMZ$W'2$F\;W<"1G _N:"]*.&HU$Y[EJ!CY/Q
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MUK:7(P!1*-8(:I76C#N9NATU1W&-)H[#<#)#K'M(]93E@O]@38\2NCEM G\
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MWUXKN@))B,B! 2((   0"@X\2! AA(%!A@0Q",'APH(4"58<:)#AD(4#9?B
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M=*W]9PLFD,+M)6YO/DIX4"BNE&UZX3 9-$TRKI^I*W_YDR9*4*!MK.DXG_
M2$1I,&C]J'A@1\&BBW'(JA8XD><[$0G>X+WOF\S[!L#H4UQ3,*_+#^6>/OS;
M<R3UB,F6G,7C/G%ODO9*_QLNT5^MAB*],@E!A5@^,5V'$7D-B'Z(=QZ6EWCU
M,1.)AWA_%1V_$AI/$1+;%RQP4RP']2(ZPR).87FV8SW@UD$R0 I#, DMV"O:
MYB^@X0@ZLE#7QE W:'TN,8+0%AK8]H/6)H35AFV9$1HZXA(TB%!#>(.9X6Q!
M"(0(AA_45"$V4Q1%Q7Q9.'43\Q$- 6WM FG*XBL*)7TRH", !F"DH!G1HC,-
MA7/"HQDZXA&:$2-S6&U&:(36)CMHXX0[LH90]1'.IWIE%QB^H1D\2'/3D6VI
MXA(_LE"9 8F/Z(8)]8@YMX21>(.5B(>P!ACH518K,0EJ E/^AQWK R"'XQ2H
MPO\6M84C\)-;.302U%4C/\=6[2,WV-4GIR1;66<Q$ =U6#1_7;(4\=0R&B=4
MN'1W;B-I6 %@QY%C,U-\>B=J6DB-]F8N@,59] 1RBQ$TYO(]62$KN1<VV3@5
M5-<ND!5\&U%7[@5<N!81V2=;M>=UM>9K*K2. 7./M=985^&#[#16'M&"L79#
MQO4?S<%R#D<32V8T4V01TYA=YH(HPB5@&6(2C66*^U([,J(8PF8DD"5%#H*.
MZY%=881U\T(Y(YDO$");U\@15\-PYE2-,6EB*1(9C;6.:I)CG>A(-A%/Q>$Y
M;!&/%N$>GX4HJP5WHY&"[,>"X@)A/\DHC24#IH<_K"/_%W1W.>I1A$+'9!Y@
M>I&5CR@$>PL8(,S$1-4E,3;D)T.996<YBF8B61(#<2!"/$1"&RK28C(D?XV2
M)CXC<-UV+\G7%%1D+[0C)824)/.U(67";>O1%R\FDX]98N,"6/D30XVY8D3T
M:7U!0N0U&EB"6E"$01BQ%D32-)HV>)7'*^<'8.0!-XD08CQY/F+'(;:U;%56
M96HG6EH1&ND5%G#C+\/@AWG8A#EHA#5'9!7E3=TH-BLR0X7I%6IV3< 5FY<V
M+B[G6=K8:Y+S&@JB-XHR*E237S,Q1EWR,[Z1,&NF3!Y)&%HY**0#&'QR%"MS
M(G-AE9!IGYK3*:]",\2GC1\4_SF\5$PK)!G<II)0=5?MY!<8 IN.X S3MGW8
M5H/0!FV9X9J3\",U*"RRI))U=%741)CU62'/-P3#, D0.ET0BFVNJ2,Z FVD
MT#3'64LZM&P_)2)E\I$,8C81 3IJ$F'C QG04V!IET&0\R$]&2*:T41%!'<(
MX1"_P7OO>4<N,V.0Q1;?IXTR:CC, 5;0,ILH8FCW":8&5%3/R!@JF5$Z-1DA
MYDY'IR1C$S]78C]K=%,M=2O9YA$ )GW":5!$,5TNT8+G*(YL0W>CV*6U":)^
M]Q.NF3AB834DRIY9L7VFQA_V-V6X54&.8U<E=28H93-WZ2WEIA-*)25!-C$W
M!4CQ@?\FBR-)J'03'-$SMXB/_+0>W5%I%D$4%3B?'9>8[\D6QE=+AQJFP1HI
MX9,>6D5!8$9(@*6CSS,;; ,;B?.3N*=C<AI+';$CD8$6$]1,R^)(>J98_G=B
MR.%_A*D]?:0?CS0)1W4T( 9?] B>YKI?%1%9#;,@S$$FI5-%+\(PE+.E9A8K
MCIEV,@$YK:);(0E;$Z8=?G9D 9,_SH& #I1%>A)"9 2456E4Z9$_FL8<B JL
MPNJQD*(694@D /1\ &1=?N$KD;=X*!$:37%S7>(EOW*!F,&:FB8M4!$W&,AZ
MA[>S J0^:K8O]0IAS3&'$;*!9$4_K@&N0%-9,/5-]%9&G/'_:E4I::58L432
MJ;<YF_$!,1VK-=W6-;-Z=1_&@$R:'T@)2PH!/0>Y'3K!4?WW<F?S%T9G<%.H
M$TRJ*OXX%P[$'*1TJ.;)$(+2A<[ZL87+H><5@ZUY7K7A+YD!-Z)D<\+"+#;'
M@X[;IXP8+:,DN;L9$@*H;MK&*R H?2&H+'TZ9Y!VC>&Q*/53$@+;@K5QN3AG
M<ZIR7I-HN[<[@F3(A-;V9<NFB/Q4KV4")-U1(+/G>V^&O+;W$-AF)^ WLY)G
M>(CG?-JV$2&!AK+E@2LAAC$+6=J;)H]G'$D&+!FT4B-2K[1#,^4+N"[H>V>C
M."GQ>MX5$2$!9[^W*) 620 F-T>[_WY5!V>X5ZO8@:3@Y[^==$RPA7IK,Q\=
M:K@-+"E.HCI!N2>&@R/7:*FETR ;NR ^.SZ5$02AB#UQ9*X4P6MM\6,8<AT.
M@T)G=(XS,TN<U;KX6(^>5*S)J[R^)Q-:ITP]2C9K0T)#\*>QY*Z;5!_SQ!V/
MYX"JAYXXW( @:!Q.G,-^=9J]LI%<2#/& 1IQMIL -137Q;KUTV*6ID==)D2B
M^R9%\KB:X1%X:%V@\2L@."S!XE"ENX,QR!JA:[VI,DH,U:V)P2R)^X'#0KHB
M^(:"0E<)Z,")O#'TZAU=2' 0]DL&\Z^IB$&*28IG!*=%$CS?64Q::Q1'=3K/
M12-V<JKO8O\N5+EG;J:\7\QYK2R/JDR/_8.4J2@PFY%!,>$(_N*UA@)MMB6,
MF[-)W2M&%>&)]*1F(S8]VGI$&]FPX BDI&0]HID4]+.VYM13!'1!E0.3Y/(<
M%_0B@?M(@J@0]1G-P!,A"TF BJS._;%)S2F%T*(TR<44:NH21L%9#EL\$HEE
MP?-,R3=W=*)._YD6*<58'/'-C<80$O5;Y)JD,51(*X49FM8E'*5WS4L@KGF'
MS()MC[I$1:.="#U24]@S!]E'_H9<"GTP*@Q\'TIVHYJ0'BPU"Z+0JFBK]#)R
M/R&_W1D]).@<4D05.=0F@U$DY+AUXAJ-C_&AK5BWZ\S490%JF2+_&7GRC8[S
MEV49%:C$)@A7?06Q;>>X8W0')-*5.%ZTL4R1*?="G<AL%AT*KL47NAC$TVO$
MD[E',P6R2!O1I!CTQ! H$I([U/0+HJT(-%>-/N8"U2QGAJ+7:"+V$)!S*VD;
M<^Y(MVL:7Q(%&:NUD1%D%.E5E\[(C<D4:'VAIB*R;8P45%87+ZV*1BP4HP69
MSDUMGZ(E*C!A3=V9F5QFDT"-RP[C6F35DC'AV&#RL.D\<#I]V\HVK8'9$>DH
M&^3J&0U3N\:BN4Z,?=+6U5;D3#V9>H,B,-8G/((LL[PRNCW81ATY%HTBP,Y(
ME5>RWD\1(1RG+KZW95XRM7?A0X1#,;GG_V]_ 2?6]UANU(R!=%3BHQ]EEVJ\
MN!YZ1DULU1 <]TC?QL.&\LMHE)!?.JFPC>&75:5V&3?</4FX9EDFV3J"C2<>
M?( B[L_>$C%N>9UAXIS)/5F!TMQZ*U^0&[FC&]V4&Q*N*1/ITLTVNE++%.&2
M<VS61J$F&IPCF'B> 26H]489LCB[>BO8@<8]&7Y*J"@C6AW0XS\^61YK9]#+
M>]-/+IIC!Z0XBD7/8R]DZAQPB\0TX0Q/)Y(@RN6<K)"[G.$8KD2]A!-9Y$2+
MM*:0-79!!VL]#4,L^*]\1*W5,T%-X>%LZC:\Z9;.;18N@4&#7%;@W3 =[K07
M="E!<JN$I6GEVO]_7<6) EEP\_%3H&54@417(.CH$9&#6O5(I!#.;0YEM-WH
M5'Q7M'4:?6$]?W59"K<N]DUH=T)\/>$AVAJ*AN.9P"OA &KG]Y/GU4X6^>E(
M]+%!9EI&E!::RZW2A"03%-/LPLO;P"0>KQ*OQ^WDJXIG,[X?QG.V*&6U-Y)L
MRXA,3_Q9[L1P+CG.%T)QPWTTF 4[PTQ>ZKBI4RY$I9V-8L),/\)2;<Z)O0$]
MO2MBO9)],%<K;].%1A5)ZF(2R41_!ZY"LH$HO#?4\OKG0G9#/UDHH3TI>&[M
MB 8UXM'">F,>%G^4@;),W?$0)]Q5P&T:-5J2457!9OT8#0_RR>8:4$G_/Y1^
M[:,.Y6^<>LAW-W9V/HS\EBJ((O,T.)87>3*ZU-?"2$I++2'>)N#A)4H!NUZ"
MI(?Q*0<H.3L#MRJ.9^GCF" 6&C'BO84W>)J!&&=G'/=L/L7.8DH?1 R"48X^
ML&MKIFCI+>05*@QI5P*B0#,?K((]I8*!/3Y^MB(91Z5\.A;Y$R]!Y#IJ,#Q:
M-@08$6L7-C^>66'DJ24XJ1^-5:DY7:P>:VB.W/.;-B%W$*6M-VMQA/J;[0/"
MJ>[64X%+RT:J%OD=$J3P(Q(.C!PG,L&[U&2U;JV4>)'Z(CXHA";*+*YI-4/-
MC>SD1PK[=:322HCQ:J*";)X%QF*/.WRBEG?&_\XRC_F'QHZ1G75!!1 ^@@
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M2EH,JL\,<L2LH^B2, A2%-+**0?9@TXWJ-*[3CB(P*KJ/(DHDBE!E6+\*RW
M>FKHH9<<0HA%Z$@IK* @7:LJ(J%$+"A&[KRJ+\*_J+3R2BRSU')+Z!#[BBJH
MTD))-/2"PLD^QX+*:CN'6DL13(^"F$0_K.(::$W8F&R+.[D8VRL[&;WL"3^V
MF/.!E):B4K$H&:W:2J*K"-+I3*KD++1)+B%T*1&9/M0L-0$MG,FO-"L3"+/_
MPS!MC)2!Q%J,3115Y4BWM3XB[<G3M*,N0*T">PP]F<"3BR$Q8=*-HTGSE)*E
MHPI+2"S8,'I3UMF.="S(Y[C4=EMNN_76RML00Y9-ETI*BZN$]!371Y@H1,]-
MFNKS"((0?_Q.TB29#'3*UAJ*=%I*&W0//_V4>VJ80B'4=$#%7*J,I" <2<2G
M;%>:V,&9,L[THY@<^0P L;+"ECH<47/MHR%"0M!+<9^:4U0?P7.2*,S62[9-
M[.KK\3N%4L9IJ_^>:U%/&DTZS2 IP9KDV!SOK>[6= -4%:L __WV:JRSUII;
M <&DE*KT*HHOW?/V2C@GDG),N\U;<U89K60M A5/_P43W1774>G$+M46L?4K
M0OYV6WC1W'Z[Z#S=KM+IM,1,A*QKC;5-VRP?)C[JL;0#Y1$]DC"J_"*O8F7)
MMT32R@])G6"CKTISUTXKR>=210DKKH(H?><*A8P\(0IY Q7(/U^;:1*K6F<3
M3[-#%1=8?=W<^GGHHY?>N0<?;(_VUE$"6O41CW_)HNZH(VC>\K /+"C=U*M8
M0HI1WA5 =7TM"2W )?6/<.+458E68EO+BGY,0< L=ON62C8#D<HU)3[+,]9(
M&CBOB)5H&&L16N.(![)@I4EUBUJ2L[H2KH+$;R9 .\O3&@@A.B5&5^"SF4_2
M9\&*.+ Q,D0:K([&0*G$RO\@H)I>#WWXPVXUZ$Q?:@E6WA,36 GO0&B"5\R4
MY#6"A"1BO-%0D@9U'=FU;"-*#%8(S327C="F,0!L3D,^!KGD+!%92N&) WM"
M1OL,81(ZVQ9N$L(I[7A ++19G\-:I+*)'&5.R=-B".?HDM-!REE4(R!=4L>0
M_*!12.&1"%(F$9=!-:2+'(--8K92$_[5Z"1K4B/Q!E(SA_@1)ML3TJ4:A3I[
M70J(LZ1E+9/SHR^*\$F"<PFH7N6;F='$/$=\VI(4HK+RX>Q'.NK*343'GIYA
MJS=1RU/7V!4662('04?!(7)T.9)^.4@@<)Q=03ZTL"!RR"PA\<$D2-*4@W1S
M0PW_.=U%(. ,1RP)C(FY8$^8.1%?JC$\"WD-3^"5NY2P1S>#;.9L>-8F=!IQ
M1M9ZE.*H4QZI+ M)N)-*'\'RNHG:4J0C):FB-O@FWV1T3.TK&\;L,Y$0H@PP
M[J).G/*Y/YK&#'R_"UBB((485E;(F&#['@#(:;"&)$(O?2Q.SB3EKC.=RI5R
M<6<!H6A4/>Z$<J4#T_)XLQVO;$6/$"#%;LQV/8=<,#Z;+.C7&L>1[25$C),$
M)CHGL31C=9%,%I'1@3(I$G)=9B"Q,B5U>A.6ITS$F6?K*LY8DLV21E:RS\-E
MI4 HE!4ZAC1R1=>72N,BSF['?#"1(@#[-\(JFLFET &,_YBB-"MRG8E=QX0L
M<<*CQVX:)V ,"=NY!LO(+B'KC%RK%%<<,1**F 5T&EI/)WDT3\YLQDCAPPH#
M(:#6]V10@!1#*)HD4J<6HL],%221=O8'M)YI-XM/?0H?Y7HO%!'O06DYD'E#
M&"EJ5FF-^YQL?_V[-:2-[++_H=4JVW?%3D[I227Y:R\!8].AW$Q4-/%+1&XH
M(9$@RT\?F<M#3 83C+I%0^6<DAECZR0[BJNH+,LHXT3T&ZQ<\B,"&UV6!G)<
M.9+'1YQR4.J&0BN?R(!5-0$)@T>65A.E9BE]\FMNBW(SS#Q)RB_:'\BX S&'
MD.HC&/DM =FH&MA<C+=6CERR#O_R-X>8]B&AVE=U1/M?.,>9:P@*:J,&2CL'
MQ=5]W&O2"DUBV.[$::DK0E]+KY@N#!%PSPBYHE/T*2G&<57$C>'A=YM$'L9(
M$CCH(O13QUO(H:3,EXK&4D(^<ZR)[>0BOU/C&B%C._K\U%@O/B14';/,I(5P
M9B^EJ)^H!LR9W-162>R37.CDR%LYF'<.)-8%NX859V;PA5X,[H]=*&=L9QM<
M$M&5K@-4P;T$"4C+/! 1!;6VT8X;9&E^L1=GY#WUR!,ZD^+-]XA8$SU+&C@I
M4U*\.[F82-+X+89!ZT,,M+@=QE-\V;I3B!)<1PC03SQN.E?02&SJP:Z3*B.!
M%5ODE.3_,#V*;(M5&(GQ1NFCN?@FQPWY4Y!G1%#J*50ZBJ95_ F;"W:IVPG/
M2-GB1:W ,$[;0R>ZP6Z6*MEU$*C=>=6_(<<3H![)5NNVW1*1?:"<HCE="JZQ
MGF6H:Y9<$P#ZWI-+_'-F4JZV(#)VLJ)NLBN(M#1-3-F.:V4^8X<D LU9>C:^
MIH)@$_)9?"!3BF;FR"94"FOM,>%T07KUI,<MV,G^8ASRIG7*$/_H7X]979&7
MF9O*:]5$'AZ[+MO80/TDR"8PYE?!BOYZV%=;?B>=UO+T;)VE-&QFCPP+U+PB
MZ!'/9,WTH:^_L,74KK*REWRF,TI"O.^0@!,M!R%71AQS7-FS_VYU0IFK5(P&
M*2F*#NRF:Y^FRTCI(%V$34WWHFH=O[CI%^NIPO_1!=&[?BO^#=K!3:D G17*
MZ\B)B..NC%(3ELHTO)L5@F(+P7*-U#"E=GNB&DDL<1,__G.KV,M HL.E_IF+
M;P,W[%$D8HDK#(0TT7J4C"@MH?J+HKDUM4&Q&ONW:\J]^@ E'B([MT@9@^.\
M)0,0!WD=H<.ASQJQ*QLL5)$K+CL499J= .D)@<"?^LD][K 6X3&WF."=Q]F<
M)RF_[<"NT>$LWL(6"RPQN5H_LI 92#*K(F(FT'(/EU.?&4D:K) 6^@* I6&F
M*=F<D0LZ]= ?_=) 0(R]BK,(B:.QYO\:'=(S$6+*IZNZM-I(MA !BOW3HL5X
M#X0PD#G\+85KNPS;(H_;C@;#0=;!' <J'3GR*)$8H"X9(EW[K;[KQ+$(BLKA
ML+9I+$GY%#O[P+9+,>I KVCR(FB)"(6#)$F1#=APFKT*(1DXI$BR+GJ[#PXD
M-3J;BNE0'?+(IR09'<11I5\LDQ%Q'FB90KN()^6QG=\YG51T)$U!(R@,1'<D
M*6(A1XFB/2*:.=$RHNN0.]7JH-HP*[AA1$=[L3H,-[G@+OZ*BD9+'&_#%X[(
MN8$C"\JPLL>HOK]P0MCYP5GC)*_*'8CTBE6KB<HQ(M>+P1#ZD!.AI"8!D+HQ
MMXEJK[EY#>K_ XM76YJZ8Y<AV0V-D!/&6\>]X+39FB0ZTA@\XPY7+!!0[*:X
M^3,#DXM$RXC:T8HC>0ACG$0%HQN3$"WY^[EWW$H-;"TKDI*Z X]L J^>O!6.
M(Y:GPYM*X@JO**$789^"]![Y ,'148HM'#5\3"K\B9+_B3B0F YH*BZ(C @%
M:1!52Y7%&:PGI"LDN9S%9$4)H1W,4*X%2JG(X3I*1"^CR2NL-)-7"ZLW/,&B
M$C)%W L%&S['\SD4V;[&PK.%V)ZSD):$VI&"<B)U8\Q[BY$U>:2$0)C50Z<Z
MA)3PL@F?(C6N/,[):L.7$XZM0Q,/XY.96$RP*Z+G1 T!2JL48K$I_T20A[*G
MU1NXY7M-@0G%VO(D"FF5+#O(O^ .L="*3['-,^L^RP@=>*(:-]'!)PP-I\E%
MM/$ O>,,3HFR*V&V#\LR_8B5W1 -/P.\KXLX2.-)M#&/_4PZ^UB^,,PJ*?LN
M&&,1?W&:7D&0MYN=-7N)M3&J?W$T+Y&(WC&)G_$YY^%$Y(S1D>H\ICNLEO&L
MNJ28BC-!ZV-'S70S07O11,&WS/DSX[.L@>N9PK@3M@"\YQ.QLT3/ZLPM*S2H
MK/)/*&$TL=..(7%":.N7$D(+>C&X0U04#R">&-&.52M,!=$7-ATSS8I.Q"LH
M:H0\U"FV&5H+\N ='KHJ AT8M%0P)YDV ?^:!&GQL95LB4,[F51Z/$MK+!9I
M#2*YKJPH&!"<B,1"0"VLKJF144^=40&1,+ND-NOC.O,!KXIPD139%_S"BK=Q
M05.M%"O:+%NQS$*RQP[T%<3 J^#@. >R$][#L!I;-B[5B=/14DZ;B&TL%Y$S
MD3GZD"D:$N6Q.,> C"D)&7"Z#*:8S,59G*:HU/?AS5N3BN-#B%=#"ZTXB\G@
MUI%XC%3+I\21B.*4J##T0%[<%7 "BA?*$2_9IVE$N:H8&T0S.<=8E@(SI7R1
M&OG EKBAG1"%T4^-6.D9*)0Y'HDS3>)L30FS5L<+FA03NTA$NXS)ECT,H2YZ
MO"XK3C#I4^OXNK'_@\+T\A4F;<>AX-B-P+[HR+1#/+JJB@F]6#.TT QY+3M5
M% J;%8IPZA+E"R,=#4:#J"<535'OP(FL?+PH8KH]X2710) & :6E^Y1@P\F4
M0%+[<)%38JD#J]"G91RQD@CL6](WFQ"*43TL'-M$Q$R)S=OI41A&(DKJ^"+F
M1(Q8.9<?D19ALJ.!#(W[^5$68PWU<![5(TRO&MEEJZQK00Q1K))?L0SU-([(
MN]F3.(C/>#Z8$Q0 )5&]."Y+(0MKR0V0.=HH,JE@+2?K6!%QLPZD6:1Y22C#
M $LRK1"!T A7*;F_R#4.A;2.^!_6/4O-ZAO8.!JA&E1RE"G.^9EC(ZB&_PT"
M9SB0KX.2/O/><8U:PZ@8FM5;\^4[A.2BH3&F??DUW^',4AT<NXP+!N&<1ER)
M4:7>]%(?89V=]A&)\'E2DQ*C]4J.SQT?BFD*:^5 FXLG:*D.XEF-B>$,J3.I
MS2 *V!V3A(&*!>JJYO47ML!=BKBC]N0,L= [T$B9RFA/R!@;6=&PXXF\G,2Q
M#BFQHG&)\?*- M[1IQ4M[ZR[/(0G"K)#,Q$C87+.?N'3C-(G=#I?)]8:-#+B
M/7M4M5,A7@D*CML@Q"4).^$F%;W>"EVS!IH*&EI!2ER)&\Y+@LA<HA#C"E4.
MV>R((^J9QLE)IDC5U&BG AE3'?PUUL&@X,K@=__92)&0SI9 P?>3BK\988#B
MTDM\0A/Q2(/ JU[1I<9RHNI MXCX#!T+ET%,S?V9CU="&O.0NC^%7D;]%Y8+
M-O&J-O>5*>$]4"%]8EH.(DIL.4ICDF>Z.Q#%B2\;-B@*CYV0HM*AJ'+S0V6L
MBF>\#Z?<Q6YDR(UP2/"\F\%#CL^=.$Y-)7MA#"[E'L<H'<VHNC0!+@R[X)J5
MW0TFT:L -A8E/I%#$L?KF;U#K7>1"",!J+?43J]<CS/4T'DIQ-+8UZO\"GN5
M&M@H4KH=F-JK$]6(B*51HH/*F<]+"J#R0)*L98RV92G#5(+2Y(YC#WNBC[S
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M=BS9LF;/HDVK=BW;C1Q13LWHHR* (0,QSGR+DV[!JRZ?6IW+TN9<B N#8@0
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MCW@]4_T@XSER6M7\C6B@A..Q3*ET#R_AAV8TF%+@$ZRUA@:ZY]W89TN.9X6
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M\H;%25<:G]R2W7;=?1?>>',JU"9J0Y*L(!QC<@HU^+R;Z=%%.72)I*Q&O/'
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M:4E$!P$ O@#^AT .P<LNHW:28Z'*EJ4972A)B2'?42@HT.'/)"3BDFVU)2-
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M,0*HC@.P75:W.>U2[ WBF(3G?\K3_C9!3N5/ .H)\VDUC56*?Q\@ ,CP 0&
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M**=ST6!#E/8"LINJ<EW+ 5OT4N%HS2-E_'9B/)\DRWEM!.LOU3CGK@Y>&L?
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MZXTRT@YLK/)S2+%'[U)DFYVN!U(]CYMN_=![PI)I=W_M'?_T?O[__?W_!S#
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MWT?;W'$[D=2$()&Q#,+MQ:5BG0C!S3"6R<B&C-QV"-4RLU/ 7%=+C*IEX8.
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M_X@?J*&*.BJI*76D4TX&TE2H21"N9VF4T.79E*0%!1&>FH<*F%IU8H5E'&\
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M6MV\V,'R1B]7=$H3#AZ326+"8MMD@K:JWV\<:":/Z?@_=/NFF_\B%C1&IA)
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ML82?FUQ]NV]UZ]>Q9]>^G7O?H1Z 2[VXT+5&I0:K!J%Z&L!XE._C=H9J=:?
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M7A#K5<CMWENES^3MGY=U@M]V&+6>LJB.A ALDJRXECYDDAAE[%3'.=RUP$-
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MW()8_<1J-VM'H(YK/24JNNL_?"!Q4U=C+]5.^'0I!FE,"Z+G)$)(,J-D=+6
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M=IB%(UD9 &/8\U@F*_0)KV"FB6,G4^_C;=-C/[!-@@CJD=5L_P?I43 A-G/
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M/A:J:["7SJ:5H4T)-!A#!"IIDH@QMM62#QCS:*G34<VWXJ R0^F:5 ;1>9U
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M9,73'!3/XDY(KE[BO)<J_K?5^];O:/+$BU\$25&(3"<MAWW*71\EQKS8'Y"
MO>QJ#[O9^X>F+B+9[?JS+20W6"&NH8[-D1K96V?=S>_%"/]"VW3?^(HRM+LZ
M1]!49>Y37GPFPX*%MI,"URJC)1<6 SZG1(.4VA;"+C?Z6*?9 ^U4Y=>A1<E\
M\0KRM R4OB*5+0<QL([ZU%L(Q:OK7M2HOPM)Q';B@#]45B=>Y%4:AQ(^1HW
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MT38G+]:L1B0PRP]6NK*<CW%D& ^[#ZQ*XJ(;#4=**[(@^3SX08WASUKEJ5X
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M2SJ26JO!MZ5PA?464/809Z+7*IL^]25#F;HVA:9;[2S=ID7L^!2#T2T5=#Q
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M"NE*9XE.B7C2NQ%3%1+((AH4H\4=FKIPNT5!-<PDI)P7A*DQ4Y200>O=U5N
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MS39!WH* 4=Y4S_/@6ELM#@X]W4=U#X@LS@$>31$=6%QL5Y[1Q._]A'F(R_-
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M/VT5A+&]=V%X6"B/#54Z<\RN:YSWO')V9!C=.:S9@CN44%<Z8'S,$@O=3?7
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M6"G;^:%4Q)N"]G1QAY>"JJ6TZCN:IV)ING!'V(ODD6LB<W#2]7@*0D>IY#+
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MJ)38@OC8]6)F$CWI!FR4J1R,U(>MC96+94[Y4]LJHSVS,$TA)Z,02NX%J[I
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M%D'\5\T(%:[!B4>$B]HHGLL]A5BP!;5L%&9@UD$LC5'!4*;UF]"@W,NLQ'W
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MUN"BT8@Q)3^+=8BERGC+O&C&14:-70#1Q^)D-P2,EA@M/2S_SOSD4<5^;]0
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M;DC>PD(I%^UA7TJ6M HEY>-O!(4!@3(WA"-_;+.)@H)IXV-FZ(,'$U8O\D7
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M2_08MB7&B72EDZ\5(DB^YC<& @:%CM%WSH.4F=B-3+5P+T01+I^:: "![87
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M[4FW=S%NA#Y72S^%)IA9 .+$4GZ)]*=4;OF5Y=E4EOE6U4:D_6<9=OX)1-2
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M,KH!VUMO06-B;+'&>DJ4]W=:*U4?S).!3%@;"ABV/92VR9H@-$E.(2B(N.B
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MC(!+4T&L!%)^-2YPNY&=62BR/@!2"7H=TJ4B(RFH@"W,4/]#8#VMUM+E#>N
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MJURP5D3-BW'G2;\;N:Y_#$0FP=Q&'-[=+C_MPBZ,96O2NVQ/I\(:7:+0>Z/
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M0("+?P".,R1=L#T$H@A*JCU0DV6>0?136LR5SQA<U' A?33)A.P,Y&&9:7I
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M/,/,\*P'/(.83 +..I!\;6C+V.S.ZDZO\I;"B0_/HJ*S!BA[!>T]22U2':U
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MO-0@^:6$9<L[;WD@_5FS,_#[%.I5RRCH@^L@P9\/M0&$!P  9)":!"&(P2
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M\9X>7//67?=M/SUE(H7@QU_/":F^49JLX9I\L,J:@8?QP*<(@2([2%2'> 8
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GWN__'O #7_ 'G_ +W_ /'_$37_$7G_$;W_$?'_(C7_(G'X4" @ [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g382043lai003.jpg
<DESCRIPTION>G382043LAI003.JPG
<TEXT>
begin 644 g382043lai003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" .K M # 2(  A$! Q$!_\0
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M9CM?@-_=/O0!:HK/^T3/NA4[;B(@D'HX]C4\5T)461<X)P5/53[T 6:*04M
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %-=0X*L,@\$4ZFMGMUH SYH=FV.;/
ME@_NI!U0^]2PS,&V2#;*.O'#CU%6,B3*,.HP1ZU2FB\LK%(3Y9(\N0#E#[T
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MQC(<'N1VJ&]U#["?W:[I)20;<]2V,Y'MZU)%;/>1PRW\FYG3A8F_=@^GO^-
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M(]JTH9LX&0RMRC#N*J:A"WVBU>$+YPDQENA&T]::LB1*\B*PBS^]C Y1O44
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M:<N'&>"/2IJ@MD5%;:NTL<L/>IZ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M@N0"JY&.>&_NGUJ>FNH8889'<4 5(IGWB*1@)E''HX]JE!PI9?N\EL]JK7$2
M1JJ2[O*+?(XZQG_"DN)96MIXMG^D>6WE[3Q)QQB@"MIZ-?F34T8EY#M@!Z!
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MHP3CRE96#1-]QO3ZU6U89:QR,G[2M %^'< 0^-P[CO4M1Q((P5!)&<\]JDH
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M$;5+LJP*E(R#Z]:9Y;-K=RT3;6$2<D<'D\&H89&AU*[D6+Y-L?F(.J]>1ZT
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MQ2@\J?3-2P2L28V($Z_>']X>HHGB\C>Z+OA/WX@,_B*@QD1C?A?^64PZCV-
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M3\Z;1\P_QJ Q./+W7,A@XV2#&4/H:TU;: "<J>AJ&:$Q[I(T\Q2/FBP/F_\
MKT 58C<[FC:<B<#Y?E&'7U%3M:R3Q@-=/D'AM@R#[5",!8PSD1$_NI.Z'T/M
M5F*5VE\N3:LRC/'1QZB@"C+#=(7)N2MRJ$CY0%D456@GDDB\QIS%;A%9U&,J
MQY)%;%W&EQ9R \[5.#W!Q7*72W N[3R(M\IA6,@C*,I'I_>_PH Z3<R,JR7^
M-_*,0O(JKJ4$UG:23Q2[XAS)$RCYOI40T^T\I)'B$T<2['#CYTQUQ_.K>J,/
M[)F3@J4RI'0B@"O9E7N;H!BH,W[N4?PG X-:$3ON*MA9Q]X=G'J*J6L>V6^*
MINC,HWI_P$<BIV"XC4L2A_U,O=#Z$T 7U8.F:I:A8&YMG5,AF7:P&,.*DBF8
M2%&4+,O)&>''J*LAO,3CC/Z4 <\+B2!YX$D?R4:(?.!NC+'G\.*UHTESB2YD
M.[[K+C!%5=2TB66Z:]M9PLOR9C<?(^WUJL6U.* NK6IA+?.I!S&?\* -5[)I
M%*O/*0>W'^%5)+2X$A5[AU8?ZB7@_@U"2:IE5\ZTY&00I((]J':_\R)+LV[0
MROLP@(8#_&@!R&60%#+(LT?#I@8/N/:ITA>/:%N9?+/W>G'UXJ*6-O,CCE;Y
MT_U,V<<^C5+%,[;UD15D4_O5'<>HH 9-92+NECE=BWWUXPP_*JK0[(AF>=K8
MGL%W0G\N!6FKE,'K&P_$4V:$H3+  2P^=#T8?XT 9OVBYMM2L[>28N9689.,
M2 #/;O5J[)F:VAR4#L=V,9! [5G7H2*]TT;B83(^WCF(X_D*N-(_]H6:389P
M6VR#@.,?SH 1K:?S,27#I,/]5)\N&]CQ3(XI4<M#-(&5OW\)QQ[KQ_\ KK4*
MQW$91P<^GI59U/GQK(QCE7_5R#HX]#0!:MEPF?-,F>A.*GJ"V14WE4VDG+#W
MJ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "H+HC"AL@'J_\ =J>HIP=N<97!
MROK0!6CF(D6*5L2#E6'20?XU.Z1SHRDCW]0:H%8UB"G+6QZ$#F)O\*L13/N\
MJ; E'*MVD% %#4E/V&XWL5D2)_+D/ <8Z&J^G,RZA<R1H,"&+S8R>0,'D?YY
MK5U3;+HUWN&?W3$^W%9=G&SZE+\^R801%'[-P>#ZT ;D$@:-6#!D8?*0*CN(
MF1O,C 9#_K$/<>H]ZJHWER,\*D8;]_$>H/J/\\U=BF5@N#N1ONG% %3:NQ1N
M/DY!1^Z'WJ:&5S)MDP)@.O9QZBG30E&:1%RK??3U'TJL0GE*&.83S$_>,T :
M*D."?S%0SP98RP@"8#'(X8>AJ.%Y 2DV!,HSQT<>M6D=77(_*@"A&_D@M$I\
MLD^;'W0^H%5LAM/NR&W SD@_B*T9[=B_FPX$H&/]X>AK%WF.POF"_N3<,77N
MAR.: .@EC65&1NAZBJ$L8RL4K,I7_53YYSZ'_/-75DP^&Y!/RMZT^1!(I! (
M/!!H K6\ID!64;9@,.HZ'W%4KZ'[/-;:A;IN,&4D_P"N9^]^(Z_G4\D;?*DS
M%64_N)<\Y]#3X;AF9DD4"X5?G3LP]1[4 .*B4"YM2'+#GGY7%0I*MNF06:V)
MY&/FC/O[4Q;2337WV)W6[L2T!/ )[J>WTI3>0R3,T1\JX'$D4HQD4 7 68#+
M+OZAQT(I9$2YC:-UX/53P1[U1BFA1=J.# Q)V[N4-7#N+!=P$N,JW9A0!#(K
M"18V8I(O,4O9O8U)!*2QWC:X'SI_4>U3;4G0QL.1U![54>-U<)(^)%),4H[^
MQH LRHLZ!D?:XZ,.U88E?3+Z1"%6"9MS*3C:YZ_@>Q]:)M7GM=1G63Y8XPFZ
M,+D@G'/TYK9DBBO8OE96)'!&#P1W]J *T<J1*/GWVS'ALY,;>A]JOQNW1^/?
MUK&MH+FS?$*^8B@+)#(>=OJI[CV-)_:UM:1CS%E%KGY6*DE#G&#^- &W/"D\
M3(^<'N#@CZ5099$F7D"X4'8QZ2+Z'WJ6QU*"^W;),NI*E2,'CV-6)HX[A"C\
MC/8\B@"*.8,API!'WU/!'X5(LFS <Y4_=;_&J;[C, 647 &(V[.OH:FBGCE#
M;0>#B1#U4T %Q$(W+JF^-O\ 6)CMZBJQ(1 C.QCZPSCJA]#6@CE2 2"I'RM_
M2JLL#1B1T4-&V?-C Z^X]Z &-(Q@D1\)/L;*Y^5^.HK$99VN+$PI*P1$W>7V
MX_0_TK7F&+7:[EHB/W$HZH<' -5--A$UVDS;OM$,"8 .%<$<T 7V\SS03A+I
M1\O/RRBJ.I$)I=SY/^H(/FH<YC/M[5LN(KF(#D'L>A4UE:KN^Q3[_DN$3J#A
M9%S_ )^E $^F2+Y]T-Q(:4;2/]T58GC\ABZKNB?)D3'Z@5G:=-Y,U[*J_N!-
M^]7JR' Y'M6M'+T!(*-RC"@"JVW8B%S@8,,P_A]C4L,KM( _R3@?.O9QZBDF
MA:%G95#0OS*F?U'^%0NNY(@7[_Z/,!G:?0T ::.KC(.14%Q"V_S8?]8.H[./
M2H8IY"Y5DVW" ;QV8>HJXL@=-PZ=\]J ,Y9%B#%0?L_)=>\1^GI40D6]U>)%
M?>EJ"[L/[S#"C\N:=?W+FY\K3@6NROS''R >K>_M3+&&*PM2%9FA8DREOO*Y
MZDT :\L:RQE&&0:HS(1(L<C%77F&7U]C5F*8!PC'.1E7_O5+)&)4*L.#UH I
MQ7#-A'4+*O$B'O[CUJPC%< '<IZ'TJH\;+(L;\,AS!+U_ U)#)O9U*D2+_K$
M/0^XH JZE$%U6P>)02S/N7LW'\ZAN/+66T#%OLY=L'O&<?RJQ=MC5--R<J7?
M:1V^7O1J$02_MI43<S,VY?[PQ0!8BF.[;*1O&=C]I!_C5CY)XSN7Z@]JSB8Q
M;X9&-F?NG'S1-G] /TJU#,P98ICME_A.,"04 68=XSYA!/8CO4M,0@DG^+O3
MZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *0TM13N8T+ ;@.2!U_"@"": JQD
MB Y^^F.''^-5B%1!NRUN2-A_BB/^%7([@,JN.4;H33)X"K-)"JG=_K$QPX_Q
MH J7TC?V?<Q3$>;Y+%6'208_G46GHD]].K#I#$#[<'I3=0*QZ1.%#&$QMM/>
M(XINENYU.=)& ?R8BO/##!H OF-S+M8[9E_U<@Z./0TQ7:/<Z*/E/[^+T]P*
MO/&DT95P,]\'D&J<JDSJN_9.HS&W02#T- %B*8-&C;MR./E;%-E@,99XQN!^
M^GK]/>JJ/Y9>0*1SB:+.=N/XEJ]'(H1<,&5ONF@"GA-J_,?*)_=/W0^A]JFM
MI6#&.7:)T&3M'#CU%/FB*;I$ 92/G3'!'M[U58+Y:#>3'G,4O=#[T :*OY@!
M (S6+<1,+"\D VR>>>O1AD5H0RLTI60 3!>?[K#U%5/D-A=[G8K]H/)'(.10
M!*KB'+Q@^1D[XR.8SZU<CE/ R"#]UAT--N(,R&6+'F8P0>C#T-5%E\M"Z!C"
MQ.^/^*,_X4 :$L*S1E7&0>H-4I49&2*5R#G]U-Z'T-6HI,A0S J?NMG[U/EC
MCF0JXRK<4 5(IRQ9& %PN-Z=B/44ZX4"UF( *^6VW(SM.*CDCVNJ2M@@_NYA
MU!]#39)%:"Y5OEE6)@ZYX(QU% %.XT:WCT[[3!&%F6/>V"1N.W^=68F$$*N"
M6M2!E?XHV_PI\ASI#?Q)]G_+Y:F-N<+-$H\PH 0>C#_&@"1"< 9!<_=;LPJ1
ME2="DBY]15%)?(3<H;[,3RN/FC/^%6_=, C[I'1J .:U-2-3E#;\J4=)@.F%
MQCWZU:\.3N1(K\$*N4[CMGZ5)>Z?<WE]/Y9 0[<AC[<D5:%J()(T4!)D7$<N
MW[P_NMZT 7)(EE421MAQ]UA_*LKR_,UIC) "PM\/&1P>3R/>M&WN-RO^[*NI
M^>/^H]JJNOFZ[E&PPMLJV/\ :/6@"O/%"GV8#;]E:4!6Z,IP>">N.*T([6!2
M(W7]YCKN//O52Y %S Y0^8)/WD74,-K<CWJ572-5+.6MV^ZQZQGT/M0 ZWTZ
MVEMOG#,<GDL<BJ;V[6VJVJQ82=U<!]Q(D ' (K5LW'D@,0&+-WZ\U5OT634[
M%?7?@CKT% #TN8G5CD80[98\_=-3B4(0CR*0WW3NK,M[=7@MR8XQ.$RC$9$@
M[@^]3Q6UM<2[O(1=G#QL.0?:@"2[C6."9H]AB93YD9(P>.U8T:>=''%L7_4Q
M[)BY&T]0#CM6Y/;0K;2HT2E2A(./:L^R78C,(R\9@BWQ^V.H]Z $CBN#*8VM
MX%E R?WC8D'J*+RW+6;2O!"43!(W-D?G5LJ%2-6;=%D&*7NA]ZBU"8G3;J.4
M+',$SUX8>HH CM4;[7>;&"W EX!^[(N!UJRL@57>-<Q#/G1'JA]13;&-;EKT
M'@>:,,O4':.:E=7\\ D)<*/E8?=E'O0!:BD!"@MN!Y5J@N(1"K-M+PGF5!_,
M5!'((P\D:GR@3YD9ZH?:KT4H91SE#RK#TH P;JYN/[2$<4H\E#&(I/XANSD$
MUH1Q/,S+/)+YJXW1[L*P]L52O$6/4+S:N4W0EE';KR*T),C:'.5)_<S 9*GT
M:@"[##%&FV)0H[@5'-;X8R0@;^X[./0U'#(WG,'^6=!\R]F'J*MI('3(!ZXQ
MW% &>CK$N]03!GYD/6(^P]*NI)T&[.1P>S5'<6Y+B6' <#!!Z/[&JPE$09MC
M>26^9.\1]?I0!?EB2:(HZY!_.J4BE'"2/M?_ )8R^OL:MQOEADY!&0PZ$4^6
M-9D*, 10!C32A]3L1MVN'?S4_P" ]15FX=1>V..4W-@^G%5+^*1-5TU68!U=
M_*D'?Y>AJ:2427EJKIB5&;S(Q].OTH NW$)#>;" 2?OJ>C#_ !JLNQ5&07MB
M>#WC/^%7(B$  .8^WJ*8]NR2-+".6^^C=&% $\&_#;\9SP0>H]:EJ"UC2,,$
M8D$]#_#[5/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-JWWD(^:(_X4 -U>*1I+>:-!(8RQ*$X)&.WO699WLVJR6T\<:Q1HS"*9SRY
MQ@CTK;G?YHU9N"&VGKNXK*\,1K+H%M&^2IDD!_,T :D4KMD[0LO_ "UBS^HJ
MPC"-0"2T9Z'T]JJ2QLCHLC[9$_U$OK[&I89S*Y"\.AQ+&?YB@"XB@9; !;KB
MGTQ.I.>#TI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD.)UZ-VD'M[U=1PR\ CV/:@!ELBH&VH4!.2.V:GI!2T %%%% !1110 4444
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M;64C(S^8QAFSU[E6_,T ;T,PP#D-'_"WI]:&@*2EX3][[Z]FJJ"5=VC3_KO
M3S]15J*9=B'):-ONMZ>QH DM@H3Y"Q7L#V]JGIB  G"X_K3Z "BBB@ HHHH
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M54:(^:JRL5E7_5RC^(>AH NV[!DRKAD[>HJ6J]MLR^U"AS\PQCFK% !1110
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MH WGA$D91ONFJ,L1255>7#K_ *J7^AJW'*-JAFR#C:V>&]*?+$DJ%&&0>HH
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M?EE'?L1Z&JH;R@[QKB,_ZZ+N#ZBK?F%&+@YCS@C^[3;B(NHEB;;(#\I]?8T
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M/.NBH>U+;P5#0Y<<C//]:D\4#/A^Y'LO_H0JG*(UO7$P0SO,OES%R-HXPO\
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MP -QKF-<B>;52D894&P$JH.6(/7)[=:Z"WG$F67AAPZ'M5"_L;F?4X[BSD$
M\LH\A?AO3Y>^* )H;@P6T1=S+$R@++Q\IQWK11\D@\'^=49+=H+;>P$F$_?*
M%P']\>M-CD$ 52Y>!_N2'K%[&@#3!R*R]8T8ZD]O*DGERP%B#C[V1CK6C&^0
M%;J._K4E &5"@LXB8E+1K_K8^X/]X"K:NL@#!E.1F-NU.GM]SB6/Y9!W]1Z&
MJBN8MTL:X3/[V'N#ZB@"E<G-_=))R=\&[\S5V>,J?+<]"3%*.J'WJE,0][.R
MD,K/!M;UY-;959%*LHYZ@]Z *T,C,VR3 F4?.O:0>HJPIVGKE/3TJE+'Y3K'
M)D)_RRE'_+,^A-2PSDLT<@/FH.>,"0>HH DG@PWG08$G?T<>AJJ'2'YEC/D,
M<.G>)O7Z5=5PF6!^3O[5'/ 699H6^<#D=G'H: '=0I##=_ WM3R%G1HW&0>&
M%4 _E;Y%Y@/$D0ZQGUJV2A\L;\-U1@>OUH RM1C>/4]-C+8D#OY,O;IT:K#7
M&_4+177;,C,'4=/N]1[4:FCS/ Z(IDB+,48D9X]16;IU[)J\=I<[?(4.ZPNV
M=V1Q@^U '0S0K<("&VLO*-Z&JJJQG.S:DP/[U2.)!ZBI;>;>S%ALF089/7W'
MM4KQ)<(IQ\R\A@<8- $D!4@[#\HXQZ5+4<>>=R@-W([U)0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !5#50^Q"L;.@)W;7VX]#5^FL/QH P&6Z+H6WB3'[N7S
MN&'H:FC:X<.#&ZLGWD\[GZ].E6YHC""&7=;-U4=4/K]*C<DNF7"S8_=29X?V
M- "+'<N RQL0?^FU02V=VFYXXFP<F1#+]_\ ^O6C;W&XLK*5=?OKUQ^/>K*L
M&&1R* .<^:$*9H)7L]Z[6\[_ %9]QZ5JVBDM-\V'$[_CTJ+58!';22(O#,N]
M1_%R.:2VF$+3Y#-$;A_G_N'CK[4 7I(TG4AA\PYSW!JFR/YJ\^7<*/EDQ@2#
MT(JWDL0P(!'0]FITT*W$>QP,YR,]5]_K0!1C< NZ1,H)_?0]U/\ >%789D90
M4;>AZ,*J,LBR('D"W X5^@E'H:(7*2LT8*J3^]A/5#ZB@#14 #@ #VIU1Q2+
M(@*$,IZ$=ZDH **** "BBB@ HHHH CDS_>QQ2Y&T^PI)=I!# D$<_2C&,XZ8
MH P/+=M+/()$Q<[3M!'4?A5UY-\MPBSYQ$,Q#^=5K]XX[!FCC\U$FVR*/F+?
ME]:7<EOJ=P00)$B!X'*@_P"- %_1XQ%81@ CDG!'3/:FZV$-@PD7<IXV^M2Z
M;.\]HCR*58YX)R:CUB<V]H'"Y^<#/<>] $5Y@+;;G)?@ #//'M5UU'G+\Q!Q
MSGN*?%AHD;(((!XJ&Y#R.BQDHP^8L!GB@"26ZC@9%D)!<X&!4 U>T:18TD+.
MP)"@<X'4_2GM:F1XY#+EDZ$J._6H!I\,<PD#JLH!4$*,A?2@"_'*DJ!HV#*>
M01TH)X)S@>M4C+%IULJ^;\H(555>>>U0+KMO+>O9[)#, ?D*8SCK0!I'8QVM
M@Y'?N*IS0^2I1E+6I/<\QGL1[5574XQN+"5K?L0F#&PZ@U;%^K+L>*5G(Z;.
MM #"I\Y,L// _=R <./0UCZI=*;AO-MFD<)B.(2[663MQZ'L:TIIXH5:.2&7
M[.3G 4YC/M6;JFHHKPK):S37&<PE ,RCT_6@#=7S!I"+.P:7RAN8="<420&-
M#)$@8,/GBQ]__P"O69+K%K9V1#1S0QJ%C977[IQQSG]:T+?5(IK:.79(L3[=
MKE< YZ4 -CE\D*#S;Y^5S_RS/H:O1R9.&Z^H[U6N(2FZ2,;E;/FQX^]]/>H(
MI4A5<L7MR?D;O$?0^U &ID'I5>>!BWFQ'$H_7V-*EPN,,PW=CZU()5<<&@#F
MI6\N^N62,J#)!YB9SM.3R*W]ZL4.X$'[K#O[5D7PSJ=PR_?#P#'KR>M6Q,(6
M=D4&$,?,C_B0^HH OY$T;QR* >A4U5G@*[$+E1G,4F/N'T-/6:*3:WF @?<?
MUJ1I8IE,<N,8Y4CK0!##.S%HW0)*OWE/1QZBIU81IN.0I[?W:IRQK&$69R.?
MW$H!RA]#4L<[;R)2%F7[R]G'J* )983O\Z(#>1SGHX]#516$"Y52]N#\T?>$
M^OTJXDBQY.X>6>QSP>]1RJJN98"!)QO&.''H: ([AP9H=S#D-M(_B^6LOPU&
MLOA^VC8#!EDR/3YC5II$@=#'EH,L"G>$X_E5/PK(C:%9NKY)EDVOG.>30!J2
M1LLB)-)M93^YFSU]C_GFIX)V=F7&V5?OH>_N/:GNT<Z&.4<=UJFY5759G*N/
M]3-G]#0!J*02<'-.JO:2M(C>8@213A@.A^E6* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *AGE\K:2#L/WF_NU-4%R&P&4D[0<QC^.@ #;B%;'J">XJK/$(,J
M06MR>G>,^H]J9'((<,,O;L>1WA/^%7D;<OS8(]?6@"D5.\?./-4?NI">'!['
MUJ>WG:3<67;(O#QYZ?3VJ*:'[/D;=UNQY _Y9GU'M4;ACM0R[9.L4X/#^QH
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M%% !1110 4444 %%%% !1110 4444 %5;RX6 )DX=L[>"15JJUW:_:E5?,=
M/[IQ0!7CU"%P,[E/\:;&)!_*I%OH@<'?M['8W^%4#9R+,,W$J3@820L,2CT-
M2PQ!U=?-G#+_ *R/=RIH I362JTTL-S<%99"[Q%#W/:HA L1"_;;HV_.) IR
MA]#6TMHZRG?<3E6^Z=PXJ*?3_+5BDDSJ^=\>_K]/>@#.E@G$2_9[NZ,V\84J
M<$9YS^%:=J);JT=;HCS4E90ZC&,'@BJ4JRVL8<3R/"778V<[1G[K?XUH6FX>
M?AAGSWX]1Q0!&Z2B8' %PO1B,+*/>DC<1@LB$H3^]C'6,^M7)46YC(R58=".
MJGUJH8Y/,ZJEPO4@<2@=O\]* +<,@<<$,A'RL#G(J&>#R2SJI:)N'C[#W%0Q
MR^1EXD(3/[R+O$?6KB3[\<C:W*L.AH I@#Y%9\I_RRFSR/8UF*^_3I0<"477
M*]B/,ZBMJ2#R22B[X6^_'Z>XK".&TIB3G_3&\N4?]=.AH Z":-;B+AN0<JPZ
M@BLB\U&2UO1'Y&;@Q[FPV%=<XR:U(9@9&1E*2@9*>H]161JUM<7.J12VRR86
M(*'4[<'=T_\ K4 .TS58;F-]@!@(R4W9:(GV]*L66DK:QB$7<YB)++\V 0>:
MI:-8S6K*WE>7.8SYJ-P)!G@_6M.)_*5BA)MR>01\T1_PH NBTB"LNP8;J,=:
MJNC(RI(VUU_U<OK[&K,,I*A6(/HPZ-3Y84DC*.,J?TH Y^ZFW:A*'C\IULWW
M+_P+J/:N@C(,8P<\5SFI+(FJ,CM\_P!C?9(>_/ -;4,P.5VX=!\T?MZT 8=]
MNCU7475@ RHA4_Q?*?UI^CR"&-Q(S?9B%VMG)0_X4RZF5=4U&0[2I55&\XYV
MGH/6K>FP2;&GARZ,JJT;=" .?QH U<MD#(#]F[,*<R+<(0RY]0>U4XY4@C!)
MW6F[AN\9]#[5<!!E!Z,1Q_M"@"G)&ZR*K2!9U&8Y2.''H:S;Z??=73;"CBV3
M=&1T_>5O,$N8V# Y!Z'JIKGM4207EPLC?OEMDVN!U_>=* .A63RB-V"C=&'\
MJKWD#1*\L*A@RD21]F]_K3H9PR<(05^_$W4>].=V$,@8Y5E)##MQTH PM,N3
M,H2>8M"B*%DW9*-[^G-;4$[&<Q3*JSXX/:0#N*RM/M4B\I[==RM IFAP,.3C
MGZU<)18QOD+09S'-GYHCTP: +Y"74;J&(8'\4-8D<#V&L21 %9+C]]$W\+L!
MAE/U !K4CDD$VR0*L^.".DH]:DN8$O8&3<4D'W6'6-O6@!L,RR*Q1?N\/&1]
MTU8$@7 )^]]TGH:RVF>!XQ<D1W0X$O.R4>_I5N&=)HB^-RY^=.I4T ,OH/*A
MF>-=T;+^\C Z^X]ZB(&Q$9R8F_U4XQE#V!J\')4[\%3T;L1Z5#-;A S1QAXV
M_P!9$!U]Q0 0/F4I(=LP'W>SCUJ>:%+F'!/T8=5/J*H'8%7+GR_^6<XZH?0U
M8AF96V2_+*/7HX]10!&XD\Y<L%NE''991[TV-S$&DC7]T6_?1]3$?45<>..Y
M7K@@\-W4U4;=YORX%R!TSA9@/6@"A.P>]N&1E8$P%6'IFM6:#RR[(H:)_P#6
M1G^8K%E94O+@HA6,-#OCS]PY["M]9@/O$$-RK]J *95=J+O.SK#,/X?8U/%.
M^65DQ.G50.''J*2> Q%F5=\+C]Y'_45">8UQ+\I/[F8?PGT- &BK!UR.E07$
M#!_-A/S8^9.SC_&FP3MDJZ[9@,LI[CU%6E8,* ,V,I&C%23"3\Z=XC]*NPR'
M #$8_@;/WA3)X"'\Z!07_B7^^*J1N8E)Y>V+<KW@/^% %NZ.)H1Z[@?RK"\-
MQ"31+9E;:ZS2[6_$]:OZE=R0O;+'&\TC,P54Q\_R^IZ54T".XL(+:QO+=D<2
M.0PY5L\T :"L4D:2(#S?^6T/K[CWJPDB.B'=O1C\K>E/N8-X#1_+(.C#^M54
MW+(S11[6ZRQ9Z^XH T5IU1PL&!*L&'ZBI* "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *0TM132"/!;A>['H* $F@2:,H1CT('*GU%4G1A(BLX2X7A&[2CT-7D
M?HK'+8SD=Z)H$G0JX^A[CZ4 5H)0R,6W*V</&3RAJ:-]IP?F3^%LU5,;^:%+
M8G3[CGI*/0TZ*;<&PF"/]9$.JT 1:K%Y=LSQCY690R?WN>U-MI5B>16R8VF?
M;+_</'!J6_8_9 #T\Q,'\138T91<,%#H9WWQXZ]* +@.'(_Y:#J/4421I<P_
M,"",X/=3[55C80A1NW0,3Y;]T/H?:K99RHVXWCG'8T 4F202CH+A.^.)121/
ML/F)N$+<21$<Q'UJ[(J7*$'@@]>ZFJ;*ZS%AC[0H].)5H NQR9;L5(&UQWKG
M9D9-,D/)A:].Y!QC][U%:<3^0#)&K&)F^>+O$>_X>U4'F"Z+*V"RK=E@?7]Y
M0!HC)V([-GK#<'J?8U+#-N9E90MPO+Q^ON*I>9<;'=+)C;2C=M\P<>X]*@-W
M<OLA>W;(YBN/,'([9/O0!M2PBX7@E6 ^5AU%9LMTRW+*(7>X0#S$CY5P>G\J
M<FI3H)3-:;)(E+2 /U'J/K0H\[4KLHI'R1E&SC!YH A_M+[-&7%I<-:9P?EY
MC/\ A5U-1=@ ;2?D9'3FJUP\PWGR MP%^9-V%D%/CD:%<K'FT)(QWB/^'\J
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD$%9%'SQGK]15M6#J#V-9TD;JZQL^V5?]7-ZCT-30SEF;*[73[\?]1[4 +-
M4)>&,,&^^G3=_P#7KG[YUCGNAO9X6@0!CG,?S]#[5U"L'3*L#[BL6_A0:G(7
M5C%) %8 '#<^U &FN25.,2 ?@PI\D:7*889VD'W!]:QEFAA8'[5<M;'H<G*'
MWXZ4YIT4G][>%\\%0<,* +CK)YBJS!;D?ZN0#AQZ&GP39+C!!'WX6ZJ?6JAE
MMYGCB+WGS' )R,-]:RFO98]5D@ECNHGC'RSLQPX'3/'.<\8H Z=&9!B1@P/*
MM44\!0L\2[D(_>1XX;_Z]9L5U'<$@RW<>!^\C(.5/H.*F2:(,5>>Z93RKC-
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M)_#(/0U+'*)(W.W '$D?=34\D:746ULC!XP<$'UJHRN)P-VVY4?*Q^[(/0T
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MCD!^0GYP.>,9JM<Q>46D1=\;#]Y'_>]Q[U"DGD;%+Y@<_NV[I['VH O3PK.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_*7?>'YXQVXJA=;9-#?RU2.97P53[LN&YQ^-:%U(_P#;VGH_WL'(%5S&IT1
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MY\L]5QRAJ>-]NU';)/W6]15(>8+AB JW"CYQCY95]JE@E22/*!A&3RI'S(:
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M&ZX.<]<>GO5B>U2*)EV!H&.67J5/J*CD#,\>9%$@YAF'0^QH N31+.%>,A9
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M#^1JDX8,Q2,8Z3PGN/5: +V5D)CD&3CIV(JI+&L(5'#>03\A YC/^%-B<1A
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MOJ*6.18X@R'-F>GK&WH?;^57)84N$5D.TC[K <@U2(=)6,2@7 _UL1/RR#U
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M>WK566(0 1.3Y.1L8=8S[^U,AG6%4^?= _\ JI#S@^A-701('CE3DC!!Z$4
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M/0U8MY=X)^Z?XT/5#_A0!6.[YV6+@?Z^'/ZBE@G$:*=P:W?B*3N#Z&K<T0E
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M^ZCED.,CR9P>3['_ #S0!IHP;.#G%/J&!V;<'CVL#R1T/TJ:@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "FM3JK7HE"AX6'RYW*5SD4 -EA*L98ERV/F7LX_Q
MJLZQM%MY:!CC(ZQ&J]UJDEDEO,THDMI#M9@@RGO4$GB'3>98KZ,G[K*4^_\
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M$X^8=JI/$8 L4F[RO^6<F>4/8'VI(9S"B(S@PM@0S9SGV-7@1*&C=?F[@^E
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M)!_>(4&8S4\EBD\6W>I##!.P<TTV\Y/F#Y9H^,CI*/0BK$6X!7$97>>4_NT
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MND:M*%8@21VX*M[@YY% &U16%_PE!_Z >M?^ H_^*H_X2@_] /6O_ 4?_%4
M;M%87_"4'_H!ZU_X"C_XJC_A*#_T ]:_\!1_\50!NT5A?\)0?^@'K7_@*/\
MXJC_ (2@_P#0#UK_ ,!1_P#%4 ;M%87_  E!_P"@'K7_ ("C_P"*H_X2@_\
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M[16%_P )0?\ H!ZU_P" H_\ BJ/^$H/_ $ ]:_\  4?_ !5 &[16%_PE!_Z
M>M?^ H_^*H_X2@_] /6O_ 4?_%4 ;M%0V]RMQ!'+M>,NH;RY!AESV([&H;[5
M+;3MGGL<OG"J,G@9/'TH N457BOK>:))$F3:X# EATJ431L,JZD>H- #Z*9Y
ML?\ ?7\Z/.C_ .>B?G0 ^BH_.B_YZ)_WT*7S8_[Z_G0 ^BF^8G]Y?SH\Q/[R
M_G0 ZBFB13T8'Z&J-UK5I9SB&0NTFW<0BYVC.,GTH T**A^UP8_UT?\ WV*<
M)HV&1(A![AA0!)13/-3^^OYT>:G]]?SH ?13/-C_ +Z_G1YT?_/1/^^A0 ^B
MF>='_P ]$_[Z%'FI_?7\Z 'T4SS$_OK^='FI_?7\Z 'T4SS$_OK^='F)_?7\
MZ 'T4WS$_O+^='F)_>7\Z '451O]4CL)+-2AD^U7"VXVD?*2K')_[YJ]0!F:
MK"OVFSN#DNDJH >1\Q'/UXJCI^E17]J+B0E79GR$  ^\:O:]<PV5E%<W#A(8
MIXV=CV&ZET%UDTB!T.5?<ZGU4L2#^1H J2>%K.60/)+<Y P DI0?D*;_ ,(?
MIW7SKW/_ %\M6]10!A#PC8+TGOO_  ):D/A*PSGS[[_P):MZL_4DW7%N"6"L
M=K;?3UH R#I$&E:SICVT]R?-D='628L"-N>AJSJ%NMKJ\5S&Q9I]X99!D#"<
M8]*DU88UG11V$SC_ ,<J'Q/>0:<UE=7<@C@5W4N?4H0!0 FFZ-%<Z7;3N[;Y
M8E9@% &2/2GOX4LY)&=YKO+?W)BH'X"M+25,>DV2."&$* CT.T5=H Y\>$K
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M9&PCG=V.: *0T"$=+S4/_ @TA\/P]?MFH?3[0:?#:ZDJH)+I6VH,Y'5N_/\
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M?^?D_P JY?2B?^%M:N,\?91Q_P!\UT^F?Z[4/^OEOY5S&F?\E?U?_KS7^2T
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MU6/)B7&W,<G7@9_*NWKAE\,)X;FTL)<O/Y^IQ$[E P1')7<T <Q\1>/!-_\
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M'I5.TDC^T.%B9&D&\DMD''%7#5&R4I<S@G)8[ON8XSZ]Z (=*YEO_P#KZ?\
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MI*A^V6__ #WB_P"^Q1]K@[3Q?]]B@":EJO\ :X?^>\/_ 'V*7[7#_P ]XO\
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MO&@?]]2?XT :9O-BL# 2%8*,=#G'^--_M QJ&\AOF/.T'@8XS^=9WVKQ&/\
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M;PSJ!-$D@!R R@X-"6\,;!DB12.X6I:* "BBB@ HHHH **** "BBB@ HHHH
M8T,;G+1H3ZE:3R(O^>2?]\BI** (_(B_YY)_WR*/(B_YY)_WR*DHH :J*@PJ
MA1[#%(88V;<T:%O4J,T^B@"/R8O^>:?]\B@P1'_EFG_?(J2B@"+[-#_SR3_O
MD4?9X?\ GDG_ 'R*EHH B^SP_P#/*/\ [Y%'V>'_ )Y)_P!\BI:* $"A0
M!V%,:")FRT:$^I45)10!%]GA_P">4?\ WR*/L\/_ #RC_P"^14M% $7V:'_G
MC'_WR*3[+!_SQC_[Y%344 1?98/^>,?_ 'R*/LT'_/&/_OD5+10!%]FA_P">
M4?\ WR*7[/#_ ,\H_P#OD5)10!%]FA_YXQ_]\BC[/#_SRC_[Y%2T4 1_9X?^
M>4?_ 'R*/(B_YY)_WR*DHH :JJ@PJ@#T IU%% !1110 4444 %%%% !1110
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4_N+^0I]% #515^Z /H*=110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g382043lai004.jpg
<DESCRIPTION>G382043LAI004.JPG
<TEXT>
begin 644 g382043lai004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" /  M # 2(  A$! Q$!_\0
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M ;E-WKMW;ACUS6?Y.HMAEOH@O_7'K^M4KY;W3[>2X,T<L>5WQ&/ (R <<\4
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MAW#*1^ZF]?\ 9/O5BYA8E9;9@LHQG/1E]#5,J@B;Y"T!.)(<<QMGJ* -)'Z
M@!NXJ:L^WEVR*DK>8#_JY1T(]#[UH4 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %(P!'-+2&@#.FC;?ME;YADQ3
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MP&".<?I3SJ=XV0;;@C!'EOS^E2JX4O)$K*2?W\'?_>%78I1C(?,79L]/:@#
MNM3FL[4>=%Y<*Y(D9''EGMSBK]I>-=V4<DF$G:,G(/#\&JUT7U**YNF;_1H8
MV^SC'WF'!?Z=A2Z:F-!@63)A,9*L.J'F@"YH^8])MSC(V\KZ5:G@\QDEA<+(
MHPK=L>A]JS]'D(L+1'.V4)\OHPS6H#@Y49!ZCTH H8(\YDC##_EM!Z^XIT<A
MB6-6<2V[?ZN7NA]#5J6#>PEC;$JCY3VQZ'VJDT:8<HA,;']_ 1U]Q0!HJWF
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M>Z'F'*;&[H=PIEQN&HZ:OF!HB\ACD]!MZ&K.L,7TB1& W97(]1N% #LR&<8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0!9C<[</U'?UK)C02^)+U6Z-;QX]NM3Q2+"JKDM;-@1-W0^AJ*#CQ/> G/\
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MK/TL_P"@69 "W"0K\O9UJU)*S13(R;)E0AU)X88ZBC3H4N-$M 21B)<,."*
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M7YAG)JYY!MXXX;B1G*\1W!'S9]ZQ]&+*MEL0&<02[@> XW#I0!LR/<L5GAM
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M!K-<MW\X<U7G:ZA63-BKVS#<Z"0''N*O1RI-&2"3&#@H>J$5.K;?E?G/0^M
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MYL8%".5.* *CQ>5HA8?-"UL"Z$9V_+U%36C%+>V65N&1?)D_X#T-/''A\?\
M7L/_ $&FQP"&RC8)N@:-=Z?W>.HH M!B6+)PX^\I[CU%.DC6XB!&58<JRCD5
M4C=HV1)'W(?]3+Z^QJWO*G*\-W3U]Z *8#^>&50MTH^=>@D7UJQ#-'(C,"2N
M<,#U0^E27$"7*!MQ5ARK+P15-O,$YV;%N@H+*>%D7UH O?,47+X).01W%354
MMV1U7R\E">0>JFKE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV_SQ4L,K)(D4K?-_RS<?\M![^]2W%NR9EMU!?NAZ/55U3RNYMFY./O1'V]J
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M'3,$F&[D;AS0!?U.VGN6MWMR04!8_.5ST_7WK12UA$@G,4?G8P9-HW?G4JJ
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M+;A-^W8]Q@J?RJ2;3K=56&9%$9.8YL#<I[ TW[*!,?W,*W2+]W;\LJ_Y_*@
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M-%Q Y<2P "0?DX]#4$<DI9@P1;@??0<AQV(J:-VC3*G<G0\<K0!4W(JN50O
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MR'M\O45?TE?^))IH9B/W*^5+Z''0U6U9Q)<V;J5=/(N<2#OE!BK>D0E-#LW
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ML2Y4GAQ@<BLO^V6V?V,;*4W8@"LF1TQC=]*OI"\,$,,S%0$&R7/,;8'!H T
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M^H]JF63!4#[A^Z1_*JDB2*0&;9,O^KE[-[&IH9@X;Y=K]9$/;W% !- 4+/&
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M)]JVZ "H;E&=!L8JP/!QFIJ:W2@#.'60K'A_^6D9Z/[BB.3[.J_,7ML_*_\
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M+O W[;A!PV.)1Z&H]+SYU_A@&^U,<?@*T)(DN$PW4=.>5- %*8FZL)HX\J[
MJ48\H:S=#NH[F^"I=3[DWDPR\Y'0#/3@@U>O66-)6N!LEB0L9!TD3N*ATZ[C
M658UM%ACF0LBJ<G(ZYXXX- &JD+),65_E8?,G;/J*L'I4,;\#.2IZ-ZU,>E
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MVN,*0"3Z9JO!):/<:/\ 9[.:.8.H=RI4+\IR&/<F@#KNU5;O3[:^D@>XC#M
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M_6IX)29G5D"7"@;U[,/44RX@^S@D+OMG^^G]T_WA4;*,I')*2AYAN W*GT-
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MJ>C#TH 4X;8=Y4_POUR*M5FVY"%!;IF%F^=">8S]*TJ "BBB@ HHHH ****
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MN87+"1TWH$//S#)_*K$*22$A9[A,'YT++E#^72EOEEMH//CN)6(D10&88(+
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M'O6%I!DAU.42R".W=28U1@ZJQ/=^OYT =0A#J&P>>QJ2JT;%VP6PXZXZ&K-
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M*=T- $=S#Y._Y-UNX/F(.Q]16;J;.D^F+GS(S<?NY,YR-AZUT.=W3IZUA:U
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MI0!1L4 U*[D61B&ZIDD*:75/OV8_Z;?^RFM' K-U3_6V7_7;_P!E- #]!_Y
MEK_N_P!36A6?H7_(%MO]W^M:% !534(_-LIT*[@R'Y<]:MTA4'J* .:OV<^"
M[@2$.ZKM) Z_,*DB9WO0'"C%Q'M*CM@U<\3@#PW>X3=\@XSCN*STM;^WNK*:
MZN(Y(WD4;47!S@X- '2CI0>0:%^Z,T$9[T 95QY4MF2_RQI+A K;<?7&?>G*
MZMJ,W[TG;%@(5XSW(-6I;&&6,I@J&?>VWC)]ZDG&+=_]T_RH HB17T>1&XQ"
M1SWXK-T-,>']-63H(QY<HYV'/>K3,RV 690?W+>5(.G3H:/#2*WA>QC(!_=#
M(]>M $ZM)Y[$*$N%'S+GY91ZBK4,XDC+J2%/!4]4-5WCV%4EW!5QY4O=3Z&F
M*6$Q; 6Y4?.O02K[4 6Y;<EO.A8"3]&'H:JE%\MBJDQ/GS8CU4^HJS#,ACW1
M\H?O ]5^M.FAR1+ <2 =>S#T- '.ZF[?;-/5FW1[)]DF>HV=#[UI^'MDV@6<
M9Z>2H(/?BLG4EC^TV95<1E;C?&>JDKZ>E7_#\NW1K!'  \E?*D['CH: +LL0
MC98I6)3/[J0=4/O1AQ.74*MRJ_,/X91_C5Q2LJF.0 MCY@:IR(8_DE^X/]5+
MW'L: )H)U\OS$SY3'D$<H:J:P09M/8$']\>1_NFGYF\P.H"W '[R/^&1?;WJ
MI?.CM8>5P@G;*,,%3M- #=%BV>'+1BIDA:/YTZ[>>HJ^'*/&DKY'6*;U]C[T
MWPV<^'[/_KG4D\'D*WR;[=L[T')7W% %R.0N2K##+UIES;K<* Q((.0PZ@U4
MCDVE4>3*D_N9<\'V/O5Z)]Q*L1O'4?UH SMI\]]A"W*#Y@1\LJTV%UC1FC1C
M"Q_>1$<QGUK1G@69,$<CD$=0:I.)A*&556Y P1VE6@"Y$_'+!@>C#O56[A:&
M&9D7?$R,7BQ[=14:;(U+1QD6Q)\Q"/FC/KCTJT\P\A\MN#(=K]CQ0!DH0-*@
M67A!!F*9?X3MZ&K>G2M]GCP-DJQKN0G[XQU%110F/15=06C:W&Z/'0[>HHM@
M?L=J)).?+4PS#L<?=- &E(D=S "I((.5*]5-5@LAN&((2Y48()^605)#.22K
M ).!\R=F]Q4SK'<H"#T/RL.QH I(1#%N3)MRWSI_%&?\*NI)EAN(8$?*P[BJ
MA5_,W *MTO#*3\LBTU&CAW&)7-OGYTQS&W^% %L0^0W[E<HS98'M[BK=5HI1
MA=S@@_=/K5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ J"Y( 4,#@G&1_"?6IZ:PSZ?C0!4CED#^5(0L@^Z>SC_
M !J2/ALQ\(#\Z^_K5>X@6)"LI9H&(P<\QGUI4F*NL,I FQE&[./\: )[B$2[
M7C.)5'R-V_&JHD9'9D3Y@?WT?K[BKB,?X0,#AA39XO-P\9 D7[K?X^U "(1*
MBLIRIY0_W?K4N 5*X!)ZY[U04LC-)$O0_OXO7W6K2LDJ*P8%3]QAQB@"O-;J
MGR,/W.<HPZQM]?2FC?O X%PHX;H)15Y1O!23!..1V-4IH?)(21CY!(\MAUB/
MU]* )[65&60KD8/S(?X3WIT\)D_>1X$J_=.>OL:J[9?,4;E6Y4<-_#*M689E
M<%U!QG:R=U- %8DMND6+Y3D3Q'K]15:_)BT\J,M"SQ^6W<?.O!K4GA,F)(V*
MR#H>Q]C69J.UK&48*G?&)8QT'SKR* )])8?:+\9Y^TM_(5H30+.N&ZCH1U!K
M#T^18+F\60GRVNSY;]<' ZFMN.0EBKC##MVH INKB;/2Z4<'M(OI4\4X9"47
M !PR'JIJ6>!9TVMD8Y!'4&J920/\K!;I1P<<2#TH T :4]#4%O()8PR# ).Y
M3U!J9B0A/M0!B71_XEVM_P"^W_H"U';.VN7,3QD?V?;$$.#S-(!_Z"/UJCJ4
MD]VNKVEN"(%=FN)NQ&Q<(OOZ^E=#9RVT5E"D;0*@C "JP  QZ4 4&1?M]XL0
MWRF(@[N1UXXI5LF06!C5P(OO?+G_ /54]M''#J4]S]HC(E[%AQ5W[5#G/G1?
M]]B@"*TLVMV<D]6S][.?<^]7:K_;(?\ GO#_ -]BC[;!_P ]X?\ OL4 6*R]
M6.9;+_KL?_035S[;!_SWA_[[%9FJW4)ELBLT143$G#C@;30!;T+_ ) MK_N?
MUK0K.T DZ%:$XY3M]:T: "BBB@#*\3<^';P=R@_F*;<SQ2+IZ)(C,MPF0#G'
MRFD\6*TGA>_1,;FBP 3C//K69&L+S:4L5@\+PR(K.>-ORGC_ &LT =4#D9I:
M08P,=*6@ J.X_P!0_KM-25%<?\>\G^Z: ,5E7^R9/+^>!HF$D9ZJ<=0*B\-R
M[-!TU9,@F(>6_8]>#5^:#=IAECP)/((]FXZ&L[P^/+\-V1/SP&$;TSRASU%
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M1%*IP_I(*OT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#D%?O1^_O3"2LR.6592,+(/N2^Q]#5Y6.=KGGL?6JL\/DJWREK=OO)_</J*
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MK?ZRP_Z^/_930!)X=_Y -IQCY.GXFM*LWP]_R ;3_<_J:TJ "BBB@#)\4?\
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MY9#*(IG59UP=P/RR+_C6E0 4444 %%%% !1110 4444 %%%% !1110 4444
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MN929HY_WL1 ^1MK>E;=U"L("R ^03\I'6,^OTK,U+>+W3U;YIQ/Q-CB1=IH
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MU,.@H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "HYM^ 8P">X/<5)44S ;06VEC@4 0Q7$;*6C;*9P?]D^E$T#;Q
M+"<.!@@]'^M0?-Y[M''LF'WT[2+ZU/;RJRAHSNC/OR* *LFSRI 03 3B10>8
MSZBI(79&2*1@V1^ZE_O#W]ZGFMV+^="?G Y4=&'O59HX_*;AC"Y^=<\Q'U%
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M+E0/+F*?+*N,X-5/M;7/B"R*)+!"HPZ,,#S.>,?KF@#I8]VT%NN.0.E/ID8
M08Z4^@ HHHH RO$Y"^&[YB0 (\DGL,BJDNIV\[Z9$A?<\R,F5(#C:>0:L^*A
MN\,WZ]"T>!QGN*H;[J6;2UD$ 2&=%8KG+':>1Z"@#I5Z"EI!TI: "J&N$C0K
MXCKY+?RJ]5'6^=#OL]/);^5 $-HBR:);A@"?(!]P=M5--/\ Q+K,;O+N!$/+
M<GB3U!JJ+FZ4:7##&VQ[7+'LWR\\^W6M+246?0;12/\ ED.0>5/:@!T;;"S0
M+A5_U]OW4^HJU%<  .S*86^ZX[>U57\T2JK;5NT_U<AZ2CT--5P%DE6$Y_Y;
MP=2O^T!WH M36Q5FDA4$-G?'V?W^M5F1#%RQ,/\ RSD'WH3[U:CN %3;\T;_
M ''[#ZTV:%XRTL: @C$D79QZCWH R[R]NQ=65NLODO(S^9*%^^JC.<46]Q<W
M<(E@O;R2-AD$6Z\CUJKJ"@W&G<XA9IBF#]P[.AJUX<DQI-I&R!9A$-IZ+**
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M;2/^61VK^E:\4I5HXFPLFT;6[.,>OK0 ^:W$I\V)_+EZ"0#J/0^U5L.&D:%
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(:6HYBNWYLX]J
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MEXYB-6(9'5A'*P,HZ-T$@_QITUN49IH0-S??4]&_^O57;%Y2CGR,_*<8,34
M:2N"#ZCJ/2H;FW,@5XVV2*>& _0^U11NRSA)"!*1Q(.D@]/K5I) XZ$'N#VH
M SF+)O:.//\ SU@_J*LQLC*H5]R?P.#T]JDN+<N0\;;95^Z?7V-5 S1AW2/
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M?.N/O#_&JNU4C7)/V9B-A'#0M5R&X1T5D_U;="?ZTV> AC)"H.?]8G]\?XT
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M=4Y[2^CMUB>YC\C.1(4.Z,_G6FKK*BD,&B;[C^AJ8-N)CD +8Y&.&H RT_M
M3E&N81)M^1C'\LGZT](KY82R3Q9)RRF/_P"O4D\"*IBGYM6(V.#\R&GPSN)?
M+EQYV/D/9U_QH <D5^PS]HC4>T?_ ->@QWX.!=1_]^O_ *]7$^Z!C''2GT 4
M/+U'_GYA_P"_7_UZ/)OSUN83_P!L3_C5^B@"AY%]_P _40^D/_UZ#!?9XNH\
M^OE?_7J_10!1\B__ .?N/_OU2>1?C_E[3_OU5^B@"@(M0_Y^8_QB_P#KU6U.
M.^_LN[W7* >4W_++VK8JGJ__ "![W_K@_P#Z": *NG\Z5:F,@/Y"Y!Z,-M.T
MZ%+C1;='ZA <CJI]JK6,H32+))E(C>%523^Z=HZU-I.#IEN4)WK$,J?XA0 Y
ME?SE!(2Z4?*W\,@]#4D<JRK("I'/[R(GE/<58=([N( Y'N.JFJC"03#H+A 0
MK=!*OI0!:63;M1B"I^X_K[&HIH/)9FC0-&^3)'_44D<L<D;$ XZ21GJIJ6-R
MA".<J?\ 5MZCWH S]JK&B2D^46S#,.L9[ U9AE8SB-_DN%&2<860>U,=7 >5
M4$D,A(FCZY'J!Z^U, 'E1*7!@)!MYAR8SZ&@"_+''>0E'X'7@X*GUJHRR+*
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MYD,3?N[C;E21D./6LV]C/V36)$.5WL'3L1L7D>]7&9/+3S),P''ERC[R-[T
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MX)92X6552Z49(7[KCU%6#Y=U$0. ._=30!15Q&&FA5C'DB: GE/<?YYJY%*
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M!16*$_,I/W31<V[./-MV"3C[I/0_6@"I%((E0,P:W?\ U,O]T_W35Y':0;)
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MXF7H>Q'H:IHVP/+#&WEDXEM\<J?45I1N)%! ..X/:H[BWW.LL?RRKT/9O8T
M,@F 5!G*'[C^OM4=Q"86:6&/S%88DAQPWN/>H%<PR-)&I,9/[V''*'N15V*9
M2$PVZ-N5<4 58XXML:EFFB+YC?J8_8FM.JDR-!('MU!WD;TZ<>HJW0 M%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^$:E_P"@_K7_ '^C_P#B* -VBL+_ (1J7_H/ZU_W^C_^(H_X1J7_ *#^M?\
M?Z/_ .(H W:*PO\ A&I?^@_K7_?Z/_XBC_A&I?\ H/ZU_P!_H_\ XB@#=HK"
M_P"$:E_Z#^M?]_H__B*/^$:E_P"@_K7_ '^C_P#B* -VBL+_ (1J7_H/ZU_W
M^C_^(H_X1J7_ *#^M?\ ?Z/_ .(H W:*PO\ A&I?^@_K7_?Z/_XBC_A&I?\
MH/ZU_P!_H_\ XB@#=HK"_P"$:E_Z#^M?]_H__B*G\*W4U[X5TRXNI6EGDMT9
MW;&6..IQ0!H77_'I-_N-_*O)OV?O^0?K?_76+^35ZS=?\>DW^XW\J\F_9^_Y
M!^M_]=8OY-0!Z_117/:2]SOUO[-L>871\L2L=O04 =#134W>6OF !\?-CIFG
M4 87C7_D3M4_ZXG^8KA/C]_R -*_Z^F_]!KN_&O_ ")VJ?\ 7$_S%<)\?O\
MD :5_P!?3?\ H- 'I>C_ /($L/\ KWC_ /015VJ6C_\ ($L/^O>/_P!!%7:
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MWYP$!&1G@\^M7J "LP3+/JT+K)$8\,J 'DXZ_P"?:M.J[2PQ7,4.S#OG:0O
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MHP/2G?4!D,J2*1&X;:=K<\@^A]ZDI*6D 4444 %%%% !1110 4444 9/BO\
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M44 %%%% !1110!D^*_\ D4-9_P"O&;_T U5\6_\ )/=7_P"P;+_Z+-6O%?\
MR*&L_P#7C-_Z :J^+?\ DGNK_P#8-E_]%F@#E_@5_P B'-_U_2?^@I7I%>;_
M  *_Y$.;_K^D_P#04KTB@ HHHH **** "BBB@ KQOXF_\EA\*_\ ;O\ ^CS7
MLE>-_$W_ )+#X5_[=_\ T>: /9**** (+N6:&)3;P^:[.%QG  [DFHI+>:*Y
M>YCGE<$8,+$; /50!G/XU<HH SKJUFU72XX9P(6D9&F0'H <D _A2Z?IOV:.
M03;"3.TJ^62 !T _ <5H44 0_9H_L_D8;R_3><^O7.:>(PF\I]YN>2>M/HH
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MG_OW%_\ '*W** ,/_A))_P#H7M9_[]Q?_'*/^$DG_P"A>UG_ +]Q?_'*W**
M,/\ X22?_H7M9_[]Q?\ QRLP:G>_\)2=1_X1_5_(-D(,;(MV[>6Z>9TQ77T4
M >1>-M)UOQ%XWT35[+0=0%M8F,RB3R@QVR;C@;^>*]!_X22?_H7M9_[]Q?\
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? $!K+_OT*UK:VAL[:.WMHDBAB4(D:#"J!T % '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
